



(51) International Patent Classification:

A61K 31/70 (2006.01) C07H 21/02 (2006.01)
A61K 31/7088 (2006.01) C07H 21/04 (2006.01)
A61K 38/00 (2006.01) C12N 5/00 (2006.01)

(21) International Application Number:

PCT/US2018/020124

(22) International Filing Date:

28 February 2018 (28.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/464,811 28 February 2017 (28.02.2017) US
62/542,241 07 August 2017 (07.08.2017) US

(71) Applicant: **EPIZYME, INC.** [US/US]; 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **GRASSIAN, Alexandra Rose**; 25A Highland Avenue, Cambridge, Massachusetts 02139 (US). **DREW,**

Allison; 254 Florence Avenue, Arlington, Massachusetts 02476 (US).


(74) Agent: **ERLACHER, Heidi**; Cooley LLP, 1299 Pennsylvania Avenue, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: INHIBITION OF SMARCA2 FOR TREATMENT OF CANCER

FIGURE 1



(57) Abstract: The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancer. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers with decreased activity or function, or loss of function, of SMARCA4 with a SMARCA2 antagonist.

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

INHIBITION OF SMARCA2 FOR TREATMENT OF CANCER

RELATED APPLICATIONS

[001] This application claims the benefit of and priority to U.S. Provisional Application Nos. 62/464,811, filed February 28, 2017, and 62,542,241, filed August 7, 2017, the entire contents of each of which are hereby incorporated by reference.

FIELD OF DISCLOSURE

[002] This disclosure relates to modulation (e.g., inhibition) of SMARCA2 for treating cancer.

SUMMARY

[003] The present disclosure provides treatment modalities, e.g., strategies, treatment methods, patient stratification methods, combinations, and compositions that are useful for the treatment of disorders, e.g., proliferative disorders, such as certain cancers. Some aspects of this disclosure provide treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, associated with a certain biomarker, or patient stratification methods based on detection of a biomarker.

[004] Some aspects of this disclosure provide methods comprising modulating (e.g., inhibiting) a SMARCA2 activity in a cell exhibiting a decreased activity or function of SMARCA4 (e.g., a loss of function of SMARCA4).

[005] Some aspects of this disclosure provide methods of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a SMARCA2 antagonist to the subject or a cell of the subject. In some embodiments, the subject or cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[006] Some aspects of the disclosure relate to a SMARCA2 antagonist for use in the treatment of cancer in a cell or subject, wherein the cell or subject exhibits decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[007] Some aspects of the disclosure relate to a SMARCA2 antagonist for use as a medicament for the treatment of cancer in a cell or subject, wherein the cell or subject exhibits decreased activity or function of SMARCA4 when compared to a control level of the activity

or the function of SMARCA4.

[008] Some aspects of the disclosure relate to the use of a SMARCA2 antagonist in the manufacture of a medicament for the treatment of cancer in a cell or subject, wherein the cell or subject exhibits decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[009] Some aspects of this disclosure provide methods of inhibiting an activity of SMARCA2, comprising contacting SMARCA2 enzyme with a SMARCA2 antagonist. In some embodiments, the SMARCA2 enzyme is within a cell, e.g., a cancer cell, and the method comprises contacting the cell with the SMARCA2 inhibitor, wherein the cell comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[010] Some aspects of this disclosure provide a SMARCA2 antagonist for use in inhibiting an activity of SMARCA2, wherein the SMARCA2 antagonist is contacted with a SMARCA2 enzyme. In some embodiments, the SMARCA2 enzyme is within a cell, e.g., a cancer cell, wherein the cell comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[011] Some aspects of this disclosure provide a SMARCA2 antagonist for use as a medicament for inhibiting an activity of SMARCA2, wherein the medicament is contacted with a SMARCA2 enzyme. In some embodiments, the SMARCA2 enzyme is within a cell, e.g., a cancer cell, wherein the cell comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[012] Some aspects of this disclosure provide the use of a SMARCA2 antagonist in the manufacture of a medicament for inhibiting an activity of SMARCA2, wherein the medicament is to be contacted with a SMARCA2 enzyme. In some embodiments, the SMARCA2 enzyme is within a cell, e.g., a cancer cell, wherein the cell comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[013] Some aspects of this disclosure provide methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a SMARCA2 antagonist, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[014] Some aspects of this disclosure provide a SMARCA2 antagonist for use in treating cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[015] Some aspects of this disclosure provide a SMARCA2 antagonist for use as a

medicament for treating cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[016] Some aspects of this disclosure provide the use of a SMARCA2 antagonist in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[017] In some embodiments, the biomarker is a decreased activity or function of SMARCA4. In certain embodiments, the biomarker is loss of function of SMARCA4.

[018] Some aspects of this disclosure provide methods of identifying a subject sensitive to treatment with a SMARCA2 antagonist, comprising detecting a decreased activity or function of SMARCA4 compared to a control level of the activity or the function of SMARCA4 in the subject and administering the SMARCA2 antagonist to the subject, wherein the subject has a cancer and wherein an improvement in a sign or symptom of the cancer indicates a sensitivity of the subject or of a cancer cell of the subject for the SMARCA2 antagonist.

[019] In some embodiments, the control level is the level of activity of SMARCA4 in a subject that does not have cancer.

[020] In some embodiments, the subject is a participant in a clinical trial. In some embodiments, a criterion for participation of a subject in the clinical trial is a decreased activity or function of SMARCA4, or loss of function of SMARCA4, in said subject or a cell of said subject.

[021] In some embodiments, the present disclosure features a method comprising inhibiting a SMARCA2 activity in a cell exhibiting loss of function of SMARCA4.

[022] In certain embodiments of the methods disclosed herein, the SMARCA2 activity is an ATPase activity.

[023] In certain embodiments of the methods, uses, or medicaments disclosed herein, the SMARCA2 activity is not a bromodomain activity.

[024] In some embodiments, the methods of the disclosure comprise contacting a cell with a SMARCA2 antagonist. In certain embodiments, the cell is in vivo, ex vivo, in vitro, or in situ. In certain embodiments of the methods disclosed herein, the cell is in a subject.

[025] In some embodiments, the cell is ex vivo or in vitro. In further embodiments, the cell is isolated or derived from a subject that has a tumor.

[026] In some embodiments, the tumor is malignant. In some embodiments, the tumor is metastatic.

[027] In some embodiments, the methods of the disclosure comprise administering a SMARCA2 antagonist to a subject.

[028] In some embodiments of the disclosure, the SMARCA2 antagonist does not modulate SMARCA4. For example, the SMARCA2 antagonist does not inhibit SMARCA4.

[029] In some embodiments of the disclosure, the SMARCA2 antagonist targets a helicase domain of SMARCA2.

[030] In some embodiments of the disclosure, the SMARCA2 antagonist targets an ATPase domain of SMARCA2.

[031] In some embodiments of the disclosure, the SMARCA2 antagonist does not target a bromodomain activity of SMARCA2.

[032] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by a genetic mutation.

[033] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by an epigenetic alteration.

[034] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by a decrease in SMARCA4 gene transcription, SMARCA4 gene transcript translation, or a combination thereof.

[035] In some embodiments of the disclosure, the SMARCA2 antagonist is selected from the group consisting of antisense RNA, shRNA, siRNA, CRISPR/Cas9, transcription activator-like effector nucleases (TALEN), Zinc Finger nucleases (ZFN), antibodies, antibody fragments and antibody mimetics.

[036] In some embodiments, the SMARCA2 antagonist is a SMARCA2 inhibitor. In certain embodiments, the SMARCA2 inhibitor is a selective SMARCA2 inhibitor.

[037] In certain embodiments of the methods disclosed herein, the cell is in a subject, and the method comprises administering a SMARCA2 inhibitor to the subject.

[038] In certain embodiments of the disclosure, the SMARCA2 inhibitor inhibits an ATPase activity of SMARCA2.

[039] In certain embodiments of the disclosure, the SMARCA2 inhibitor selectively inhibits an ATPase activity of SMARCA2.

[040] In some aspects, this present disclosure features methods of treating cancer, comprising inhibiting a SMARCA2 activity in a subject in need thereof, wherein the subject has a cancer characterized by loss of function of SMARCA4.

[041] In some embodiments, the SMARCA2 antagonist is a SMARCA2 inhibitor. In some embodiments, the SMARCA2 inhibitor is selected from the group consisting of BMCL 2968, I-BET151, JQ1, and PFI-3. In some embodiments, the SMARCA2 inhibitor is PFI-3.

[042] In some aspects, this present disclosure features methods of treating cancer, comprising inhibiting a SMARCA2 activity, e.g., a SMARCA2 helicase activity or a SMARCA2 ATPase activity, in a subject in need thereof, wherein the subject has a cancer characterized by loss of function of SMARCA4.

[043] Some aspects of this disclosure provide methods comprising modulating a SMARCA2 activity in a cell exhibiting a decreased activity or function of SMARCA4. In some embodiments, the cell is in vivo, ex vivo, in vitro, or in situ. In some embodiments, the cell is in a subject, and the method comprises administering a SMARCA2 antagonist to the subject. In some embodiments, the cell is ex vivo or in vitro, and wherein the cell is isolated or derived from a subject that has a tumor. In some embodiments, the tumor is malignant. In some embodiments, the tumor is metastatic.

[044] Some aspects of this disclosure provide methods of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a SMARCA2 antagonist to the subject or a cell of the subject, wherein said subject or cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[045] Some aspects of this disclosure provide a SMARCA2 antagonist for use in treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[046] Some aspects of this disclosure provide a SMARCA2 antagonist for use as a medicament for treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[047] Some aspects of this disclosure provide the use of a SMARCA2 antagonist in the

manufacture of a medicament for treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

[048] In some embodiments, the control level is the level of activity or function of SMARCA4 in a subject that does not have cancer. In some embodiments, the method comprises administering the SMARCA2 antagonist to the cell or the subject based on the decreased activity or function of SMARCA4 in the cell or the subject.

[049] Some aspects of this disclosure provide methods of identifying a subject having a cancer as a candidate for treatment with a SMARCA2 antagonist, comprising detecting a level of activity or function of SMARCA4 in a cancer cell in the subject, comparing the level of activity or function of SMARCA4 detected in the cancer cell to a control or reference level, wherein the subject is identified as a candidate for treatment with a SMARCA2 antagonist, if the level of activity or function of SMARCA4 in the cancer cell is decreased as compared to the control or reference level. In some embodiments, the method comprises obtaining a sample comprising a cancer cell from the subject.

[050] Some aspects of this disclosure provide methods of identifying a cancer cell as sensitive to treatment with a SMARCA2 antagonist, comprising detecting a level of activity or function of SMARCA4 in the cancer cell, comparing the level of activity or function of SMARCA4 detected in the cancer to a control or reference level, wherein the cell is identified as sensitive to treatment with a SMARCA2 antagonist, if the level of activity or function of SMARCA4 is decreased as compared to the control or reference level. In some embodiments, the control or reference level of SMARCA4 activity or function is a level of SMARCA4 observed or expected in a healthy cell of the same origin as the cancer cell.

[051] In some embodiments, the SMARCA2 antagonist inhibits SMARCA2 helicase activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or abolishes SMARCA2 activity. In some embodiments, the SMARCA2 antagonist inhibits SMARCA2 ATPase activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or abolishes SMARCA2 activity. In some embodiments, the SMARCA2 antagonist is a selective SMARCA2 antagonist. In some embodiments, the SMARCA2 antagonist inhibits SMARCA2

activity at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 1000-fold, at least 10000-fold, or at least 100000-fold more efficiently than SMARCA4 activity. In some embodiments, the SMARCA2 antagonist does not inhibit SMARCA4.

[052] In some embodiments, the SMARCA2 antagonist targets a helicase domain of SMARCA2. In some embodiments, the SMARCA2 antagonist targets an ATPase domain of SMARCA2. In some embodiments, the SMARCA2 antagonist does not target a bromodomain activity of SMARCA2.

[053] In some embodiments, the decreased activity of SMARCA4 is caused by a genetic mutation. In some embodiments, the decreased activity of SMARCA4 is caused by an epigenetic alteration. In some embodiments, the decreased activity of SMARCA4 is caused by a decrease in SMARCA4 gene transcription, by a decrease in SMARCA4 gene transcript translation, by a post-translational modification, by a loss of protein-protein interaction, or a combination thereof.

[054] In some embodiments, the SMARCA2 antagonist is a small molecule SMARCA2 inhibitor. In some embodiments, the SMARCA2 antagonist is selected from the group consisting of antisense RNA, shRNA, siRNA, CRISPR/Cas9, transcription activator-like effector nucleases (TALEN), Zinc Finger nucleases (ZFN), antibodies, antibody fragments and antibody mimetics.

[055] Any of the above aspects and embodiments can be combined with any other aspect or embodiment.

[056] Other features and advantages of the invention will be apparent from the following drawings, detailed description, and claims.

BRIEF DESCRIPTIONS OF FIGURES

[057] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[058] The above and further features will be more clearly appreciated from the following detailed description when taken in conjunction with the accompanying drawings.

[059] **Figure 1** is a graph showing CRISPR pooled screen data, illustrating sensitivity (LogP RSA) to SMARCA2 knockout. Cell lines are colored by SMARCA4 expression: blue represents high SMARCA4 expression, red represents low SMARCA4 expression. Cell lines which are sensitive to SMARCA2 knockout tend to have low SMARCA4 expression.

[060] **Figure 2** is a graph showing a transcriptomic analysis of NSCLC cell lines that have RNA seq. data available in Cancer Cell Line Encyclopedia (CCLE). The Figure demonstrates that only cell lines with low SMARCA4 expression are sensitive to SMARCA2 knockout.

[061] **Figure 3** is a series of images of immunohistochemistry (IHC) slides of non-small cell lung cancer tumor samples, screened for SMARCA2/4 protein expression. Panels A-F show samples with protein expression as follows: Panel A: double negative sample (loss of SMARCA2 and SMARCA4); Panel B: SMARCA4 negative sample; Panel C: SMARCA2 negative sample; Panel D: wild type samples; Panel E: double positive sample (SMARCA2 and SMARCA4 expression present).

[062] **Figure 4** is a graph validating the anti-proliferative effect of SMARCA2 knockout in SMARCA4 mutant cell lines. The figure shows the percent change in target CRISPR cells lines over time following infection with the viral delivery vector for the CRISPR construct in SMARCA4 mutant cell lines.

[063] **Figure 5** is a graph demonstrating that inhibition of the ATPase domain drives antiproliferative effects in cells. The graph shows the antiproliferative effect of SMARCA2 knockout as a function of CRISPR guide target.

[064] **Figure 6** is a series of graphs illustrating antiproliferative effects of bromodomain inhibitor PFI-3. Panel A shows that PFI-3 binds to SMARCA2 with nanomolar affinity. Panel B shows that PFI-3 does not impact cell growth in SMARCA4-wt or mutant cell lines.

[065] **Figure 7** is a series of graphs demonstrating that isolated full length SMARCA2 is well behaved in activity assays. Panel A summarizes the signal to background ratio (S:B) in an ATPase high throughput bioluminescence assay. The S:B ratio was found to remain linear for 90 minutes, with a value of 10 at 5nM of SMARCA2. Panel B is a plot of luminescence as a function of SMARCA2 concentration. Panel C is a plot showing the results of a biosubstrate analysis. The value of K_M was determined as 640uM and 5.8 mM for ATP and mononucleosome, respectively. Panel D illustrates DMSO tolerance. Panel E illustrates

uniformity of the assay. The z-factor was determined to 0.70. Panel F illustrates the determination of IC_{50} values for reference inhibitors.

[066] **Figure 8** is a series of graphs demonstrating behavior of SMARCA4 in an activity assay. Panel A summarizes the signal to background ratio (S:B) in an ATPase high throughput bioluminescence assay. The S:B ratio was found to remain linear for 90 minutes, with a value of 7 at 5nM of SMARCA4. Panel B is a plot of luminescence as a function of SMARCA4 concentration. Panel C is a plot showing the results of a biosubstrate analysis for ATP. The value of K_M was determined as 133 mM. Panel D is a plot showing the results of a biosubstrate analysis for mononucleosome. The value of K_M was determined as 2.1 mM. Panel E illustrates uniformity of the assay. The z-factor was determined to 0.71. Panel F illustrates the determination of IC_{50} values for a reference inhibitor.

[067] **Figure 9** is a series of graphs illustrating the behavior of purified SWI/SNF complex in an ATPase assay. Panel A is an illustration of SWI/SNF complex purification from HEK293 cells using a SMARCB-1 flag.

[068] **Figure 10** is a series of graphs illustrating that the purified SWI/SNF protein complex demonstrates similar kinetic parameters to SMARCA2. Panel A is a plot of SWI/SNF and SMARCA2 activity as a function of mononucleosome concentration. Panel B is a plot of SWI/SNF and SMARCA2 activity as a function of ATP concentration. Panel C is a plot of ATP levels as a function of time for various concentrations of the SWI/SNF protein complex. Panel D is a plot of luminescence as a function of the SWI/SNF protein complex concentration.

[069] **Figure 11** illustrates the detection and validation of a small molecule SMARCA2 ATPase inhibitor (ADP). Panel A is a plot of surface plasmon resonance response of the binding affinity of the SMARCA2 inhibitor to truncated SMARCA2 as a function of time. Panel B is a plot of surface plasmon resonance response of the binding affinity of the SMARCA2 inhibitor to truncated SMARCA2 as a function of inhibitor concentration. The K_d value was determined as 7 μ M. Panel C is a plot of ATPase inhibition in full length (FL) and truncated (TR) SMARCA2, measured using a 2-amino-6-mercapto-7-methylpurine ribonucleoside/Purine Nucleoside Phosphorylase (MESG/PNP) assay. The IC_{50} values of the SMARCA2 inhibitor were determined as 28 μ M and 23 μ M, for FL-SMARCA2 and TR-SMARCA2 IC_{50} , respectively.

[070] **Figure 12** is a Western Blot Analysis for SMARCA4 and SMARCA2 for various non-small cell lung cancer cell lines.

DETAILED DESCRIPTION

[071] The present disclosure provides treatment modalities, methods, strategies, compositions, combinations, and dosage forms for the treatment of cell proliferative disorders, e.g., cancers, associated with decreased activity or function of SMARCA4 (e.g., loss of function of SMARCA4). Some aspects of this disclosure provide patient stratification methods based on detection of a decreased activity or function, or loss of function, of SMARCA4.

[072] In some aspects, this present disclosure features methods comprising modulating a SMARCA2 activity in a cell exhibiting a decreased activity or function of SMARCA4 (e.g., loss of function of SMARCA4).

[073] In some aspects, this present disclosure features methods of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a SMARCA2 antagonist to the subject or a cell of the subject.

[074] In some aspects, the present disclosure features a SMARCA2 antagonist for use in the treatment of cancer in a subject in need thereof.

[075] In some aspects, the present disclosure features a SMARCA2 antagonist for use as a medicament for the treatment of cancer in a subject in need thereof.

[076] In some aspects, the present disclosure features the use of a SMARCA2 antagonist in the manufacture of a medicament for the treatment of cancer in a subject in need thereof.

[077] In some embodiments, the subject or cell of the subject exhibits a decreased activity or function of SMARCA4 compared to a control level of the activity or the function of SMARCA4.

[078] In some aspects, this present disclosure features methods of modulating an activity of SMARCA2, comprising contacting a cell with a SMARCA2 antagonist, wherein the cell comprises a biomarker of sensitivity to SMARCA2 inhibition.

[079] In some aspects, the present disclosure features a SMARCA2 antagonist for use in modulating an activity of SMARCA2, wherein said use comprises contacting a cell with a SMARCA2 antagonist, wherein the cell comprises a biomarker of sensitivity to SMARCA2 inhibition.

[080] In some aspects, the present disclosure features a SMARCA2 antagonist as a medicament for modulating an activity of SMARCA2, wherein said medicament is for contacting with a cell, wherein the cell comprises a biomarker of sensitivity to SMARCA2 inhibition.

[081] In some aspects, the present disclosure features the use of a SMARCA2 antagonist in the manufacture of a medicament for modulating an activity of SMARCA2, wherein said medicament is for contacting with a cell, wherein the cell comprises a biomarker of sensitivity to SMARCA2 inhibition.

[082] In some aspects, this present disclosure features methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a SMARCA2 antagonist, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[083] In some aspects, the present disclosure features a SMARCA2 antagonist for use in the treatment of cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[084] In some aspects, the present disclosure features a SMARCA2 antagonist for use as a medicament for the treatment of cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[085] In some aspects, the present disclosure features the use of a SMARCA2 antagonist in the manufacture of a medicament for the treatment of cancer in a subject in need thereof, wherein the subject or a cell of the subject comprises a biomarker of sensitivity to the SMARCA2 antagonist.

[086] In some embodiments, the biomarker is a decreased activity or function of SMARCA4. In certain embodiments, the biomarker is loss of function of SMARCA4.

[087] In some aspects, this present disclosure features methods of identifying a subject sensitive to treatment with a SMARCA2 antagonist, comprising detecting a decreased activity or function of SMARCA4 compared to a control level of the activity or the function of SMARCA4 in the subject and administering the SMARCA2 antagonist to the subject, wherein the subject has a cancer and wherein an improvement in a sign or symptom of the cancer indicates a sensitivity of the subject or of a cancer cell of the subject for the SMARCA2 antagonist.

[088] In some embodiments, the subject is a participant in a clinical trial. In some embodiments, a criterion for participation of a subject in the clinical trial is a decreased activity or function of SMARCA4, or loss of function of SMARCA4, in said subject or a cell of said subject.

[089] In some embodiments, the control level is the level of activity of SMARCA4 in a subject that does not have cancer.

[090] In some embodiments, the present disclosure features a method comprising inhibiting a SMARCA2 activity in a cell exhibiting loss of function of SMARCA4.

[091] In certain embodiments of the methods disclosed herein, the SMARCA2 activity is an ATPase activity.

[092] In certain embodiments of the methods disclosed herein, the SMARCA2 activity is not a bromodomain activity.

[093] In some embodiments, the methods of the disclosure comprise contacting a cell with a SMARCA2 antagonist. In certain embodiments, the cell is in vivo, ex vivo, in vitro, or in situ. In certain embodiments of the methods disclosed herein, the cell is in a subject.

[094] In some embodiments, the cell is ex vivo or in vitro. In further embodiments, the cell is isolated or derived from a subject that has a tumor.

[095] In some embodiments, the tumor is malignant. In some embodiments, the tumor is metastatic.

[096] In some embodiments, the methods of the disclosure comprise administering a SMARCA2 antagonist to the subject.

[097] In some embodiments of the disclosure, the SMARCA2 antagonist does not modulate SMARCA4. For example, the SMARCA2 antagonist does not inhibit SMARCA4.

[098] In some embodiments of the disclosure, the SMARCA2 antagonist targets a helicase domain of SMARCA2.

[099] In some embodiments of the disclosure, the SMARCA2 antagonist targets an ATPase domain of SMARCA2.

[0100] In some embodiments of the disclosure, the SMARCA2 antagonist does not target a bromodomain activity of SMARCA2.

[0101] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by a genetic mutation.

[0102] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by an epigenetic process, e.g., silencing of a SMARCA4 gene, post-transcriptional or post-translational modulation of the half-life of a SMARCA4 gene product, e.g., inhibition of translation of a SMARCA4 transcript into SMARCA4 protein, or increased turnover of a SMARCA4 protein.

[0103] In some embodiments of the disclosure, the decreased activity of SMARCA4 is caused by a decrease in SMARCA4 gene transcription, SMARCA4 gene transcript translation, or a combination thereof.

[0104] In some embodiments of the disclosure, the SMARCA2 antagonist is selected from the group consisting of antisense RNA, shRNA, siRNA, CRISPR/Cas9, transcription activator-like effector nucleases (TALEN), Zinc Finger nucleases (ZFN), antibodies, antibody fragments and antibody mimetics.

[0105] In some embodiments, the SMARCA2 antagonist is a small molecule SMARCA2 inhibitor (e.g., ADP). In certain embodiments, the SMARCA2 inhibitor is a selective SMARCA2 inhibitor, e.g., in that it inhibits SMARCA2, but not SMARCA4 or a different helicase, or in that it inhibits SMARCA2 more efficiently than SMARCA4.

[0106] In certain embodiments of the methods disclosed herein, the cell is in a subject, and the method comprises administering a SMARCA2 inhibitor to the subject.

[0107] In certain embodiments of the methods disclosed herein, the SMARCA2 inhibitor inhibits an ATPase activity of SMARCA2.

[0108] In certain embodiments of the methods disclosed herein, the SMARCA2 inhibitor selectively inhibits an ATPase activity of SMARCA2.

[0109] Some aspects of this disclosure provide methods of treating cancer, comprising inhibiting a SMARCA2 activity in a subject in need thereof, wherein the subject has a cancer characterized by loss of function of SMARCA4.

[0110] In some embodiments, the SMARCA2 antagonist is a SMARCA2 inhibitor. In some embodiments, the SMARCA2 inhibitor is selected from the group consisting of BMCL 2968, I-BET151, JQ1, and PFI-3. In some embodiments, the SMARCA2 inhibitor is PFI-3.

[0111] Some aspects of this disclosure provide methods of treating cancer, comprising inhibiting a SMARCA2 activity, e.g., a SMARCA2 helicase activity or a SMARCA2 ATPase activity, in a subject in need thereof, wherein the subject has a cancer characterized by loss of

function of SMARCA4.

SMARCA2/SMARCA4

[0112] Some aspects of this disclosure are based on the recognition that SMARCA2 is a synthetic lethal target in SMARCA4-mutated cancers or cancers associated with decrease or loss of activity or a function of SMARCA4. Some aspects of this disclosure thus provide methods or medicaments for decreasing or abolishing survival and/or proliferation of cancer cells that exhibit a loss of SMARCA4 function by inhibiting SMARCA2 in such cells.

[0113] SMARCA2 and SMARCA4 are SWI/SNF related, matrix associated, actin dependent regulators of chromatin and mutually exclusive paralogs in the SWI/SNF complex. SWI/SNF complexes regulate many cell processes by direct modulation of nucleosomal structure. The catalytic subunits SMARCA2 and SMARCA4 have ATP-dependent helicase activity that repositions nucleosomes.

[0114] SWI/SNF complex members are mutated in about 20% of human cancers (Kardoch et al. *Nat. Genet.*, 2013, 45(6), 592-601, incorporated herein by reference in its entirety). For example SMARCA4 mutations occur across a diverse range of cancer types with varying population size and clinical need.

[0115] Table 1 below provides a summary of the frequency of SMARCA4 mutations in certain cancer types.

Table 1: SMARCA4 mutations in certain cancers

Cancer Type	SMARCA4 Mutations (%)	US Cases/Year	5 Year Survival (%)	Estimated SMARCA4-Mutant Patients/Year
Ovary - SCCOHT	>95%	<300	33%	<300
Bladder	8%	75,000	77%	6000
Stomach	6%	22,000	28%	1320
Lung	4-5% (NSCLC)	220,000	17%	~10,000

Glioma/GBM	2-5%	20,000	Variable	~360
Head and Neck	4%	36,000	56%	1440
Kidney	3-4% (Clear cell, Papillary)	64,000	72%	~2000
Uterine/Cervical	3-4%	12,000	68%	~400
Pancreas	3%	46,000	7%	1380

[0116] However, SMARCA4 expression can also be regulated by post-transcriptional and post-translational mechanisms. As such, an analysis of mutation frequencies only is likely to underestimate protein loss, and observing only mutations of SMARCA4 may underestimate decrease or loss of activity or a function of SMARCA4 in a patient. Decrease or loss of activity or a function of SMARCA4 can appear in patients who have not mutation of SMARCA4.

These patients can be identified by methods such as mRNA or protein assays. In some embodiments of the present disclosure, methods comprising detecting a loss of activity or function of SMARCA4 in a cell or tissue comprise assaying SMARCA4 protein expression levels by a suitable method, such as, e.g., antibody-based assays allowing for quantification of expressed protein in the cell or tissue (e.g., western blot, immunohistochemistry, ELISA, etc.).

[0117] Exemplary sequences for SMARCA2 and SMARCA4 are provided below:

SMARCA2

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2), transcript variant 3 (GenBank Accession No. NM_001289396.1)

```
TCAGAAGAAAGCCCCGAGATCACAGAGACCCGGCGAGATCACAGAGACCCGGCCTGAAGGAAACGTGGAAA
GACCAATGTACCTGTTTGGACCGGTTGCCTGGAGCAAGAAGTTCCAGTTGGGGAGAATTTTCAGAAGATA
AAGTCGGAGATTGTGGAAAGACTTGACTTGCAGCATTACTCTACTGACTGGCAGAGACAGGAGAGGTAGA
TGTCCACGCCCACAGACCCTGGTGCGATGCCCCACCCAGGGCCTTCGCCGGGGCCTGGGCCTTCCCTGG
GCCAATTCTTGGGCCTAGTCCAGGACCAGGACCATCCCCAGGTTCCGTCCACAGCATGATGGGGCCAAGT
CCTGGACCTCCAAGTGTCTCCATCCTATGCCGACGATGGGGTCCACAGACTTCCACAGGAAGGCATGC
ATCAAATGCATAAGCCCATCGATGGTATACATGACAAGGGGATTGTAGAAGACATCCATTGTGGATCCAT
GAAGGGCACTGGTATGCGACCACCTCACCCAGGCATGGGGCCTCCCCAGAGTCCAATGGATCAACACAGC
CAAGGTTATATGTCAACACACCCATCTCCATTAGGAGCCCCAGAGCACGTCTCCAGCCCTATGTCTGGAG
GAGGCCCAACTCCACCTCAGATGCCACCAAGCCAGCCGGGGGCCCTCATCCAGGTGATCCGCGAGGCCAT
GAGCCAGCCCAACAGAGGTCCCTCACCTTTTCAGTCCTGTCCAGCTGCATCAGCTTCGAGCTCAGATTTTA
```

GCTTATAAAATGCTGGCCCGAGGCCAGCCCCCTCCCCGAAACGCTGCAGCTTGCAGTCCAGGGGAAAAGGA
 CGTTGCCTGGCTTGCAGCAACAACAGCAGCAGCAACAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA
 GCAGCAACAGCAGCCGCGAGCAGCAGCCGCCGCAACCACAGACGCAGCAACAACAGCAGCCGGCCCTTGT
 AACTACAACAGACCATCTGGCCCGGGGCCGGAGCTGAGCGGCCCGAGCACCCCGCAGAAGCTGCCGGTGC
 CCGCGCCCGGGCGGCCGCCCTCGCCCGCGCCCCCGCAGCCGCGCAGCCGCCCGCGGCCCGCAGTGCCCGG
 GCCCTCAGTGCCCGCAGCCGGGCCCGGGGCGAGCCCTCGCCCGTCTCCAGCTGCAGCAGAAGCAGAGCCGC
 ATCAGCCCCATCCAGAAACCGCAAGGCCTGGACCCCCGTGGAAATTTCTGCAAGAGCGGGAATACAGACTTC
 AGGCCCGCATAGCTCATAGGATACAAGAACTGGAAAATCTGCCTGGCTCTTTGCCACCAGATTTAAGAAC
 CAAAGCAACCGTGGAACATAAAGCACTTCGGTTACTCAATTTCCAGCGTCAGCTGAGACAGGAGGTGGTG
 GCCTGCATGCGCAGGGACACGACCCCTGGAGACGGCTCTCAACTCCAAAGCATACAAACGGAGCAAGCGCC
 AGACTCTGAGAGAAGCTCGCATGACCGAGAAGCTGGAGAAGCAGCAGAAGATTGAGCAGGAGAGGAAACG
 CCGTCAGAAACACCAGGAATACCTGAACAGTATTTTGCAACATGCAAAAGATTTTAAGGAATATCATCGG
 TCTGTGGCCGGAAGATCCAGAAGCTCTCCAAAGCAGTGGCAACTTGGCATGCCAACACTGAAAGAGAGC
 AGAAGAAGGAGACAGAGCGGATTGAAAAGGAGAGAATGCGGCGACTGATGGCTGAAGATGAGGAGGGTTA
 TAGAAAACCTGATTGATCAAAAGAAAGACAGGCGTTTAGCTTACCTTTTGCAGCAGACCGATGAGTATGTA
 GCCAATCTGACCAATCTGGTTTGGGAGCACAAGCAAGCCCAGGCAGCCAAAGAGAAGAAGAGAGGAGGA
 GGAGGAAGAAGAAGGCTGAGGAGAATGCAGAGGGTGGGGAGTCTGCCCTGGGACCGGATGGAGAGCCCAT
 AGATGAGAGCAGCCAGATGAGTGACCTCCCTGTCAAAGTGACTCACACAGAAACCGGCAAGGTTCTGTTC
 GGACCAGAAGCACCCAAAGCAAGTCAGCTGGACGCTGGCTGGAAATGAATCCTGGTTATGAAGTTGCCC
 CTAGATCTGACAGTGAAGAGAGTGATTCTGATTATGAGGAAGAGGATGAGGAAGAAGAGTCCAGTAGGCA
 GGAAACCGAAGAGAAAATACTCCTGGATCCAAATAGCGAAGAAGTTTCTGAGAAGGATGCTAAGCAGATC
 ATTGAGACAGCTAAGCAAGACGTGGATGATGAATACAGCATGCAGTACAGTGCCAGGGGCTCCAGTCTCT
 ACTACACCGTGGCTCATGCCATCTCGGAGAGGGTGGAGAAACAGTCTGCCCTCCTAATTAATGGGACCCT
 AAAGCATTACCAGCTCCAGGGCCTGGAATGGATGGTTTCCCTGTATAATAACAACCTGAACGGGAATCTTA
 GCCGATGAAATGGGGCTTGGAAAGACCATACAGACCATTGCACTCATCACTTATCTGATGGAGCACAAAA
 GACTCAATGGCCCCCTATCTCATCATTGTTCCCTTTTCGACTCTATCTAACTGGACATATGAATTTGACAA
 ATGGGCTCCTTCTGTGGTGAAGATTTCTTACAAGGGTACTCCTGCCATGCGTCGCTCCCTTGTCCCCCAG
 CTACGGAGTGGCAAATTCAATGTCTCTTGACTACTTATGAGTATATTATAAAAGACAAGCACATTTCTTG
 CAAAGATTCGGTGGAAATACATGATAGTGGACGAAGGCCACCGAATGAAGAATCACCAGTGAAGCTGAC
 TCAGGTCTTGAACACTCACTATGTGGCCCCCAGAAGGATCCTCTTGACTGGGACCCCGCTGCAGAATAAG
 CTCCTTGAACCTCTGGGCCCTCCTCAACTTCTCCTCCCAACAATTTTAAAGAGCTGCAGCACATTTGAAC
 AATGGTTCAATGCTCCATTTGCCATGACTGGTGAAGGGTGGACTTAAATGAAGAAGAACTATATTTGAT
 CATCAGGCGTCTACATAAGGTGTTAAGACCATTTTTTACTAAGGAGACTGAAGAAAGAAAGTTGAATCCAG
 CTTCCCCGAAAAGTGAATATGTGATCAAGTGTGACATGTGAGCTCTGCAGAAGATTCTGTATCGCCATA
 TGCAAGCCAAGGGGATCCTTCTCACAGATGGTTCTGAGAAAGATAAGAAGGGGAAAAGGAGGTGCTAAGAC
 ACTTATGAACACTATTATGCAGTTGAGAAAAATCTGCAACCACCCATATATGTTTCAGCACATTGAGGAA
 TCCTTTTGCTGAACACCTAGGCTATTCAAATGGGGTCATCAATGGGGCTGAACGTATCGGGCCTCAGGGA
 AGTTTGAGCTGCTTGATCGTATTCTGCCAAAATTGAGAGCGACTAATCACCAGTGTCTGCTTTTCTGCCA
 GATGACATCTCTCATGACCATCATGGAGGATTATTTTGCTTTTCCGAACTTCTTTACCTACGCCTTGAT
 GGCACCACCAAGTCTGAAGATCGTGCTGCTTTGCTGAAGAAATTCAATGAACCTGGATCCAGTATTTCA
 TTTTCTTGCTGAGCACAAGAGCTGGTGGCCTGGGCTTAAATCTTCAGGCAGCTGATACAGTGGTCACTTT
 TGACAGCGACTGGAATCCTCATCAGGATCTGCAGGCCCAAGACCGAGCTCACCAGCATCGGGCAGCAGAAC
 GAGGTCCGGGTACTGAGGCTCTGTACCGTGAACAGCGTGGAGGAAAAGATCCTCGCGGCCGCAAAATACA
 AGCTGAACGTGGATCAGAAAGTGATCCAGGCGGGCATGTTTGACCAAAAGTCTTCAAGCCACGAGCGGAG
 GGCATTCCTGCAGGCCATCTTGGAGCATGAGGAGGAAAATGAGGAAGAAGATGAAGTACCGGACGATGAG
 ACTCTGAACCAAATGATTGCTCGACGAGAAGAAGAATTTGACCTTTTATGCGGATGGACATGGACCGGC
 GGAGGGAAGATGCCCCGAACCCGAAACCGAAGCCCCGTTTAAATGGAGGAGGATGAGCTGCCCTCCTGGAT
 CATTAAAGGATGACGCTGAAGTAGAAAGGCTCACCTGTGAAGAAGAGGAGGAGAAAATATTTGGGAGGGGG
 TCCCGCCAGCGCGGTGACGTGGACTACAGTGACGCCCTCACGGAGAAGCAGTGGCTAAGGGCCATCGAAG
 ACGGCAATTTGGAGGAATGGAAGAGGAAGTACGGCTTAAAGAGCGAAAAAGACGAAGAAATGTGGATAA
 AGATCCTGCAAAAGAAGATGTGGAAAAAGCTAAGAAGAGAAGAGGCCGCCCTCCCGCTGAGAAACTGTCA
 CCAAATCCCCCAAACCTGACAAAGCAGATGAACGCTATCATCGATACTGTGATAAACTACAAAGATAGGT
 GTAACGTGGAGAAGGTGCCAGTAATTTCTAGTTGGAAATAGAAGGAAACAGTTGAGGGCGACAGCTCAG
 TGAAGTCTTCATTAGTTACCTTCAAGGAAAGAATTACCAGAATACTATGAATTAATTAGGAAGCCAGTG
 GATTTCAAAAAAATAAAGGAAAGGATTCTGAATCATAAGTACCGGAGCCTAGGCGACCTGGAGAAGGATG
 TCATGCTTCTCTGTCAACCGCTCAGACGTTCAACCTGGAGGGATCCAGATCTATGAAGACTCCATCGT

```

CTTACAGTCAGTGTTTAAAGAGTGCCCGGCAGAAAATTGCCAAAGAGGAAGAGAGTGAGGATGAAAGCAAT
GAAGAGGAGGAAGAGGAAGATGAAGAAGAGTCAGAGTCCGAGGCCAAATCAGTCAAGGTGAAAATTAAGC
TCAATAAAAAAGATGACAAAGGCCGGGACAAAGGGAAAGGCAAGAAAAGGCCAAATCGAGGAAAAGCCAA
ACCTGTAGTGAGCGATTTTGACAGCGATGAGGAGCAGGATGAACGTGAACAGTCAGAAGGAAGTGGGACG
GATGATGAGTGATCAGTATGGACCTTTTTCTTGGTAGAACTGAATTCCTTCCCTCCCTGTCTCATTTCT
ACCCAGTGAGTTCATTTGTTCATATAGGCACTGGGTGTTTTCTATATCATCATCGTCTATAAACTAGCTTT
AGGATAGTGCCAGACAAACATATGATATCATGGTGTAAAAAACACACACATACACAAATATTTGTAACAT
ATTGTGACCAAATGGGCCTCAAAGATTCAGATTGAAACAAACAAAAAGCTTTTGATGGAAAAATATGTGGG
TGGATAGTATATTTCTATGGGTGGGTCTAATTTGGTAACGGTTTGATTGTGCCTGGTTTTATCACCTGTT
CAGATGAGAAGATTTTGTCTTTTGTAGCACTGATAACCAGGAGAAGCCATTAAAGCCACTGGTTATTT
TATTTTTTCATCAGGCAATTTTCGAGGTTTTATTTGTTTCGGTATTGTTTTTTTACACTGTGGTACATATA
AGCAACTTTAATAGGTGATAAATGTACAGTAGTTAGATTTTACCTGCATATACATTTTCCATTTTATGC
TCTATGATCTGAACAAAAGCTTTTTGAATTGTATAAGATTTATGTCTACTGTAAACATTGCTTAATTTT
TTGCTCTTGATTTAAAAAAAAGTTTTGTTGAAAGCGCTATTGAATATTGCAATCTATATAGTGTATTGGA
TGGCTTCTTTTGTACCCCTGATCTCTATGTTACCAATGTGTATCGTCTCTTCTCCCTAAAGTGACTT
AATCTTTGCTTTCTTTGCACAATGTCTTTGGTTGCAAGTCATAAGCCTGAGGCAAATAAAATTTCCAGTAA
TTTCGAAGAATGTGGTGTGGTGCTTTCCTAATAAAGAAATAATTTAGCTTGACAAAAAAAAAAAAAAAA

```

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2), transcript variant 2 (GenBank Accession No. NM_139045.3)

```

GCGTCTTCCGGCGCCCGCGGAGGAGGCGAGGGTGGGACGCTGGGCGGAGCCCGAGTTTAGGAAGAGGAGG
GGACGGCTGTCTCAATGAAGTCATATTCATAATCTAGTCCTCTCTCCCTCTGTTTCTGTACTCTGGGTG
ACTCAGAGAGGGAAGAGATTGAGCCAGCACACTCCTCGCGAGCAAGCATTACTCTACTGACTGGCAGAGA
CAGGAGAGGTAGATGTCCACGCCACAGACCCTGGTGGCATGCCCCACCCAGGGCCTTCGCCGGGGCCTG
GGCCTTCCCTGGGCCAATTCTTGGGCCTAGTCCAGGACCAGGACCATCCCCAGGTTCCGTCCACAGCAT
GATGGGGCCAAGTCTGGACCTCCAAGTGTCTCCATCCTATGCCGACGATGGGGTCCACAGACTTCCCA
CAGGAAGGCATGCATCAAATGCATAAGCCCATCGATGGTATACATGACAAGGGGATTGTAGAAGACATCC
ATTGTGGATCCATGAAGGGCACTGGTATGCGACCACCTCACCCAGGCATGGGCCCTCCCCAGAGTCCAAT
GGATCAACACAGCCAAGGTTATATGTCAACACACCCATCTCCATTAGGAGCCCCAGAGCACGTCTCCAGC
CCTATGTCTGGAGGAGGCCAACTCCACCTCAGATGCCACCAAGCCAGCCGGGGGCCCTCATCCAGGTG
ATCCGCAGGCCATGAGCCAGCCCAACAGAGGTCCCTCACCTTTCAGTCCTGTCCAGCTGCATCAGCTTCG
AGCTCAGATTTTAGCTTATAAAATGCTGGCCCGAGGCCAGCCCCCTCCCCGAAACGCTGCAGCTTGCAGTC
CAGGGGAAAAGGACGTTGCCTGGCTTGCAGCAACAACAGCAGCAGCAACAGCAGCAGCAGCAGCAGCAGC
AGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGC
GCCGGCCCTTGTTAAGTACAACAGACCATCTGGCCCGGGGCCGGAGCTGAGCGGCCCGAGCAGCAGCAG
AAGCTGCCGGTGCCCGCGCCCGGGCGGCCCTCGCCCGCGCCCCCGCAGCCGCGCAGCCGCCCGCGG
CCGCAGTGCCCGGGCCCTCAGTGCCCGCAGCCGGCCCCGGGGCAGCCCTCGCCCGTCTCCAGCTGCAGCA
GAAGCAGAGCCGCATCAGCCCCATCCAGAAACCGCAAGGCCTGGACCCCGTGGAAATTTCTGCAAGAGCGG
GAATACAGACTTCAGGCCCGCATAGCTCATAGGATACAAGAACTGGAAATCTGCCTGGCTCTTTGCCAC
CAGATTTAAGAACCAAAGCAACCGTGGAATAAAAGCACTTCGGTTACTCAATTTCCAGCGTCAGCTGAG
ACAGGAGGTGGTGGCCTGCATGCGCAGGGACACGACCCTGGAGACGGCTCTCAACTCCAAAGCATAACAA
CGGAGCAAGCGCCAGACTCTGAGAGAAGCTCGCATGACCGAGAAGCTGGAGAAGCAGCAGAAGATTGAGC
AGGAGAGGAAACGCCGTGAGAAACACCAGGAATACCTGAACAGTATTTTGCAACATGCAAAAGATTTTAA
GGAATATCATCGGTCTGTGGCCGGAAGATCCAGAAGCTCTCCAAAGCAGTGGCAACTTGGCATGCCAAC
ACTGAAAGAGAGCAGAAGAAGGAGACAGAGCGGATTGAAAAGGAGAGAATGCGGCGACTGATGGCTGAAG
ATGAGGAGGGTTATAGAAAATGATTGATCAAAAGAAAGACAGGCGTTTAGCTTACCTTTTGCAGCAGAC
CGATGAGTATGTAGCCAATCTGACCAATCTGGTTTGGGAGCACAAGCAAGCCAGGCAGCCAAAGAGAAAG
AAGAAGAGGAGGAGGAGGAAGAAGAAGGCTGAGGAGAATGCAGAGGGTGGGGAGTCTGCCCTGGGACCGG
ATGGAGAGCCCATAGATGAGAGCAGCCAGATGAGTGACCTCCCTGTCAAAGTGACTCACACAGAAACCGG
CAAGGTTCTGTTCCGACCAGAAGCACCCAAAGCAAGTCAGCTGGACGCCTGGCTGGAAATGAATCCTGGT
TATGAAGTTGCCCTAGATCTGACAGTGAAGAGAGTGATTCTGATTATGAGGAAGAGGATGAGGAAGAAG
AGTCCAGTAGGCAGGAAACCGAAGAGAAAATACTCCTGGATCCAAATAGCGAAGAAGTTTCTGAGAAGGA
TGCTAAGCAGATCATTGAGACAGCTAAGCAAGACGTGGATGATGAATACAGCATGCAGTACAGTGCCAGG
GGCTCCAGTCTACTACCCGTGGCTCATGCCATCTCGGAGAGGGTGGAGAAACAGTCTGCCCTCCTAA

```

```

TTAATGGGACCCTAAAGCATTACCAGCTCCAGGGCCTGGAATGGATGGTTTCCCTGTATAATAACAACCTT
GAACGGAATCTTAGCCGATGAAATGGGGCTTGGAAAGACCATACAGACCATTGCACTCATCACTTATCTG
ATGGAGCACAAAAGACTCAATGGCCCCCTATCTCATCATTGTTCCCTTTTCGACTCTATCTAACTGGACAT
ATGAATTTGACAAATGGGCTCCTTCTGTGGTGAAGATTTCTTACAAGGGTACTCCTGCCATGCGTCGCTC
CCTTGTCCCCCAGCTACGGAGTGGCAAATTCATGTCTCTTGACTACTTATGAGTATATTATAAAGAC
AAGCACATTCTTGCAAAGATTCCGGTGGAAATACATGATAGTGGACGAAGGCCACCGAATGAAGAATCACC
ACTGCAAGCTGACTCAGGTCTTGAACACTCACTATGTGGCCCCCAGAAGGATCCTCTTGACTGGGACCCCC
GCTGCAGAATAAGCTCCCTGAACTCTGGGCCCTCCTCAACTTCCTCCTCCCAACAATTTTTTAAGAGCTGC
AGCACATTTGAACAATGGTTCAATGCTCCATTTGCCATGACTGGTGAAAGGGTGGAATTAATGAAGAAG
AAACTATATTGATCATCAGGCGTCTACATAAGGTGTTAAGACCATTTTTACTAAGGAGACTGAAGAAAAG
AGTTGAATCCCAGCTTCCCGAAAAAGTGAATATGTGATCAAGTGTGACATGTGAGCTCTGCAGAAGATT
CTGTATCGCCATATGCAAGCCAAGGGGATCCTTCTCACAGATGGTTCTGAGAAAAGATAAGAAGGGGAAAG
GAGGTGCTAAGACACTTATGAACACTATTATGCAGTTGAGAAAAATCTGCAACCACCCATATATGTTTCA
GCATTTGAGGAATCCTTTGCTGAACACCTAGGCTATTCAAATGGGGTCATCAATGGGGCTGAACTGTAT
CGGGCCTCAGGGAAGTTTGAGCTGCTTGATCGTATTCTGCCAAAATTGAGAGCGACTAATCACCGAGTGC
TGCTTTTCTGCCAGATGACATCTCTCATGACCATCATGGAGGATTATTTTGTCTTTTCGGAACCTCCTTTA
CCTACGCCTTGATGGCACCACCAAGTCTGAAGATCGTGCTGCTTTGCTGAAGAAAATTCATGAACCTGGA
TCCCAGTATTTTCAATTTTCTTGCTGAGCACAAAGAGCTGGTGGCCTGGGCTTAAATCTTCAGGCAGCTGATA
CAGTGGTCATCTTTGACAGCGACTGGAATCCTCATCAGGATCTGCAGGCCCAAGACCGAGCTCACCGCAT
CGGGCAGCAGAACGAGGTCCGGGTACTGAGGCTCTGTACCGTGAACAGCGTGGAGGAAAAGATCCTCGCG
GCCGCAAAATACAAGCTGAACGTGGATCAGAAAGTGATCCAGGCGGGCATGTTTGACCAAAAGTCTTCAA
GCCACGAGCGGAGGGCATTCTGTCAGGCCATCTTGGAGCATGAGGAGGAAAATGAGGAAGAAGATGAAGT
ACCGGACGATGAGACTCTGAACCAAATGATTGCTCGACGAGAAGAAGAATTTGACCTTTTATGCGGATG
GACATGGACCGGCGGAGGGAAGATGCCCGGAACCCGAAACGGAAGCCCCGTTAATGGAGGAGGATGAGC
TGCCCTCCTGGATCATTAAGGATGACGCTGAAGTAGAAAGGCTCACCTGTGAAGAAGAGGAGGAGAAAAAT
ATTTGGGAGGGGGTCCCGCCAGCGCCGTGACGTGGACTACAGTGACGCCCTCACGGAGAAGCAGTGCGTA
AGGGCCATCGAAGACGGCAATTTGGAGGAAATGGAAGAGGAAGTACGGCTTAAGAAGCGAAAAAGACGAA
GAAATGTGGATAAAGATCCTGCAAAAGAAGATGTGGAAGAAAGCTAAGAAGAGAAGAGGGCCGCCCTCCCGC
TGAGAAACTGTCACCAAATCCCCCAAACCTGACAAAGCAGATGAACGCTATCATCGATACTGTGATAAAC
TACAAAGATAGTTTCAAGGCGACAGCTCAGTGAAGTCTTCATTCAGTTACCTTCAAGGAAAGAATTACCAG
AATACTATGAATTAATTAGGAAGCCAGTGGATTTCAAAAAAATAAAGGAAAGGATTCGTAATCATAAAGTA
CCGGAGCCTAGGCGACCTGGAGAAGGATGTCATGCTCTCTGTGCACAACGCTCAGACGTTCAACCTGGAG
GGATCCCAGATCTATGAAGACTCCATCGTCTTACAGTCAGTGTTTAAGAGTGCCCGGCAGAAAAATTGCCA
AAGAGGAAGAGAGTGAGGATGAAAGCAATGAAGAGGAGGAAGAGGAAGATGAAGAAGAGTCAGAGTCCGA
GGCAAAATCAGTCAAGGTGAAAATTAAGCTCAATAAAAAAGATGACAAAGGCCGGGACAAAGGGAAAGGC
AAGAAAAGGCCAAATCGAGGAAAAGCCAAACCTGTAGTGAGCGATTTTGACAGCGATGAGGAGCAGGATG
AACGTGAACAGTCAGAAGGAAGTGGGACGGATGATGAGTGATCAGTATGGACCTTTTTCTTGGTAGAAC
TGAATTCCTTCTCCCTGTCTCATTTCTACCCAGTGAGTTTCAATTTGTATATAGGCACTGGGTGTTTC
TATATCATCATCGTCTATAAACTAGCTTTAGGATAGTGCCAGACAAACATATGATATCATGGTGTAAGAA
ACACACACATACACAAATATTTGTAACATATTGTGACCAAATGGGCCTCAAAGATTCAGATTGAAACAAA
CAAAAAGCTTTTGATGGAAAATATGTGGGTGGATAGTATATTTCTATGGGTGGGTCTAATTTGGTAACGG
TTTGATTGTGCCTGGTTTTATCACCTGTTTCAAGATGAGAAGATTTTGTCTTTTGTAGCACTGATAACCAG
GAGAAGCCATTAAAAGCCACTGGTTATTTTTATTTTTATCATCAGGCAATTTTCGAGGTTTTTATTTGTTCCG
TATTGTTTTTTTACACTGTGGTACATATAAGCAACTTTAATAGGTGATAAATGTACAGTAGTTAGATTTT
ACCTGCATATACATTTTTTCCATTTTATGCTCTATGATCTGAACAAAAGCTTTTTGAATTGTATAAGATTT
ATGTCTACTGTAAACATTGCTTAATTTTTTTGCTCTTGATTTAAAAAAAAGTTTTGTTGAAAGCGCTATT
GAATATTGCAATCTATATAGTGTATTGGATGGCTTCTTTTGTCAACCTGATCTCCTATGTTACCAATGTG
TATCGTCTCCTTCTCCCTAAAGTGTACTTAATCTTTGCTTTCTTTGCACAATGTCTTTGGTTGCAAGTCA
TAAGCCTGAGGCAATAAAATTCAGTAATTTCAAGAATGTGGTGTGGTGCTTTCCTAATAAAGAAAT
AATTTAGCTTGACAAAAA

```

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2), transcript variant 4 (GenBank Accession No. NM_001289397.1)

GCGTCTTCCGGCGCCCGCGGAGGAGGCGAGGGTGGGACGCTGGGCGGAGCCCGAGTTTATAGGAAGAGGAGG
 GGACGGCTGTCATCAATGAAGTCATATTCATAATCTAGTCCTCTCTCCCTCTGTTTCTGTACTCTGGGTG
 ACTCAGAGAGGGAAGAGATTGAGCCAGCACACTCCTCGCGAGCAAGCATTACTCTACTGACTGGCAGAGA
 CAGGAGAGGTAGATGTCCACGCCACAGACCCTGGTGCGATGCCCCACCCAGGGCCTTCGCCGGGGCCTG
 GGCCTTCCCCTGGGCCAATTCTTGGGCCTAGTCCAGGACCAGGACCATCCCCAGGTTCGTCACAGCAT
 GATGGGGCCAAGTCCTGGACCTCCAAGTGTCTCCCATCCTATGCCGACGATGGGGTCCACAGACTTCCCA
 CAGGAAGGCATGCATCAAATGCATAAGCCCATCGATGGTATACATGACAAGGGGATTGTAGAAGACATCC
 ATTGTGGATCCATGAAGGGCACTGGTATGCGACCACCTCACCCAGGCATGGGCCCTCCCCAGAGTCCAAT
 GGATCAACACAGCCAAGGTTATATGTCACCACACCCATCTCCATTAGGAGCCCCAGAGCACGTCTCCAGC
 CCTATGTCTGGAGGAGGCCAACTCCACCTCAGATGCCACCAAGCCAGCCGGGGGCCCTCATCCAGGTG
 ATCCGCAGGCCATGAGCCAGCCCAACAGAGGTCCCTCACCTTTCAGTCTGTCCAGCTGCATCAGCTTCG
 AGCTCAGATTTTAGCTTATAAAATGCTGGCCCCGAGGCCAGCCCCCTCCCCGAAACGCTGCAGCTTGCAGTC
 CAGGGGAAAAGGACGTTGCTTGGCTTGCAGCAACAACAGCAGCAGCAACAGCAGCAGCAGCAGCAGCAGC
 AGCAGCAGCAGCAGCAGCAACAGCAGCCGAGCAGCAGCCGCCGCAACCACAGACGAGCAACAACAGCA
 GCCGGCCCTTGTTAACTACAACAGACCATCTGGCCCCGGGGCCGGAGCTGAGCGGCCCGAGCACCCCGCAG
 AAGCTGCCGGTGGCCGCGCCCGGGCGGCCCTCGCCCCGCGCCCCCGCAGCCGCGCAGCCGCCCGCGG
 CCGCAGTGCCCGGGCCCTCAGTGCCGCGAGCCGGCCCCGGGGCAGCCCTCGCCCGTCCCTCCAGCTGCAGCA
 GAAGCAGAGCCGCATCAGCCCCATCCAGAAACCGCAAGGCCTGGACCCCGTGGAAATTTCTGCAAGAGCGG
 GAATACAGACTTCAGGCCCCGATAGCTCATAGGATACAAGAACTGGAAATCTGCCTGGCTCTTTGCCAC
 CAGATTTAAGAACCAGCAACCGTGGAACATAAAGCACTTCGGTTACTCAATTTCCAGCGTCAGCTGAG
 ACAGGAGGTGGTGGCCTGCATGCGCAGGGACACGACCCTGGAGACGGCTCTCAACTCCAAAGCATACAAA
 CGGAGCAAGCGCCAGACTCTGAGAGAAGCTCGCATGACCGAGAAGCTGGAGAAGCAGCAGAAGATTGAGC
 AGGAGAGGAAACGCCGTGAGAAACACCAGGAATACCTGAACAGTATTTTGCAACATGCAAAAAGATTTTAA
 GGAATATCATCGGTCTGTGGCCGGAAGATCCAGAAGCTCTCCAAAGCAGTGGCAACTTGGCATGCCAAC
 ACTGAAAGAGAGCAGAAGAAGGAGACAGAGCGGATTGAAAAGGAGAGAATGCGGCGACTGATGGCTGAAG
 ATGAGGAGGGTTATAGAAAATGATTGATCAAAAGAAAGACAGGCGTTTAGCTTACCTTTTGCAGCAGAC
 CGATGAGTATGTAGCCAATCTGACCAATCTGGTTTGGGAGCACAAGCAAGCCAGGCAGCCAAAAGAGAAG
 AAGAAGAGGAGGAGGAGGAAGAAGAAGGCTGAGGAGAATGCAGAGGGTGGGGAGTCTGCCCTGGGACCGG
 ATGGAGAGCCCATAGATGAGAGCAGCCAGATGAGTGACCTCCCTGTCAAAGTGACTCACACAGAAACCGG
 CAAGGTTCTGTTCCGACCAGAAGCACCCAAAGCAAGTCAGCTGGACGCCCTGGCTGGAAATGAATCCTGGT
 TATGAAGTTGCCCTAGATCTGACAGTGAAGAGAGTGATTCTGATTATGAGGAAGAGGATGAGGAAGAAG
 AGTCCAGTAGGCAGGAACCGAAGAGAAAATACTCCTGGATCCAAATAGCGAAGAAGTTTCTGAGAAGGA
 TGCTAAGCAGATCATTGAGACAGCTAAGCAAGACGTGGATGATGAATACAGCATGCAGTACAGTGCCAGG
 GGCTCCCACTCTACTACACCGTGGCTCATGCCATCTCGGAGAGGGTGGAGAAACAGTCTGCCCTCCTAA
 TTAATGGGACCCTAAAGCATTACCAGCTCCAGGGCCTGGAATGGATGGTTTCCCTGTATAATAACAACCTT
 GAACGGAATCTTAGCCGATGAAATGGGGCTTGGAAAGACCATAACAGACCATTGCACTCATCACTTATCTG
 ATGGAGCACAAAAGACTCAATGGGCCCTATCTCATCATTGTTCCCTTTTCGACTCTATCTAACTGGACAT
 ATGAATTTGACAAATGGGCTCCTTCTGTGGTGAAGATTTCTTACAAGGGTACTCCTGCCATGCGTCGCTC
 CTTGTCCCCAGCTACGGAGTGGCAAATTCATGTCTCTTGACTACTTATGAGTATATTATAAAAGAC
 AAGCACATTCTTGCAAAGATTCCGGTGGAAATACATGATAGTGGACGAAGGCCACCGAATGAAGAATCACC
 ACTGCAAGCTGACTCAGGTGGACTTAAATGAAGAAGAACTATATTGATCATCAGGCGTCTACATAAGGT
 GTTAAGACCATTTTTACTAAGGAGACTGAAGAAAGAAGTTGAATCCAGCTTCCCGAAAAAGTGGAATAT
 GTGATCAAGTGTGACATGTGAGCTCTGCAGAAGATTCTGTATCGCCATATGCAAGCCAAAGGGGATCCTTC
 TCACAGATGGTTCTGAGAAAGATAAGAAGGGGAAAGGAGGTGCTAAGACACTTATGAACACTATTATGCA
 GTTGAGAAAAATCTGCAACCACCCATATATGTTTCAGCACATTGAGGAATCCTTTGCTGAACACCTAGGC
 TATTCAAATGGGGTCATCAATGGGGCTGAAGTGTATCGGGCCTCAGGGAAGTTTGGAGCTGCTTGATCGTA
 TTCTGCCAAAATTGAGAGCGACTAATCACCGAGTGCTGCTTTTCTGCCAGATGACATCTCTCATGACCAT
 CATGGAGGATTATTTTGCTTTTCGGAACCTCCTTTACCTACGCCTTGATGGCACCACCAAGTCTGAAGAT
 CGTGCTGCTTTGCTGAAGAAATTCATGAACCTGGATCCCAGTATTTTCAATTTCTTGCTGAGCACAAGAG
 CTGGTGGCCTGGGCTTAAATCTTCAGGCAGCTGATACAGTGGTCACTCTTTGACAGCGACTGGAATCCTCA
 TCAGGATCTGCAGGCCCAAGACCGAGCTCACCGCATCGGGCAGCAGAACGAGGTCCGGGTACTGAGGCTC
 TGTACCGTGAACAGCGTGGAGGAAAAGATCCTCGCGGCCGCAAAATACAAGCTGAACGTGGATCAGAAAG
 TGATCCAGGCGGGCATGTTTGACCAAAAGTCTTCAAGCCACGAGCGGAGGGCATTCTGCAGGCCATCTT
 GGAGCATGAGGAGGAAAATGAGGAAGAAGATGAAGTACCGGACGATGAGACTCTGAACCAATGATTGCT
 CGACGAGAAGAAGAATTTGACCTTTTTATGCGGATGGACATGGACCGGCGGAGGGAAGATGCCCGGAACC
 CGAAACGGAAGCCCCGTTTAAATGGAGGAGGATGAGCTGCCCTCCTGGATCATTAAGGATGACGCTGAAGT

```

AGAAAGGCTCACCTGTGAAGAAGAGGAGGAGAAAATATTTGGGAGGGGGTCCCGCCAGCGCCGTGACGTG
GACTACAGTGACGCCCTCACGGAGAAGCAGTGGCTAAGGGCCATCGAAGACGGCAATTTGGAGGAAATGG
AAGAGGAAGTACGGCTTAAGAAGCGAAAAAGACGAAGAAATGTGGATAAAGATCCTGCAAAAAGAAGATGT
GGAAAAAGCTAAGAAGAGAAGAGGCCGCCCTCCCGCTGAGAACTGTCAACAAATCCCCCAAACCTGACA
AAGCAGATGAACGCTATCATCGATACTGTGATAAACTACAAAGATAGTTTCAAGGCGACAGCTCAGTGAAG
TCTTCATTTCAGTTACCTTCAAGGAAAGAATTACCAGAATACTATGAATTAATTAGGAAGCCAGTGGATTT
CAAAAAAATAAAGGAAAGGATTCGTAATCATAAGTACCGGAGCCTAGGCGACCTGGAGAAGGATGTCATG
CTTCTCTGTGCACAACGCTCAGACGTTCAACCTGGAGGGATCCCAGATCTATGAAGACTCCATCGTCTTAC
AGTCAGTGTTTAAGAGTGCCCGGCAGAAAATTGCCAAAGAGGAAGAGAGTGAGGATGAAAACAAATGAAGA
GGAGGAAGAGGAAGATGAAGAAGAGTCAGAGTCCGAGGCCAAATCAGTCAAGGTGAAAATTAAGCTCAAT
AAAAAAGATGACAAAGGCCGGGACAAAGGGAAAGGCAAGAAAAGGCCAAATCGAGGAAAAGCCAAACCTG
TAGTGAGCGATTTTGACAGCGATGAGGAGCAGGATGAACGTGAACAGTCAGAAGGAAGTGGGACGGATGA
TGAGTGATCAGTATGGACCTTTTTCTTGGTAGAACTGAATTCCTTCTCCCTGTCTCATTTCTACCCA
GTGAGTTTCATTTGTATATAGGCACTGGGTTGTTTCTATATCATCATCGTCTATAAACTAGCTTTAGGAT
AGTGCCAGACAAACATATGATATCATGGTGTAACCAACACACACATACACAAATATTTGTAACATATTGT
GACCAAATGGGCCTCAAAGATTGAGATTGAAACAAACAAAAAGCTTTTGATGGAAAATATGTGGGTGGAT
AGTATATTTCTATGGGTGGGTCTAATTTGGTAACGGTTTGATTGTGCCTGGTTTTATCACCTGTTTCAGAT
GAGAAGATTTTGTCTTTGTAGCACTGATAACCAGGAGAAGCCATTAAAAGCCACTGGTTATTTTATTT
TTCATCAGGCAATTTTCGAGGTTTTTATTTGTTTCGGTATTGTTTTTTTACACTGTGGTACATATAAGCAA
CTTTAATAGGTGATAAATGTACAGTAGTTAGATTTTACCTGCATATACATTTTCCATTTTATGCTCTAT
GATCTGAACAAAAGCTTTTTGAATTTGTATAAGATTTATGTCTACTGTAAACATTGCTTAATTTTTTTGCT
CTTGATTTAAAAAAAGTTTTGTTGAAAGCGCTATTGAATATTGCAATCTATATAGTGTATTGGATGGCT
TCTTTTGTCAACCTGATCTCCTATGTTACCAATGTGTATCGTCTCCTTCTCCCTAAAGTGTACTTAATCT
TTGCTTTCTTTGCACAATGTCTTTGGTTGCAAGTCATAAGCCTGAGGCAAATAAAATTCAGTAATTTTCG
AAGAATGTGGTGTGGTGCTTTCCTAATAAAGAAATAATTTAGCTTGACAAAAA

```

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2), transcript variant 5 (GenBank Accession No. NM_001289398.1)

```

CTTGGAGAGGCGGAGGTGGAAACGATGCGCAGGAGTTGGCTTGGGGCTTTTTGTTTGGTGTCCCTGTTT
ACCTATTCATAATCATGGATCCCCCTCTGCTTTGTGATACTGTGAACCACGCATAACAGCAATTCCTTACA
CCACCGGGTTGAGAAGAAGGCGCCTGAGGCTGACTTCTGGACCTGCCGTACGCAGTAAAGATGTGGTT
GGCCATCGAAGACGGCAATTTGGAGGAAATGGAAGAGGAAGTACGGCTTAAGAAGCGAAAAAGACGAAGA
AATGTGGATAAAGATCCTGCAAAAGAAGATGTGGAAAAAGCTAAGAAGAGAAGAGGCCGCCCTCCCGCTG
AGAACTGTCAACAAATCCCCCAAACCTGACAAAGCAGATGAACGCTATCATCGATACTGTGATAAACTA
CAAAGATAGTTTCAAGGCGACAGCTCAGTGAAGTCTTCATTTCAGTTACCTTCAAGGAAAAGATTAACCAGAA
TACTATGAATTAATTAGGAAGCCAGTGGATTTCAAAAAAATAAAGGAAAGGATTCGTAATCATAAGTACC
GGAGCCTAGGCGACCTGGAGAAGGATGTCATGCTTCTCTGTGCACAACGCTCAGACGTTCAACCTGGAGGG
ATCCCAGATCTATGAAGACTCCATCGTCTTACAGTCAGTGTTTAAGAGTGCCCGGCAGAAAATTGCCAAA
GAGGAAGAGAGTGAGGATGAAAGCAATGAAGAGGAGGAAGAGGAAGATGAAGAAGAGTCAGAGTCCGAGG
CAAAATCAGTCAAGGTGAAAATTAAGCTCAATAAAAAAGATGACAAAGGCCGGGACAAAGGGAAAGGCAA
GAAAAGGCCAAATCGAGGAAAAGCCAAACCTGTAGTGAGCGATTTTGACAGCGATGAGGAGCAGGATGAA
CGTGAACAGTCAGAAGGAAGTGGGACGGATGATGAGTGATCAGTATGGACCTTTTTCTTGGTAGAACTG
AATTCCTTCTCCCTGTCTCATTTCTACCCAGTGAGTTTCATTTGTTCATATAGGCACTGGGTTGTTTCTA
TATCATCATCGTCTATAAACTAGCTTTAGGATAGTGCCAGACAAACATATGATATCATGGTGTAACCAAC
ACACACATACACAAATATTTGTAACATATTGTGACCAAATGGGCCTCAAAGATTGAGATTGAAACAAACA
AAAAGCTTTTGATGGAAAATATGTGGGTGGATAGTATATTTCTATGGGTGGGTCTAATTTGGTAACGGTT
TGATTGTGCCTGGTTTTATCACCTGTTTCAGATGAGAAGATTTTGTCTTTGTAGCACTGATAACCAGGA
GAAGCCATTAAAAGCCACTGGTTATTTTATTTTTCATCAGGCAATTTTCGAGGTTTTTATTTGTTCGGTA
TTGTTTTTTTACACTGTGGTACATATAAGCAACTTAATAGGTGATAAATGTACAGTAGTTAGATTTTAC
CTGCATATACATTTTCCATTTTATGCTCTATGATCTGAACAAAAGCTTTTGAATTTGTATAAGATTTAT
GTCTACTGTAAACATTGCTTAATTTTTTTGCTCTTGATTTAAAAAAAGTTTTGTTGAAAGCGCTATTGA
ATATTGCAATCTATATAGTGTATTGGATGGCTTCTTTTGTCAACCTGATCTCCTATGTTACCAATGTGTA

```

Protein sequence of human probable global transcription activator SNF2L2 isoform a (GenBank Accession No. NP_001276325.1)

Protein sequence of human probable global transcription activator SNF2L2 isoform b (GenBank Accession No. NP_620614.2)

MSTPTDPGAMPHPGSPGPGSPGPGILGSPGPGSPGSVHSMGPGSPGPPSVSHPMPTMGSTDFPQOEG
HQMHPKIDGIDHDKGIVEDIHCGSMKGTGMRPPHPGMPGPPQSPMDQHSQGYMSPHPSPLGAPEHVSSPMMSG
GGPTFPQMPPSQPGALIPGDPQAMSQPNRGSPFSPVQLHLQRAQILAYKMLARGQPLPETLQLAVQGKR
TLPGLQQQQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPOTQQQQQFALVNYNRPSPGPGPELSGPSTPQKLP
PAPGGRPSPAPPAAAQPPAAAVPGPSVPQAPGQSPSVLQLQOKQSRIPIQKPQGLDPVEILQEREYRL
QARIAHRIELENLPGSLPPDLRTKATVELKALRLNFORQLRQEVVACMRDRTTLETALNSKAYKRSKR
QTLREARMTEKLEKQQKIEQERKRRQKHQEYLNILQHAKDFKEYHRSVAGKIQKLSKAVATWHANTERE
QKKETERIEKERMRLMAEDEEGYRKILIDQKKDRRLAYLLQQTDEYVANLTNLVWEHKQAQAAKEKKKKRR
RRKKKAEEENAEGGESALGPDGEPIDESSQMSDLPVKVTHTTETGKVLFGPEAPKASQLDAWLEMNPGYEVA
PRSDSEESDSDYEEEEEEEESSRQETEEKILLDPNSEEVSEKDAKQIIETAKQDVDDEYSMQYSARGSQS
YYTVAHAI SERVEKQSALLINGTLKHYQLQGLEWMVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHK
RLNGFYLIIVPLSTLSNWTYEFDKWAPSVVKISYKGTAMRRSLVPQLRSGKFENVLLTTYEYIIKDKHIL
AKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRIILLTGTPLOKNLPELWALLNFLPTIFKSCSTFE
QWFNAPFAMTGERVDLNEEETILIRRLHKVLRPFLLRRLKKEVESQLPEKVEYVIKCDMSALQKILYRH
MQAKGILLTDGSEKDKKGKGGAATLMNTIMQLRKICNHPYMFQHIIESFAEHLGYSNGVINGAELYRASG
KFELLDRIILPKLRATNHRVLLFCQMTSLMTIMEDYFAFRNFLYLRDGTCTKSEDRALLKKFNEPQSYF
IFLLSTRAGGLGNLQAADTVVIFDSWDNPHQDLQAQDRAHRIQQNCEVTVRLRCLTVNSVEEKILAAQY
KLNVDQKVIQAGMFLQKSSSHERRAFLQAILHEEENEEDEEVPDDETINQMILARTEESFEFLFMRMDMDR
RREDARNPKRKPRLMEEDELPWIIKDDAEVERLTCEEEEEEKIFGRGSRORRDVDYSDALTEKOWLRAIE

DGNLEEMEEEEVRLKKRKRNRNVDKDKPAKEDVEKAKKRRGRPPAEKLSNP PPKLTQMNAIIDTVINYKDS
SGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCHNAQT FNLEGSQI
YEDSIVLQSVFKSARQKIAKEEESEDESNEEEEEEEDEE ESESEAKSVKVKIKLNKKDDKGRDKGKGRP
NRGKAKPVVSDFDSDEEQDEREQSESGTDDE

**Protein sequence of human probable global transcription activator SNF2L2 isoform c
(GenBank Accession No. NP_001276326.1)**

MSTPTDPGAMPHPGSPGPGSPGPILGSPSPGPGSPG SVHSMGSPGPPSVSHPMPTMGSTDFPQEGM
HQMHPIDGIHDKGIVEDIHCGSMKGTGMRPPHPGMGPPQSPMDQHSQGYMSPHPSP LGAPEHVSSPSMSG
GGPTFPQMPPSQPGALIPGDPQAMSQPNRGSPSPFSPVQLHQLRAQILAYKMLARGQPLPETLQLAVQGR
TLPGLQCCCCCCCCCCCCCCCCCCCCCCCCCCCCPQQPFPQPOTCCCCQPALVNYNRPSPGPGFELSGPSTPQKLPV
PAPGGRPSAPPAAAPPAAPVPGPSVPQAPGQPSVQLQKQSRISPIQKPQGLDPVEILQEREYRL
QARIAHRIQELLENLPGSLPDLRTKATVELKALRLNLFQRQLRQEVVACMRDRTTLETALNSKAYKRSKR
QTLREARMTEKLEKQKQIEQERKRRQKHQEYLSILQHAKDFKEYHRSVAGKIQKLSKAVATWHANTERE
QKKETERIEKERMRLMAEDEEGYRKLIDQKKDRRLAYLLQQTDEYVANLTNLVWEHKQAQAAKEKKRRR
RRKKKAENAEGGESALGPDGEPIDESSQMSDLPVKVTHTTETGKVLFGPEAPKASQLDAWLEMNPGYEVA
PRSDSEESDSDYEEEEDEEESSRQETEEKILLDPNSEEVSEKDAKQIIETAKQDVDDDEYSMQYSARGSQS
YYTVAHAISERVEKQSALLINGTLKHYQLQGLEWMVSLYNNMLNGILADEMGLGKTIQTIALITYLMEHK
RLNGPYLIIVPLSTLSNWTYEFDKWAPSVVKISYKGT PAMRRSLVPQLRSGKFNVLLTTYEYIIKDKHIL
AKIRWKYMIVDEGHRMKNHCKLTQVDLNEEETILIIIRRLHKVLRPFLRLRLKKEVESQLPEKVEYVIK
DMSALQKILYRHMQAAGILLTDGSEKDKKGGGAKTLMNTIMQLRKICNHPYMFQHIIEESFAEHLGYSNG
VINGAELYRASGKFELLDRIPLKLRATNHRVLLFCQMTSLMTIMEDYFAFRNFLYLRLDGTTKSEDRAAL
LKKFNEPGSQYFIFLLSTRAGGLGLNLQAADTVVIFDS DWNPHQDLQAQDRAHRIQQQNEVRVLRRLCTVN
SVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAIL EHEEEENEEDEVPDDETINQMIARREE
EFDLFMRMDMDRRREDARNPKRKPRLMEEDELPSWI I KDDAEVERLTCEEEEEEKI FGRGSRQRRD VDYSD
ALTEKQWLRAIEDGNLEEMEEEEVRLKKRKRNRNVDKDKPAKEDVEKAKKRRGRPPAEKLSNP PPKLTQMN
AIIDTVINYKDS SGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCH
NAQT FNLEGSQIYEDSIVLQSVFKSARQKIAKEEESEDESNEEEEEEEDEE ESESEAKSVKVKIKLNKKDD
KGRDKGKGRPNRGKAKPVVSDFDSDEEQDEREQSESGTDDE

**Protein sequence of human probable global transcription activator SNF2L2 isoform d
(GenBank Accession No. NP_001276327.1)**

MWLAIEDGNLEEMEEEEVRLKKRKRNRNVDKDKPAKEDVEKAKKRRGRPPAEKLSNP PPKLTQMNAIIDTV
INYKDS SGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCHNAQT FN
LEGSQIYEDSIVLQSVFKSARQKIAKEEESEDESNEEEEEEEDEE ESESEAKSVKVKIKLNKKDDKGRDK
GKGRPNRGKAKPVVSDFDSDEEQDEREQSESGTDDE

SMARCA4

**mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator
of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 1 (GenBank
Accession No. NM_001128849.1)**

GGCGGGGGAGGCGCGCGGAAGTCGACGGCGCGCGGCGGCTCCTGCAGGAGGCCACTGTCTGCAGCTCCCGT
GAAGATGTCCACTCCAGACCCACCCCTGGGCGGAAGTCCTCGGCCAGGTCTCTCCCCGGGCGCCCTGGCCCT
TCCCCTGGAGCCATGCTGGGCCCTAGCCCGGCTCCCTCGCGGGGCTCCGCCACAGCATGATGGGGCCCA
GCCCAGGGCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCTGGAGGGTACCCTCAGGACAACAT
GCACCAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCGGACGACCCGCGCTACAACCAG

ATGAAAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGGACCAGC
 ACTCCCAAGGTTACCCCTCGCCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCCAGCCAGTGGCCCC
 GTCTTCGGGGCCCCAGATGTCTTCGGGGCCAGGAGGTGCCCGCTGGATGGTGTGACCCCCAGGCCTTG
 GGGCAGCAGAACCGGGGGCCCAACCCCATTTAACCAGAACCAGCTGCACCAGCTCAGAGCTCAGATCATGG
 CCTACAAGATGCTGGCCAGGGGGGAGCCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCC
 GATGCCCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCCF
 GGCCCTGGCCCTGGCCCCGGCCCCGGGTCCCCGGCCCCGGCACCTCCAAATTACAGCAGGCCTCATGGTATGG
 GAGGGCCCCAACATGCCTCCCCCAGGACCCCTCGGGCGTGCCCCCGGGATGCCAGGCCAGCCTCCTGGAGG
 GCCTCCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCACGAGCACCCCTCAGAAGCTG
 ATTCCCCCGCAGCCAACGGGCGGCCCTTCCCCCGCGCCCCCTGCCGTCCACCCGCGCCTCGCCCCGTGA
 TGCCACCGCAGACCCAGTCCCCCGGGCAGCCGGCCCCAGCCCCGCGCCCATGGTGCCACTGCACCAGAAGCA
 GAGCCGCATCACCCCATCCAGAAGCCGCGGGGCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTAC
 AGGCTGCAGGCTCGCATCGCACACCGAATTGAGGAACCTGAAAACCTTCCCGGGTCCCTGGCCGGGGATT
 TGCGAACCAGAAGCGACCATTTAGCTCAAGGCCCTCAGGCTGCTGAACTTCAGAGGCAGCTGCGCCAGGA
 GGTGGTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAGCGCAGC
 AAGCGCCAGTCCCTGCGCGAGGCCCCGCATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGCAGGAGC
 GCAAGCGCCGGCAGAAGCACCAGGAATACCTCAATAGCATTTCTCCAGCATGCCAAGGATTTCAAGGAATA
 TCACAGATCCGTACAGGCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAG
 CGGGAGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGG
 AGGGGTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCTGGCCTACCTCTTGACGACAGACAGACGA
 GTACGTGGCTAACCTCACGGAGCTGGTGGCGCAGCACAAAGGCTGCCAGGTGCGCAAGGAGAAAAAGAAG
 AAAAAGAAAAAGAAGAAGGCAGAAAATGCAGAAGGACAGACGCCCTGCCATTGGGCGCGATGGCGAGCCTC
 TGGACGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCCTCAC
 AGGCACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCT
 CCGAGGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGCCGCGAGG
 CAGCACAGCCTCCCACCCTGCCCGTGGAGGAGAAGAAGAAGATTTCCAGATCCAGACAGCGATGACGTCTC
 TGAGGTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTGATGATGAATATGGCGTGTCCCAG
 GCCCTTGACAGTGGCCTGCAGTCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGT
 CAGCGCTTATGGTCAATGGTGTCTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCCCTGTA
 CAACAACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGAAGACCATCCAGACCATCGCGCTC
 ATCAGCTACCTCATGGAGCACAAACGCATCAATGGGCCCTTCTCATCATCGTGCCTCTCTCAACGCTGT
 CCAACTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGC
 AGCAAGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTAC
 ATCATCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCAACCGCA
 TGAAGAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACATATGTGGCACCCCGCCGCTGCTGCT
 GACGGGCACACCGCTGCAGAACAAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCTGCTGCCACCATC
 TTCAAGAGCTGCAGCACCTTCGAGCAGTGGTTTAAACGCACCCCTTTGCCATGACCGGGGAAAAGGTGGACC
 TGAATGAGGAGGAAACCATTCTCATCATCCGGCGTCTCCACAAAGTGTGCGGCCCTTCTTGCTCCGACG
 ACTCAAGAAGGAAGTGCAGGCCCCAGTTGCCCGAAAAGGTGGAGTACGTATCAAGTGCGACATGTCTGCG
 CTGCAGCGAGTGTCTTACCGCCACATGCAGGCCAAGGGCGTGTGCTGACTGATGGCTCCGAGAAGGACA
 AGAAGGGCAAAGGGCGGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCC
 CTACATGTTCCAGCACATCGAGGAGTCCCTTTCCGAGCACTTGGGGTTCACTGGCGGCATTTGTTCAAGGG
 CTGGACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCCAAACCTCCGAGCAACCA
 ACCACAAAGTGTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCG
 CGGCTTTAAATACCTCAGGCTTGATGGAACCACGAAGGCGGAGGACCGGGGCATGCTGCTGAAAACCTTC
 AACGAGCCCGGCTCTGAGTACTTCATCTTCTGCTCAGCACCCGGGCTGGGGGGCTCGGCCTGAACCTCC
 AGTCGGCAGACACTGTGATCATTTTTTGACAGCGACTGGAATCCTCACCAGGACCTGCAAGCGCAGSACCG
 AGCCACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCCTCTGCACCGTCAACAGCGTGGAGGAG
 AAGATCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGCGATGTTGACCC
 AGAAGTCTTCCAGCCATGAGCGGCGCGCCTTCTGACAGGCCATCCTGGAGCACGAGGAGCAGGATGAGAG
 CAGACACTGCAGCACGGGCAGCGGCAGTGCCAGCTTCCGCCACACTGCCCTCCGCCAGCGGGCGTCAAC
 CCCGACTTGGAGGAGCCACCTCTAAAGGAGGAAGACGAGGTGCCCGACGACGAGACCGTCAACCAGATGA
 TCGCCCCGACAGGAGGAGTTTGATCTGTTTCATGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCG
 CAACCCCAAGCGGAAGCGCGCCTCATGGAGGAGGACGAGCTCCCTCGTGGATCATCAAGGACGACGCG
 GAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAGGAGAAGATGTTGCGCGTGGCTCCCGCCACCGCAAGG
 AGGTGGACTACAGCGACTCACTGACGGAGAAGCAGTGGCTCAAGAAAATTACAGGAAAAGATATCCATGA

CACAGCCAGCAGTGTGGCACGTGGGCTACAATTCCAGCGTGGCCTTCAGTTCTGCACACGTGCGTCAAAG
 GCCATCGAGGAGGGGACGCTGGAGGAGATCGAAGAGGAGGTCCGGCAGAAGAAATCATCACGGAAGCGCA
 AGCGAGACAGCGACGCCGGCTCCTCCACCCCGACCACCAGCACCCGAGCCGCGACAAGGACGACGAGAG
 CAAGAAGCAGAAGAAGCGCGGGCGGGCGCCTGCCGAGAACTCTCCCTAACCACCCAACTCACCAG
 AAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGCAGTGGACGTGAGCTCAGCGAGG
 TCTTCATCCAGCTGCCCTCGCGAAAGGAGCTGCCCGAGTACTACGAGCTCATCCGCAAGCCCGTGGACTT
 CAAGAAGATAAAGGAGCGCATTCGCAACCACAAGTACCGCAGCCTCAACGACCTAGAGAAGGACGTGATG
 CTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTATGAAGACTCCATCGTCTTGC
 AGTCGGTCTTCACCAGCGTGGCGCAGAAAATCGAGAAGGAGGATGACAGTGAAGGCGAGGAGAGTGAGGA
 GGAGGAAGAGGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCAAAGTGAAGATCAAGCTTGGC
 CGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGCCGGCGGCGGCGAGCCGAGGGTCCCGAGCCAAGC
 CGGTCTGAGTGACGATGACAGTGAGGAGGAACAAGAGGAGGACCGCTCAGGAAGTGGCAGCGAAGAAGA
 CTGAGCCCCGACATTCCAGTCTCGACCCCGAGCCCCCTCGTTCCAGAGCTGAGATGGCATAGGCCCTTAGCA
 GTACCGGGTAGCAGAGATGTAGTTTCAGACTTGGAGTAAACTGTATAAACAAGAAATCTTCCATATT
 TATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCTGGCATCAGTAGCATCTGTAAACAGC
 ATTAAGTGTCTTAAAGAGAGAGAGAGAGAATTCCGAATTGGGGAAACACACGATACCTGTTTTTCTTTTCC
 GTTGCTGGCAGTACTGTTGCGCCGAGTTTGGAGTCACTGTAGTTAAGTGTGGATGCGTGCACCG
 TCCACTCCTCCTACTGTATTTTATTGGACAGGTGAGACTCGCCGGGGGGCCCGGCGAGGGGTATGTAGTGT
 CACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCCAAAAA

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator
 of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 2 (GenBank
 Accession No. NM_001128844.1)

GGAGAGGCCCGCCGGTGTGAGGGGGAGGGGAGCCGGCGAGCGCGCGCAGCGGGGGCGCGGGTGGCG
 CGCGTGTGTGAAGGGGGGGCGGTGGCCGAGGCGGGCGGGCGCGCGCGAGGCTTCCCTCGTTTGGC
 GCGCGCGCGCGCTTCTTTGTTTCGTGAAGAGAAGCGAGACGCCATTCTGCCCCGGCCCCGCGCGGAGG
 GCGGGGGAGCGCGGGAAGTCGACGCGCGCGCGGCTCCTGCGTCTCGCCCTTTTGGCCAGGCTAGAG
 TGCAGTGGTGGCGGTGATGTTTCACTGCGCCCTCAACCTCCTGGACTCAGCAGGAGGCCACTGCTGCGAGC
 TCCCGTGAAGATGTCCACTCCAGACCCACCCCTGGGCGGAACCTCCTCGGCCAGGTCCCTTCCCGGGCCCT
 GGCCCTTCCCTGGAGCCATGCTGGGCCCTAGCCCGGTCCCTCGCCGGGCTCCGCCACAGCATGATGG
 GGCCAGCCAGGGCGGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCTGGAGGGTACCCTCAGGA
 CAACATGCACCAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCGGACGACCCGCGCTAC
 AACCAGATGAAAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGG
 ACCAGCACTCCCAAGGTTACCCCTCGCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCAGCCAG
 TGGCCCGTCTTGGGGCCCCAGATGTCTTCCGGGCCAGGAGGTGCCCCGCTGGATGGTGTGACCCCCAG
 GCCTTGGGGCAGCAGAACCGGGGCCAACCCCATTTAACAGAACCAGCTGCACCAGCTCAGAGCTCAGA
 TCATGGCCTACAAGATGCTGGCCAGGGGGCAGCCCTCCCCGACCACCTGCAGATGGCGGTGCGAGGCCAA
 GCGGCCGATGCCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCTCGGTGTCCGCAACAGGACCC
 GGCCCTGGCCCTGGCCCTGGCCCCGGCCCGGTCCCGGCCCGGCACCTCCAAATTACAGCAGGCCTCATG
 GTATGGGAGGGCCCAACATGCCTCCCCAGGACCTCGGGCGTGCCCCCGGGATGCCAGGCCAGCCTCC
 TGGAGGGCCTCCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCACGAGCACCCCTCAG
 AAGCTGATTCCCCCGCAGCCAACGGGCGGCCCTTCCCCCGCGCCCCCTGCCGTCCCACCCGCGCCTCGC
 CCGTGATGCCACCGCAGACCCAGTCCCCCGGGCAGCCGGGCCAGCCCGCGCCCATGGTGCCTGACCA
 GAAGCAGAGCCGCATACCCCCATCCAGAAGCCGCGGGGCTCGACCCTGTGGAGATCCTGCAGGAGCGC
 GAGTACAGGCTGCAGGCTCGCATCGCACACCGAATTGAGAACTTGAAAACCTTCCCGGGTCCCTGGCCG
 GGGATTTGCGAACCAAGCGACCATTGAGCTCAAGGCCCTCAGGCTGCTGAACTTCCAGAGGCAGCTGCG
 CCAGGAGGTGGTGGTGTGATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAG
 CGCAGCAAGCGCCAGTCCCTGCGCGAGGCGGCATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGC
 AGGAGCGCAAGCGCCGCGCAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAA
 GGAATATCACAGATCCGTACAGGCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAAC
 ACGGAGCGGGAGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAG
 ATGAGGAGGGGTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCTACCTCTTGCAGCAGAC
 AGACGAGTACGTGGCTAACCTCACGGAGCTGCTGCGGCAGCACAAGGCTGCCAGGTGCGCAAGGAGAAA
 AAGAAGAAAAAGAAAAAGAAGGAGCAAAATGCAGAAGGACAGACGCTGCCATTGGGCGCGATGGCG
 AGCCTCTGGACGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGAT

```

CCTCACAGGCACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAA
GTAGCTCCGAGGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGC
CGCAGGCAGCACAGCCTCCCACCCTGCCCGTGGAGGAGAAGAAGAAGATTCCAGATCCAGACAGCGATGA
CGTCTCTGAGGTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTCGATGATGAATATGGCGTG
TCCCAGGCCCTTGCACGTGGCCTGCAGTCCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACA
AGCAGTCAGCGCTTATGGTCAATGGTGTCTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCT
CCTGTACAACAACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGGAAGACCATCCAGACCATC
GCGCTCATCACGTACCTCATGGAGCACAACCGCATCAATGGGCCCTTCCCTCATCATCGTGCCTCTCTCAA
CGCTGTCCAACCTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATC
CCCAGCAGCAAGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTAC
GAGTACATCATCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCT
ACCGCATGAAGAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACTATGTGGCACCCTCCGCGCT
GCTGCTGACGGGCACACCGCTGCAGAACAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCTGTGCTGCC
ACCATCTTCAAGAGTGCAGCACCTTCGAGCAGTGGTTTAAACGCACCCTTTGCCATGACCGGGGAAAAGG
TGGACCTGAATGAGGAGGAAACCATTCTCATCATCCGGCGTCTCCACAAAGTGTCTGCGGCCCTTCTTGCT
CCGACGACTCAAGAAGGAAGTCAAGGCCAGTTGCCCGAAAAGGTGGAGTACGTATCAAGTGCACATG
TCTGCGCTGCAGCGAGTGTCTTACCGCCACATGCAGGCCAAGGGCGTGTCTGCTGACTGATGGCTCCGAGA
AGGACAAGAAGGGCAAAGGCGGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAA
CCACCCCTACATGTTCCAGCACATCGAGGAGTCTTTTCCGAGCACTTGGGGTCACTGGCGGCATTGTCTC
CAAGGGCTGGACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCAAACTCCGAG
CAACCAACCACAAAGTGTCTGTCTTCTGCCAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGC
GTATCGCGGCTTTAAATACCTCAGGCTTGATGGAACACGAAGGCGGAGGACCGGGGCATGCTGCTGAAA
ACCTTCAACGAGCCCGCTCTGAGTACTTCATCTTCTGCTCAGCACCCGGGCTGGGGGGCTCGGCCTGA
ACCTCCAGTGGCGAGACACTGTGATCATTTTTGACAGCGACTGGAATCCTCACCAGGACCTGCAAGCGCA
GGACCGAGCCACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCCTCTGCACCGTCAACAGCGTG
GAGGAGAAGATCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGT
TCGACCAGAAGTCTCCAGCCATGAGCGGCGCGCCTTCTGTCAGGCCATCCTGGAGCACGAGGAGCAGGA
TGAGAGCAGACACTGCAGCACGGGCAGCGGCAGTGCCAGCTTCGCCACACTGCCCTCCGCCAGCGGGC
GTCAACCCCGACTTGGAGGAGCCACCTCTAAAGGAGGAAGACGAGGTGCCCGACGACGAGACCGTCAACC
AGATGATCGCCCGGCACGAGGAGGAGTTTGATCTGTTTCATGCGCATGGACCTGGACCGCAGGCGCGAGGA
GGCCCGCAACCCCAAGCGGAAGCCGCGCCTCATGGAGGAGGACGAGCTCCCTCGTGGATCATCAAGGAC
GACCGGAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAGGAGAAGATGTTCCGGCCGTGGCTCCCGCCACC
GCAAGGAGGTGGACTACAGCGACTCACTGACGGAGAAGCAGTGGCTCAAGGCCATCGAGGAGGGCACGCT
GGAGGAGATCGAAGAGGAGGTCCGGCAGAAGAAATCATCACGGAAGCGCAAGCGAGACAGCGACGCCGGC
TCCTCCACCCCGACCACCAGCACCCGCGAGCCGCGACAAGGACGACGAGAGCAAGAAGCAGAAGAAGCGCG
GGCGGCCGCTGCCGAGAACTCTCCCTTAACCCACCCAACTCACCAGAAGATGAAGAAGATTGTGGA
TGCCGTGATCAAGTACAAGGACAGCAGCAGTGGACGTGAGCTCAGCGAGGTCTTCATCCAGCTGCCCTCG
CGAAAGGAGCTGCCCGAGTACTACGAGCTCATCCGAAGCCCGTGGACTTCAAGAAGATAAAGGAGCGCA
TTCGCAACCACAAGTACCGCAGCCTCAACGACCTAGAGAAGGACGTATGCTCCTGTGCCAGAACGCACA
GACCTTCAACCTGGAGGGCTCCCTGATCTATGAAGACTCCATCGTCTTGCAGTCGGTCTTACCAGCGTG
CGGCAGAAAATCGAGAAGGAGGATGACAGTGAAGGCGAGGAGAGTGAAGGAGGAGGAAGAGGGCGAGGAGG
AAGGCTCCGAATCCGAATCTCGGTCCGTCAAAGTGAAGATCAAGCTTGGCCGGAAGGAGAAGGCACAGGA
CCGGCTGAAGGGCGGCCGGCGGGCGGCGAGCCGAGGGTCCCGAGCCAAGCCGGTCTGTGAGTGACGATGAC
AGTGAGGAGGAACAAGAGGAGGACCGCTCAGGAAGTGGCAGCGAAGAAGACTGAGCCCCGACATTCCAGT
CTCGACCCCGAGCCCTCGTTCAGAGCTGAGATGGCATAGGCCTTAGCAGTAACGGGTAGCAGCAGATG
TAGTTTCAGACTTGGAGTAAACTGTATAAACAAGAAATCTTCCATATTTATACAGCAGAGAAGCTGTA
GGACTGTTTGTGACTGGCCCTGTCTGGCATCAGTAGCATCTGTAACAGCATTAAGTGTCTTAAAGAGAG
AGAGAGAGAATTCCGAATTGGGGAACACACGATACCTGTTTTTCTTTCCGTTGCTGGCAGTACTGTTGC
GCCGAGTTTGGAGTCACTGTAGTTAAGTGTGGATGCATGTGCGTCACCGTCCACTCCTCTACTGTATT
TTATTGGACAGGTCAAGTCCCGGGGGCGCGGAGGGTATGTCAGTGTCACTGGATGTCAAACAGTAA
TAAATTAAACCAACAACAAAACGCACAGCCAAAAA

```

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 4 (GenBank Accession No. NM_001128845.1)

ATGTCCACTCCAGACCCACCCCTGGGCGGAACCTCCTCGGCCAGGTCTTCCCCGGGGCCCTGGCCCTTCCC
CTGGAGCCATGCTGGGGCCCTAGCCCCGGGTCCCTCGCCGGGCTCCGCCACAGCATGATGGGGCCAGCCC
AGGGCCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCTGGAGGGTACCTCAGGACAACATGCAC
CAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCCGACGACCCGCGCTACAACCAGATGA
AAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGGACCAGCACTC
CCAAGGTTACCCCTCGCCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCAGCCAGTGGCCCCGTCT
TCGGGGCCCCCAGATGTCTTCCGGGGCCAGGAGGTGCCCCGCTGGATGGTGTGACCCCCAGGCCTTGGGGC
AGCAGAACCGGGGCCAACCCCATTTAACAGAACAGCTGCACCAGCTCAGAGCTCAGATCATGGCCTA
CAAGATGCTGGCCAGGGGGCAGCCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCCGATG
CCCCGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCTTGGCC
CTGGCCCTGGCCCCGGCCCGGGTCCCGGCCCGGCACCTCCAAATTACAGCAGGCCTCATGGTATGGGAGG
GCCAACATGCCTCCCCCAGGACCCCTCGGGCGTGGCCCCCGGGATGCCAGGCCAGCCTCCTGGAGGGCCT
CCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCCAGAGCACCCTCAGAAGCTGATTC
CCCCGACAGCAACGGGGCCCTTCCCCCGCGCCCCCTGCCGTCCCACCCGCGCCTCGCCCGTGTATGCC
ACCGCAGACCCAGTCCCCCGGGCAGCCGGCCCCAGCCCCGCGCCCATGGTGCCACTGCACCAGAAGCAGAGC
CGCATACCCCCATCCAGAAGCCGCGGGGCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTACAGGC
TGCAGGCTCGCATCGCACACCGAATTCAGGAACCTTGAAAACCTTCCCCGGGTCCCTGGCCGGGGATTTCG
AACCAAAGCGACCATTGAGCTCAAGGCCCTCAGGCTGCTGAACTTCAGAGGCAGCTGCGCCAGGAGGTG
GTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAGCGCAGCAAGC
GCCAGTCCCTGCGCGAGGGCCCGCATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGCAGGAGCGCAA
GCGCCGGCAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAAGGAATATCAC
AGATCCGTACAGGCCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAGCGGG
AGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGGAGGG
GTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCTACCTCTTGACGACAGACAGACGAGTAC
GTGGCTAACCTCACGGAGCTGGTGCGGCAGCACAAAGGCTGCCAGGTGCGCAAGGAGAAAAAGAAAA
AGAAAAAGAAGAAGGCAGAAAATGCAGAAGGACAGACGCTGCCATTGGGCGCGGATGGCGAGCCTCTGGA
CGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCTCACAGGC
ACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCTCCGA
GGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGCCGAGGCAGC
ACAGCCTCCCACCCTGCCCCGTGGAGGAGAAGAAGAAGATTCAGATCCAGACAGCGATGACGTCTCTGAG
GTGGACGCGCGGCACATCATTTGAGAATGCCAAGCAAGATGTGATGATGAATATGGCGTGTCCCAGGCCC
TTGACGTGGCCTCTACTATGCGCTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGTCAGC
GCTTATGGTCAATGGTGTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCCCTGTACAAC
AACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGGAAGACCATCCAGACCATCGCGCTCATCA
CGTACCTCATGGAGCACAAACGCATCAATGGGCCCTTCTCATCATCGTGCCTCTCTCAACGCTGTCCAA
CTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGCAGCA
AGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTACATCA
TCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCAACGCATGAA
GAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACTATGTGGCACCCTGCGCCTGCTGCTGACG
GGCACACCGCTGCAGAACAAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCCTGCTGCCACCATCTTCA
AGAGCTGCAGCACCTTCGAGCAGTGGTTTAACGCACCCTTTGCCATGACCGGGGAAAAGGTGGACCTGAA
TGAGGAGGAAACCATTCTCATCATCCGGCGTCTCCACAAAGTGCTGCGGCCCTTCTTGCTCCGACGACTC
AAGAAGGAAGTCGAGGCCCAGTTGCCCCGAAAAGGTGGAGTACGTCAAGTGCGACATGTCTGCGCTGC
AGCGAGTGCTCTACCGCCACATGCAGGCCAAGGGCGTGCTGCTGACTGATGGCTCCGAGAAGGACAAGAA
GGGCAAAGGGCGGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCCCTAC
ATGTTCCAGCACATCGAGGAGTCTTTTCCGAGCACTTGGGGTTCCTGGCGGCATTGTCCAAGGGCTGG
ACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCCAAACCTCCGAGCAACCAACCA
CAAAGTGCTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCGCGGC
TTTAAATACCTCAGCCTTGATGGAACCAACGAAGCGGAGGACCGGGCATGCTGCTGAAAACCTTCAACG
AGCCCGGCTCTGAGTACTTCATCTTCTGCTCAGACCCCGGGCTGGGGGGCTCGGCCCTGAACCTCCAGTC
GGCAGACACTGTGATCATTTTTTGACAGCGACTGGAATCCTACCAGGACCTGCAAGCGCAGGACCGAGCC
CACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCTCTGCACCGTCAACAGCGTGAGGAGAGAAGA
TCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGTTTCGACCAGAA
GTCCTCCAGCCATGAGCGGCGCGCCTTCTGCAGGCCATCCTGGAGCACGAGGAGCAGGATGAGGAGGAA
GACGAGGTGCCCCGACGACGAGACCGTCAACCAGATGATCGCCCGCACGAGGAGGAGTTTGATCTGTTCA
TGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCGCAACCCCAAGCGGAAGCCGCGCTCATGGAGGA


```

GGACGAGCTCCCCTCGTGGATCATCAAGGACGACGCGGAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAG
GAGAAGATGTTTCGGCCGTGGCTCCCGCCACCGCAAGGAGGTGGACTACAGCGACTCACTGACGGAGAAGC
AGTGGCTCAAGACCCTGAAGGCCATCGAGGAGGGCAGCTGGAGGAGATCGAAGAGGAGGTCCGGCAGAA
GAAATCATCACGGAAGCGCAAGCGAGACAGCGACGCCGGCTCCTCCACCCCGACCACCAGCACCCGCGAGC
CGCGACAAGGACGACGAGAGCAAGAAGCAGAAGAAGCGCGGGCGGCCGCTGCCGAGAACTCTCCCTTA
ACCCACCCAACCTCACCAAGAAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGCAG
TGGACGTGAGCTCAGCGAGGTCTTCATCCAGCTGCCCTCGCGAAAGGAGCTGCCCGAGTACTACGAGCTC
ATCCGCAAGCCCCTGGACTTCAAGAAGATAAAGGAGCGCATTCGCAACCACAAGTACCGCAGCCTCAACG
ACCTAGAGAAGGACGTGCTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTA
TGAAGACTCCATCGTCTTGCAGTCGGTCTTACCAGCGTGCGGCAGAAAATCGAGAAGGAGGATGACAGT
GAAGGCGAGGAGAGTGAGGAGGAGGAAGAGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCA
AAGTGAAGATCAAGCTTGGCCGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGCCGCGCGGCCGAG
CCGAGGGTCCCGAGCCAAGCCGGTCTGTGAGTGACGATGACAGTGAGGAGGAACAAGAGGAGGACCGCTCA
GGAAGTGGCAGCGAAGAAGACTGAGCCCCGACATTCCAGTCTCGACCCCGAGCCCCCTGTTCCAGAGCTG
AGATGGCATAGGCCTTAGCAGTAACGGGTAGCAGCAGATGTAGTTTCAGACTTGGAGTAAAACGTATATA
ACAAAAGAATCTTCCATATTTATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCTGGCA
TCAGTAGCATCTGTAACAGCATTAAGTGTCTTAAAGAGAGAGAGAGAGAATTCGAATTTGGGGAACACAC
GATACCTGTTTTTCTTTTCCGTTGCTGGCAGTACTGTTGCGCCGAGTTTGGAGTCACTGTAGTTAAGTG
TGGATGCATGTGCGTCACCGTCCACTCCTCCTACTGTATTTTATTGGACAGGTGAGACTCGCCGGGGGCC
CGGCGAGGGTATGTGAGTGTCACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCC
AAAAAAAA

```

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 5 (GenBank Accession No. NM_001128846.1)

```

ATGTCCACTCCAGACCCACCCCTGGGCGGAACCTCCTCGGCCAGGTCTCTTCCCGGGCCCTGGCCCTTCCC
CTGGAGCCATGCTGGGCCCTAGCCCCGGGTCCCTCGCCGGGCTCCGCCCACAGCATGATGGGGCCAGCCC
AGGGCCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCTGGAGGGTACCCTCAGGACAACATGCAC
CAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTGGACGACCCGCGCTACAACCAGATGA
AAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGGACCAGCACTC
CCAAGGTTACCCCTCGCCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCCAGCCAGTGGCCCCGTCT
TCGGGGCCCCAGATGTCTTCCGGGGCCAGGAGGTGCCCGCTGGATGGTGTGACCCCCAGGCCTTGGGGC
AGCAGAACCGGGGCCAACCCCATTTAACCAGAACCAGCTGCACCAGCTCAGAGCTCAGATCATGGCCTA
CAAGATGCTGGCCAGGGGGCAGCCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCCGATG
CCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCTGGCC
CTGGCCCTGGCCCCGGCCCGGGTCCCGGCCCGGCACCTCCAAATTACAGCAGGCCTCATGGTATGGGAGG
GCCAACATGCCTCCCCCAGGACCCCTCGGGCGTGGCCCCCGGGATGCCAGGCCAGCCTCCTGGAGGGCCT
CCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCACGAGCACCCCTCAGAAGCTGATTC
CCCCGCAGCCAACGGGCCGCCCTTCCCCCGCGCCCCCTGCCGTCCCACCCGCGCCTCGCCCCGTGATGCC
ACCGCAGACCCAGTCCCCCGGGCAGCCGGGCCAGCCCGCGCCCATGGTGCCACTGCACCAGAAGCAGAGC
CGCATCACCCCATCCAGAAGCCGCGGGGCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTACAGGC
TGCAGGCTCGCATCGCACACCGAATTCAGGAACCTTGAAAACCTTCCCGGGTCCCTGGCCGGGGATTTGCG
AACCAGAGCGACCAATTGAGCTCAAGGCCCTCAGGCTGCTGAACCTTCCAGAGGCAGCTGCGCCAGGAGTG
GTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAGCGCAGCAAGC
GCCAGTCCCTGCGCGAGGCCCGCATCACTGAGAAGCTGGAGAAGCAGCAGAGAAGATCGAGCAGGAGCGCAA
GCGCCGGCAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAAGGAATATCAC
AGATCCGTACAGGCCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAGCGGG
AGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGGAGGG
GTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCTACCTCTTGACGACAGACAGACGAGTAC
GTGGCTAACCTCACGGAGCTGGTGCGGCAGCACAAGGCTGCCAGGTGCGCAAGGAGAAAAAGAAAA
AGAAAAAGAAGAAGGCAGAAAATGCAGAAGGACAGACGCTGCCATTGGGCCGGATGGCGAGCCTCTGGA
CGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCTCACAGGC
ACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCTCCGA
GGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGCCGAGCGAGC

```

ACAGCCTCCCACCCTGCCCGTGGAGGAGAAGAAGAAGATTCCAGATCCAGACAGCGATGACGTCTCTGAG
 GTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTGATGATGAATATGGCGTGTCCCAGGCC
 TTGCACGTGGCCTGCAGTCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGTCAGC
 GCTTATGGTCAATGGTGTCTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCCCTGTACAAC
 AACAACTGAACGGCATCCTGGCCGACGAGATGGCCTGGGAAGACCATCCAGACCATCGCGCTCATCA
 CGTACCTCATGGAGCACAACGCATCAATGGGCCCTTCCTCATCATCGTGCCCTCTCTCAACGCTGTCCAA
 CTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGCAGCA
 AGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTACATCA
 TCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCAACCGCATGAA
 GAACCACCACTGCAAGCTGACGCGAGGTGCTCAACACGCACTATGTGGCACCCTCGCCGCTGCTGCTGACG
 GGCACACCGCTGCAGAACAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCCTGCTGCCACCATCTTCA
 AGAGCTGCAGCACCTTCGAGCAGTGGTTTAAACGCACCCCTTTGCCATGACCGGGGAAAAGGTGGACCTGAA
 TGAGGAGGAAACCATCTCATCATCCGGCGTCTCCACAAAGTGTGCTGCGGCCCTTCTGCTCCGACGACT
 AAGAGGAAGTCGAGGCCAGTTGCCGAAAAGGTGGAGTACGTATCAAGTGCAGCATGTCTGCGCTGC
 AGCGAGTGCTCTACCGCCACATGCAGGCCAAGGGCGTGCTGCTGACTGATGGCTCCGAGAAGGACAAGAA
 GGGCAAAGGCGGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCCCTAC
 ATGTTCCAGCACATCGAGGAGTCCTTTTCCGAGCACTTGGGGTCACTGGCGGCATTGTCCAAGGGCTGG
 ACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCAAACTCCGAGCAACCAACCA
 CAAAGTGTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCGCGGC
 TTTAAATACCTCAGGCTTGATGGAACACGAAGGCGGAGGACCGGGCATGCTGCTGAAAACCTTCAACG
 AGCCCGGCTCTGAGTACTTCATCTTCTGCTCAGCACCCGGGCTGGGGGGCTCGGCCTGAACCTCCAGTC
 GGCAGACACTGTGATCATTTTTTGACAGCAGTGAATCCTCACCAGGACCTGCAAGCGCAGGACCGAGCC
 CACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCCCTCTGCACCGTCAACAGCGTGGAGGAGAAGA
 TCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGTTTCGACCAGAA
 GTCCTCCAGCCATGAGCGGCGCGCCTTCTGTCAGGCCATCCTGGAGCACGAGGAGCAGGATGAGGAGGAA
 GACGAGGTGCCCGACGACGAGACCGTCAACCAGATGATCGCCCGGCACGAGGAGGAGTTTGATCTGTTCA
 TGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCGCAACCCCAAGCGGAAGCCGCGCCTCATGGAGGA
 GGACGAGCTCCCCTCGTGGATCATCAAGGACGACGCGGAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAG
 GAGAAGATGTTCCGCCGTGGCTCCCGCCACCGCAAGGAGGTGGACTACAGCGACTCACTGACGGAGAAGC
 AGTGGCTCAAGACCCTGAAGGCCATCGAGGAGGGCACGCTGGAGGAGATCGAAGAGGAGGTCCGGCAGAA
 GAAATCATCACGAAGCGCAAGCGAGACAGCGACCGCGCTCCTCCACCCGACCAACAGCACCACCGCAGC
 CGGACAAGGACGACGAGAGCAAGAAGCAGAAGAAGCGCGGGCGGCCCTGCGGAGAACTCTCCCTTA
 ACCCAACCTCACCAAGAAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGTGG
 ACGTCAGCTCAGCGAGGTCTTCATCCAGCTGCCCTCGCGAAAGGAGCTGCCCGAGTACTACGAGCTCATC
 CGCAAGCCCGTGGACTTCAAGAAGATAAAGGAGCGCATTCGCAACCACAAGTACCGCAGCCTCAACGACC
 TAGAGAAGGACGTATGCTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTATGA
 AGACTCCATCGTCTTGAGTCCGTCTTACCAGCGTGGCGCAGAAAATCGAGAAGGAGGATGACAGTGAA
 GGCGAGGAGAGTGGAGGAGGAGGAAGAGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCAAAG
 TGAAGATCAAGCTTGGCCGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGCGCGCGCGGCCGAGCCG
 AGGGTCCCAGCCAAGCCGCTCGTGAGTGACGATGACAGTGGAGGAGGAACAAGAGGAGGACCGCTCAGGA
 AGTGGCAGCGAAGAAGACTGAGCCCCGACATTCAGTCTCGACCCCGAGCCCTCGTTCCAGAGCTGAGA
 TGGCATAGGCCTTAGCAGTAACGGGTAGCAGCAGATGTAGTTTCAGACTTGGAGTAAAAGTGTATAAACA
 AAAGAATCTTCCATATTTATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCTGGCATCA
 GTAGCATCTGTAACAGCATTAAGTGTCTTAAAGAGAGAGAGAGAGAATTCCGAATTGGGGAACACACGAT
 ACCTGTTTTTCTTTCCGTTGCTGGCAGTACTGTTGCGCCGAGTTTGGAGTCACTGTAGTTAAGTGTGG
 ATGCATGTGCGTCACCGTCCACTCCTCCTACTGTATTTTATTGGACAGGTGAGACTCGCCGGGGGCCCGG
 CGAGGGTATGTAGTGTCACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCCAAA
 AAAAA

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator
 of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 6 (GenBank
 Accession No. NM_001128847.1)

ATGTCCACTCCAGACCCACCCCTGGGCGGAAGTCTCGGCCAGGTCTTCCCCGGGCCCTGGCCCTTCCC

CTGGAGCCATGCTGGGCCCCTAGCCCCGGGTCCCTCGCCGGGCTCCGCCACAGCATGATGGGGCCCAGCCC
AGGGCCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCTGGAGGGTACCCCTCAGGACAACATGCAC
CAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCCGACGACCCGCGCTACAACCAGATGA
AAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGGACCAGCACTC
CCAAGGTTACCCCTCGCCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCCAGCCAGTGGCCCCGTCT
TCGGGGCCCCAGATGTCTTCCGGGGCCAGGAGGTGCCCCGCTGGATGGTGTGACCCCCAGGCCTTGGGGG
AGCAGAACCGGGGCCAACCCCATTTAAACCAGAACCAGCTGCACCAGCTCAGAGCTCAGATCATGGCCCTA
CAAGATGCTGGCCAGGGGGCAGCCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCCGATG
CCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCTGGCC
CTGGCCCTGGCCCCGGCCCGGGTCCCGGGCCCGGCACCTCCAAATTACAGCAGGCCTCATGGTATGGGAGG
GCCAACATGCCTCCCCCAGGACCCCTCGGGCGTGCCCCCGGGATGCCAGGCCAGCCTCCTGGAGGGCCT
CCCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCCAGAGCACCCTCAGAAGCTGATTC
CCCCGCAGCCAACGGGGCCGCCCTTCCCCCGCGCCCCCTGCCGTCCCACCCGCGCCTCGCCCGTGATGCC
ACCGCAGACCCCATCCAGAAGCCGCGGGCCCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTACAGGC
CGCATACCCCATCCAGAAGCCGCGGGCCCTCGACCCTGTGGAGATCCTGCAGGAGCGCGAGTACAGGC
TGCAGGCTCGCATCGCACACCGAATTGAGGAACCTGAAAACCTTCCCGGGTCCCTGGCCGGGGATTTGCG
AACCAGCGACCATTTAGCTCAAGGCCCTCAGGCTGCTGAACTTCCAGAGGCAGCTGCGCCAGGAGGTG
GTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCTACAAGCGCAGCAAGC
GCCAGTCCCTGCGCGAGGGCCCGCATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGCAGGAGCGCAA
GCGCCGGCAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAAGGAATATCAC
AGATCCGTACAGGCCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAGCGGG
AGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGGAGGG
GTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCCTACCTCTTGCAGCAGACAGACGAGTAC
GTGGCTAACCTCACGGAGCTGGTGCGGCAGCACAAGGCTGCCCAGGTGCGCAAGGAGAAAAAGAAAA
AGAAAAAGAAGAAGGCAGAAAATGCAGAAGGACAGACGCCTGCCATTGGGGCCGGATGGCGAGCCTCTGGA
CGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCCTCACAGGC
ACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCTCCGA
GGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGCCGAGGCAGC
ACAGCCTCCCACCCTGCCCCGTGGAGGAGAAGAAGAAGATTCCAGATCCAGACAGCGATGACGTCTCTGAG
GTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTGATGATGAATATGGCGTGTCCCAGGCCC
TTGACGTTGGCCTGCAGTCTCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGTCAGC
GCTTATGGTCAATGGTGTCTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCTCTGTACAA
AACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGGAAGACCATCCAGACCATCGCGCTCATCA
CGTACCTCATGGAGCACAACGCATCAATGGGCCCTTCTCATCATCGTGCCTCTCTCAACGCTGTCCAA
CTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGCAGCA
AGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTACATCA
TCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCACCGCATGAA
GAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACTATGTGGCACCCTCGCCGCTGCTGCTGACG
GGCACACCGCTGCAGAACAAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCTGCTGCCACCATCTTCA
AGAGCTGCAGCACCTTCGAGCAGTGGTTTAACGCACCCTTTGCCATGACCGGGGAAAAGGTGGACCTGAA
TGAGGAGGAAACCATTTCTCATCATCCGGCGTCTCCACAAAGTGTGCGGCCCTTCTTGCTCCGACGACTC
AAGAAGGAAGTGCAGGGCCAGTTGCCCGAAAAGGTGGAGTACGTATCAAGTGCGACATGTCTGCGCTGC
AGCGAGTGTCTTACCGCCACATGCAGGCCAAGGGCGTGCTGCTGACTGATGGCTCCGAGAAGGACAAGAA
GGGCAAAGGGCGCACCAAGACCCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCCCTAC
ATGTTCCAGCACATCGAGGAGTCCCTTTTCCGAGCACTTGGGGTTCACTGGCGGCATTGTCCAAGGGCTGG
ACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTCTTCCCAAACCTCCGAGCAACCAACCA
CAAAGTGTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCGCGGC
TTTAAATACCTCAGGCTTGATGGAACCACGAAGGCGGAGGACCGGGGCATGCTGCTGAAAACCTTCAACG
AGCCCGGCTCTGAGTACTTCATCTTCTGCTCAGCACCCTGGGCTGGGGGGCTCGGCCTGAACCTCCAGTC
GGCAGCACTGTGATCATTTTGTGACGCACTGGAATCCTCACCAGGACCTGCAAGCGCTGGAGGAGAAGA
TCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGTTTCGACCAGAA
GTCCTCCAGCCATGAGCGGCGCGCCTTCTGTCAGGCCATCCTGGAGCACGAGGAGCAGGATGAGGAGGAA
GACGAGGTGCCCCGACGACGAGACCGTCAACCAGATGATCGCCGGCACGAGGAGGAGTTTGATCTGTTCA
TGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCGCAACCCCAAGCGGAAGCCGCGCCTCATGGAGGA
GGACGAGCTCCCCTCGTGGATCATCAAGGACGACGCGGAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAG

GAGAAGATGTTTCGGCCGTGGCTCCCGCCACCGCAAGGAGGTGGACTACAGCGACTCACTGACGGAGAAGC
 AGTGGCTCAAGGCCATCGAGGAGGGCACGCTGGAGGAGATCGAAGAGGAGGTCCGGCAGAAGAAATCATC
 ACGGAAGCGCAAGCGAGACAGCGACGCCGGCTCCTCCACCCCGACCACCAGCACCCGCAGCCGCGACAAG
 GACGACGAGAGCAAGAAGCAGAAGAAGCGCGGGCGGGCCGCTGCCGAGAACTCTCCCCTAACCCACCCA
 ACCTCACCAAGAAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGCAGTGGACGTCA
 GCTCAGCGAGGTCTTCATCCAGCTGCCCTCGCGAAAGGAGCTGCCCCGAGTACTACGAGCTCATCCGCAAG
 CCCGTGGACTTCAAGAAGATAAAGGAGCGCATTTCGAACCCACAAGTACCGCAGCCTCAACGACCTAGAGA
 AGGACGTATGCTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTATGAAGACTC
 CATCGTCTTGAGTCCGGTCTTCACCAGCGTGCGGCAGAAAATCGAGAAGGAGGATGACAGTGAAGGCGAG
 GAGAGTGAGGAGGAGGAAGAGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCAAAGTGAAGA
 TCAAGCTTGGCCGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGGCCGGCGGGCCGAGCCGAGGGTC
 CCGAGCCAAGCCGGTCTGTAGTGACGATGACAGTGAGGAGGAACAAGAGGAGGACCGCTCAGGAAGTGGC
 AGCGAAGAAGACTGAGCCCCGACATTCCAGTCTCGACCCCGAGCCCCCTCGTTCCAGAGCTGAGATGGCAT
 AGGCCCTAGCAGTAACGGGTAGCAGCAGATGTAGTTTCAGACTTGGAGTAAACTGTATAAACAAAAGAA
 TCTTCCATATTTATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCTGGCATCAGTAGCA
 TCTGTAACAGCATTAACTGTCTTAAAGAGAGAGAGAGAGAATTCCGAATTGGGGAACACACGATACTGT
 TTTTCTTTTCCGTTGCTGGCAGTACTGTTGCGCCGAGTTTGGAGTCACTGTAGTTAAGTGTGGATGCAT
 GTGCGTCACCGTCCACTCCTACTGTATTTTATTGGACAGGTGAGACTCGCCGGGGGCCCGCGAGGG
 TATGTCAGTGTCACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCCAAAAA

mRNA sequence of human SWI/SNF related, matrix associated, actin dependent regulator
 of chromatin, subfamily a, member 4 (SMARCA4), transcript variant 7 (GenBank
 Accession No. NM_001128848.1)

ATGTCCACTCCAGACCCACCCCTGGGCGGAACCTCCTCGGCCAGGTCTTCCCCGGGCCCTGGCCCTTCCC
 CTGGAGCCATGCTGGGCCCTAGCCCCGGGTCCCTCGCCGGGCTCCGCCACAGCATGATGGGGCCAGCCC
 AGGGCCGCCCTCAGCAGGACACCCCATCCCCACCCAGGGGCCCTGGAGGGTACCTCAGGACAACATGCAC
 CAGATGCACAAGCCCATGGAGTCCATGCATGAGAAGGGCATGTCGGACGACCCGCGCTACAACCAGATGA
 AAGGAATGGGGATGCGGTGAGGGGGCCATGCTGGGATGGGGCCCCCGCCAGCCCCATGGACCAGCACTC
 CCAAGGTTACCCCTCGCCCCCTGGGTGGCTCTGAGCATGCCTCTAGTCCAGTTCCAGCCAGTGGCCCCGTCT
 TCGGGGCCCCAGATGTCTTCCGGGCCAGGAGGTGCCCGCTGGATGGTGTGACCCCCAGGCCTTGGGGC
 AGCAGAACCAGGGGCCAACCCCATTTAACCAGAACAGCTGCACCAGCTCAGAGCTCAGATCATGGCCTA
 CAAGATGCTGGCCAGGGGGCAGCCCCCTCCCCGACCACCTGCAGATGGCGGTGCAGGGCAAGCGGCCGATG
 CCCGGGATGCAGCAGCAGATGCCAACGCTACCTCCACCCTCGGTGTCCGCAACAGGACCCGGCCCTGGCC
 CTGGCCCTGGCCCCGGCCCCGGGTCCCCGGCCCCGACCTCCAAATTACAGCAGGCCTCATGGTATGGGAGG
 GCCAACATGCCTCCCCCAGGACCCCTCGGGCGTGCCCCCGGGATGCCAGGCCAGCCTCTTGGAGGSCCT
 CCAAGCCCTGGCCTGAAGGACCCATGGCGAATGCTGCTGCCCCCAGGACACCCCTCAGAAGCTGATTC
 CCCCAGCCAAACGGGCCGCCCTTCCCCCGCGCCCCCTGCCGTCCACCCGCCGCTCGCCCCGTGATGCC
 ACCGCAGACCCAGTCCCCCGGGCAGCCGGCCCCAGCCCCGCGCCCATGGTGCCACTGCACCAGAAGCAGAGC
 CGCATACCCCCCATCCAGAAGCCGCGGGGCTCGACCTGTGGAGATCCTGCAGGAGCGCGAGTACAGGC
 TGCAGGCTCGCATCGCACACCCGAATTCAGGAACCTTGAAACCTTCCCGGGTCCCTGGCCGGGGATTTGCG
 AACCAAAGCGACCATTGAGCTCAAGGCCCTCAGGCTGCTGAACTTCAGAGGCAGCTGCGCCAGGAGGTG
 GTGGTGTGCATGCGGAGGGACACAGCGCTGGAGACAGCCCTCAATGCTAAGGCCCTACAAGCGCAGCAAGC
 GCCAGTCCCTGCGCGAGGCCCCGATCACTGAGAAGCTGGAGAAGCAGCAGAAGATCGAGCAGGAGCGCAA
 GCGCCGCGAGAAGCACCAGGAATACCTCAATAGCATTCTCCAGCATGCCAAGGATTTCAAGGAATATCAC
 AGATCCGTACAGGCAAAATCCAGAAGCTGACCAAGGCAGTGGCCACGTACCATGCCAACACGGAGCGGG
 AGCAGAAGAAAGAGAACGAGCGGATCGAGAAGGAGCGCATGCGGAGGCTCATGGCTGAAGATGAGGAGGG
 GTACCGCAAGCTCATCGACCAGAAGAAGGACAAGCGCCTGGCCTACCTCTTGACAGCAGACAGACGAGTAC
 GTGGCTAACCTCACGGAGCTGGTGCGGCAGCACAAGGCTGCCAGGTGCGCAAGGAGAAAAAGAAAA
 AGAAAAAGAAGAAGGCAGAAATGCAGAAGGACAGACGCTGCCATTGGGCGGGATGGCGAGCCTCTGGA
 CGAGACCAGCCAGATGAGCGACCTCCCGGTGAAGGTGATCCACGTGGAGAGTGGGAAGATCTCACAGGC
 ACAGATGCCCCCAAAGCCGGGCAGCTGGAGGCCTGGCTCGAGATGAACCCGGGGTATGAAGTAGCTCCGA
 GGTCTGATAGTGAAGAAAGTGGCTCAGAAGAAGAGGAAGAGGAGGAGGAAGAGCAGCCGCGAGGCAGC
 ACAGCCTCCACCCCTGCCCGTGGAGGAGAAGAAGAAGATTCCAGATCCAGACAGCGATGACGTCTCTGAG
 GTGGACGCGCGGCACATCATTGAGAATGCCAAGCAAGATGTCGATGATGAATATGGCGTGTCCAGGCC

TTGCACGTGGCCTGCAGTCTACTATGCCGTGGCCCATGCTGTCACTGAGAGAGTGGACAAGCAGTCAGC
GCTTATGGTCAATGGTGTCTCTCAAACAGTACCAGATCAAAGGTTTGGAGTGGCTGGTGTCCCTGTACAAC
AACAACCTGAACGGCATCCTGGCCGACGAGATGGGCCTGGGGAAGACCATCCAGACCATCGCGTCAATCA
CGTACCTCATGGAGCACAAACGCATCAATGGGCCCTTCTCATCATCGTGCCTCTCTCAACGCTGTCCAA
CTGGGCGTACGAGTTTGACAAGTGGGCCCCCTCCGTGGTGAAGGTGTCTTACAAGGGATCCCCAGCAGCA
AGACGGGCCTTTGTCCCCCAGCTCCGGAGTGGGAAGTTCAACGTCTTGCTGACGACGTACGAGTACATCA
TCAAAGACAAGCACATCCTCGCCAAGATCCGTTGGAAGTACATGATTGTGGACGAAGGTCACCGCATGAA
GAACCACCACTGCAAGCTGACGCAGGTGCTCAACACGCACTATGTGGCACCCTCGCCGCTGCTGCTGACG
GGCACACCGCTGCAGAACAGCTTCCCGAGCTCTGGGCGCTGCTCAACTTCTGCTGCCACCATCTTCA
AGAGCTGCAGCACCTTCGAGCAGTGGTTTAAACGCACCCTTTGCCATGACCGGGGAAAAGGTGGACCTGAA
TGAGGAGGAAACCATTCTCATCATCCGGCGTCTCCACAAAGTGTGCGGCCCTTCTTGCTCCGACGACTC
AAGAAGGAAGTCGAGGCCCAGTTGCCCCAAAAGGTGGAGTACGTCAAGTGCACATGTCTGCGCTGC
AGCGAAGTGTCTTACCGCCACATGCAGGCCAAGGGCGTGTGCTGACTGATGGCTCCGAGAAGGACAAGAA
GGGCAAGGCGGCACCAAGACCTGATGAACACCATCATGCAGCTGCGGAAGATCTGCAACCACCCCTAC
ATGTTCCAGCACATCGAGGAGTCCTTTTCCGAGCACTTGGGGTTCACTGGCGGCATTTGCCAAGGGCTGG
ACCTGTACCGAGCCTCGGGTAAATTTGAGCTTCTTGATAGAATTTCTTCCCAAACCTCGAGCAACCAACCA
CAAAGTGTGCTGTTCTGCCAAATGACCTCCCTCATGACCATCATGGAAGATTACTTTGCGTATCGCGGC
TTTAAATACCTCAGGCTTGATGGAACACGAAGGCGGAGGACCGGGGCATGCTGCTGAAAACCTTCAACG
AGCCCGGCTCTGAGTACTTCATCTTCTGCTCAGCACCCGGGCTGGGGGGCTCGGCCTGAACCTCCAGTC
GGCAGACACTGTGATCATTTTTTGACAGCGACTGGAATCCTCACCAGGACCTGCAAGCGCAGGACCGAGCC
CACCGCATCGGGCAGCAGAACGAGGTGCGTGTGCTCCGCTCTGCACCGTCAACAGCGTGGAGGAGAAGA
TCCTAGCTGCAGCCAAGTACAAGCTCAACGTGGACCAGAAGGTGATCCAGGCCGGCATGTTCCAGCCAGAA
GTCCTCCAGCCATGAGCGGCGCGCCTTCTGTCAGGCCATCCTGGAGCACGAGGAGCAGGATGAGGAGGAA
GACGAGGTGCCCCGACGACGAGACCGTCAACCAGATGATCGCCCGGCACGAGGAGGAGTTTGATCTGTTCA
TGCGCATGGACCTGGACCGCAGGCGCGAGGAGGCCCGCAACCCCAAGCGGAAGCCGCGCCTCATGGAGGA
GGACGAGCTCCCCTCGTGGATCATCAAGGACGACGCGGAGGTGGAGCGGCTGACCTGTGAGGAGGAGGAG
GAGAAGATGTTCCGGCGTGGCTCCCGCCACCGCAAGGAGGTGGACTACAGCGACTCACTGACGGAGAAGC
AGTGGCTCAAGGCCATCGAGGAGGGCAGCGTGGAGGAGATCGAAGAGGAGGTCCGGCAGAAGAAATCATC
ACGGAAGCGCAAGCGAGACAGCGACCGCGGCTCCTCCACCCCGACCCAGCACCCTCGAGCCGCGACAAG
GACGACGAGAGCAAGAAGCAGAAGAAGCGCGGGCGCGCGCTGCCGAGAACTCTCCCTAACCCACCCA
ACCTCACCAAGAAGATGAAGAAGATTGTGGATGCCGTGATCAAGTACAAGGACAGCAGTGGACGTCAGCT
CAGCGAGGTCTTCATCCAGTGCCTTCGCGAAAGGAGCTGCCCGAGTACTACGAGCTCATCCGCAAGCCC
GTGGACTTCAAGAAGATAAAGGAGCGCATTTCGCAACCACAAGTACCGCAGCCTCAACGACCTAGAGAAGG
ACGTGATGCTCCTGTGCCAGAACGCACAGACCTTCAACCTGGAGGGCTCCCTGATCTATGAAGACTCCAT
CGTCTTGACGTGGTCTTACCAGCGTGCGGCAGAAAATCGAGAAGGAGGATGACAGTGAAGGCGAGGAG
AGTGAGGAGGAGGAAGAGGGCGAGGAGGAAGGCTCCGAATCCGAATCTCGGTCCGTCAAAGTGAAGATCA
AGCTTGCGCGGAAGGAGAAGGCACAGGACCGGCTGAAGGGCGGCGGCGGCGGCGGAGCCGAGGGTCCCCG
AGCCAAGCCGGTCTGTGAGTGACGATGACAGTGAAGGAGGAACAAGAGGAGGACCGCTCAGGAAGTGGCAGC
GAAGAAGACTGAGCCCCGACATTCCAGTCTCGACCCCGAGCCCCCTCGTTCCAGAGCTGAGATGGCATAGG
CCTTAGCAGTAACGGGTAGCAGCAGATGTAGTTTTCAGACTTGGAGTAAACTGTATAAACAAGAAATCT
TCCATATTTATACAGCAGAGAAGCTGTAGGACTGTTTGTGACTGGCCCTGTCTGGCATCAGTAGCATCT
GTAACAGCATTAAGTGTCTTAAAGAGAGAGAGAGAATTCCGAATTGGGGAACACACGATACCTGTTTT
TCTTTTCCGTTGCTGGCAGTACTGTTGCGCCGAGTTTGGAGTCACTGTAGTTAAGTGTGGATGCATGTG
CGTCACCGTCCACTCCTACTGTATTTTATTGGACAGGTGAGACTCGCCGGGGGGCCCGGCGAGGGGTAT
GTCAGTGTCACTGGATGTCAAACAGTAATAAATTAAACCAACAACAAAACGCACAGCCAAAAA

Protein sequence of human transcription activator BRG1 isoform A (GenBank Accession No. NP_001122321.1)

MSTPDPPLGGTPRPGPSPGPGPSPGAMLGPSPGPSPGSAHSMMGPSPGPPSAGHPIPTQGGGYPDNMH
QMHPKPMESMHEKMSDDPRYNQMKGMGMRSGGHAGMGPPPSPMQHSQGYPSPLGGSEHASSPVPASGPS
SGPQMSSSGPGGAPLDGADPQALGQQNRGPTPFNQNLHQLRAQIMAYKMLARGQLPDHLQMAVQKQKRM
PGMQQQMFTLPPPSVSATGPGPGPGPGPGPGPAPPNYSRPHGMGGFNMPFPGPSGVPPGMPGQPPGGP
PKPWPEGPMANAAAPTSTPQKLIPPQPTGRPSPAPPVPPAASPVMPPTQSPGQPAQAPMVPLHQKQS
RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELLENLPGLAGDLRTKATIELKALRLNLFQRQLRQEV
VVCMRDRTALETALNAKAYKRSKRQSLREARITEKLEKQKIEQERKPRQKHQEYLNLSILQHAKDFKEYH

RSVTGKIQKLT KAVATYHANTEREQKKENERIEKERMRLMAEDEEGYRKLI DQKKDKRLAYLLQQTDEY
 VANLTELVRQH KAAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 V DARHIIENAKQD V DDEYGV SQALARGLQSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVS LYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGS PAA
 RRAFVPQLRS GKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRLLLT
 GTPLQNKLP ELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILII RRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRI LPKLRATNHNKVL LFCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKT FNEPGSEYFI FLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRA
 HRIGQQNEVRVLR LCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAI LEHEEQDES R
 HCSTGSGSASF AHTAPPAGVNPDL EEPFLKEEDEVPDDET V NQMIARHEEEFDLFMRMDLDRRREARN
 PKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKMFGRGSRHRKEVDYSDSLTEKQWLKKITGKDIHDT
 ASSVARGLQFQRLQFCTRASKAIEEGTLEEIEEEVRQKKSSRKRRKSDAGSSTPTTSTRSRDKDDESK
 KQKKRGRPPAEKLSNPNNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFK
 KIKERIRNHKYRSLNDLEKDVMLLCQNAQT FNLEGS LIYEDSIVLQSVFTSVRQKIEKEDDSEGESESEE
 EEEEEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGSEED

Protein sequence of human transcription activator BRG1 isoform B (GenBank Accession No. NP_001122316.1)

MSTPD PPLGGT PRPGPS PGPGPS PGAMLGPS PGPS PGSAHSMMGPS PGPPSAGHP IPTQGGGYPQDNMH
 QMHKPMESMHEKGMSDDPRYNQMKGMGMRSGGHAGMGPPPS PMDQHSQGYPSPLGGSEHASSVPASGPS
 SGPQMSSGPGGAPLDGADPQALGQQNRGPTPFNQNLHLQLRAQIMAYKMLARGQLPDHLQMAVQKRP
 PGMQQMPPTLPPPSVSATGPGPGPGPGPGPGPGPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGP
 PKFWPEGPMANAAAPTSTPQKLI PPQPTGRPSAPPAPVPAASVMPPPQTQSPGQPAQPAFMVPLHQKQS
 RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELLENLPGLSLAGDLRTKATIELKALRLNLFQRLRQEV
 VVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQKIEQERKRQKHQEYLNLSILQHAKDFKEYH
 RSVTGKIQKLT KAVATYHANTEREQKKENERIEKERMRLMAEDEEGYRKLI DQKKDKRLAYLLQQTDEY
 VANLTELVRQH KAAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 V DARHIIENAKQD V DDEYGV SQALARGLQSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVS LYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGS PAA
 RRAFVPQLRS GKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRLLLT
 GTPLQNKLP ELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILII RRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRI LPKLRATNHNKVL LFCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKT FNEPGSEYFI FLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRA
 HRIGQQNEVRVLR LCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAI LEHEEQDES R
 HCSTGSGSASF AHTAPPAGVNPDL EEPFLKEEDEVPDDET V NQMIARHEEEFDLFMRMDLDRRREARN
 PKRKPRLMEEDELPSWIIKDDAEVERLTCEEEEEKMFGRGSRHRKEVDYSDSLTEKQWLKAI EEGTLEEIE
 EEEVRQKKSSRKRRKSDAGSSTPTTSTRSRDKDDESKKQKKRGRPPAEKLSNPNNLTKKMKKIVDAVI
 KYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQT FN
 LEGSLIYEDSIVLQSVFTSVRQKIEKEDDSEGESEEEEEEEEEEGSESESRSVKVKIKLGRKEKAQDRLK
 GRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGSEED

Protein sequence of human transcription activator BRG1 isoform C (GenBank Accession No. NP_001122317.1)

MSTPD PPLGGT PRPGPS PGPGPS PGAMLGPS PGPS PGSAHSMMGPS PGPPSAGHP IPTQGGGYPQDNMH
 QMHKPMESMHEKGMSDDPRYNQMKGMGMRSGGHAGMGPPPS PMDQHSQGYPSPLGGSEHASSVPASGPS
 SGPQMSSGPGGAPLDGADPQALGQQNRGPTPFNQNLHLQLRAQIMAYKMLARGQLPDHLQMAVQKRP
 PGMQQMPPTLPPPSVSATGPGPGPGPGPGPGPGPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGP
 PKFWPEGPMANAAAPTSTPQKLI PPQPTGRPSAPPAPVPAASVMPPPQTQSPGQPAQPAFMVPLHQKQS
 RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELLENLPGLSLAGDLRTKATIELKALRLNLFQRLRQEV

VVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQOKIEQERKRRQKHQEYLNLSILQHAKDFKEYH
 RSVTGKIQKLTAKAVATYHANTEREQKKENERIEKERMRLMAEDEEGYRKLIQKKDKRLAYLLQQTDEY
 VANLTELVRQHKAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 VDAHHIIENAKQDQDDEYGVVSQALARGLSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSILYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVMKVSYSKSPAA
 RRAFVPQLRSGKFNVLTTTYEYIIKDKHIIAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLT
 GTPLQNKLPPELWALLNELLPTIFKSCSTFEQWENAFAMTGEKVDLNEEETILIIIRRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRIIPKLRLATNHHKVLFCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKTTFNEPGSEYFIFLLSTRAGGLGLNLQSAQTVIIFDSDWNPHQDLQAQDRA
 HRIGQQNEVRVLRRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFQALIEHEEQDEEE
 DEVPDDETQNMIAHHEEEFDLFMRMDLDRRREEARNPKRKPRLMEDELPSWIIKDDAEVERLTCEEEE
 EKMFGGRSRRHRKEVDYSDSLTEKQWLKTLKAIIEGTLEEIEEEVQKKSSRKRKRSDAGSSTPTTSTRS
 RDKDDSEKKQKKRGRPPAEKLSNPNNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYEL
 IRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGLSIYEDSIVLQSVFTSVRQKIEKEDDS
 EGESEEEEEEGEESSESRSVKVKKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRS
 GSGSEED

Protein sequence of human transcription activator BRG1 isoform D (GenBank Accession No. NP_001122318.1)

MSTDPPLGGTTPRPGSPGPGSPGAMLGSPGSPGSAHSMGSPGPPSAGHPIPTQGGGYPQDNMH
 QMHKPMESMHEKMGMSDDPRYNQMKGMGMRSGGHAGMGPPSPMDQHSQGYPSPLGGSEHASSVPASGPS
 SGPQMSGPGGAPLDGADPQALGQQNRGPTTFNQNLHQLRAQIMAYKMLARGQLPDHLQMAVQKGRPM
 PGMQQQMPTLPFPPSVSATGPGPGPGPGPGPPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGP
 PKPWPEGPMANAAAPTSTPQKLIPPQPTGRPSAPPAPVPPAASVPMPPQTQSPGQPAQAPMVPPLHQKQS
 RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELLENLPGLSLAGDLRTKATIELKALRLNLFQRLRQEV
 VVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQOKIEQERKRRQKHQEYLNLSILQHAKDFKEYH
 RSVTGKIQKLTAKAVATYHANTEREQKKENERIEKERMRLMAEDEEGYRKLIQKKDKRLAYLLQQTDEY
 VANLTELVRQHKAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 VDAHHIIENAKQDQDDEYGVVSQALARGLSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSILYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVMKVSYSKSPAA
 RRAFVPQLRSGKFNVLTTTYEYIIKDKHIIAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLT
 GTPLQNKLPPELWALLNELLPTIFKSCSTFEQWENAFAMTGEKVDLNEEETILIIIRRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRIIPKLRLATNHHKVLFCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKTTFNEPGSEYFIFLLSTRAGGLGLNLQSAQTVIIFDSDWNPHQDLQAQDRA
 HRIGQQNEVRVLRRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFQALIEHEEQDEEE
 DEVPDDETQNMIAHHEEEFDLFMRMDLDRRREEARNPKRKPRLMEDELPSWIIKDDAEVERLTCEEEE
 EKMFGGRSRRHRKEVDYSDSLTEKQWLKTLKAIIEGTLEEIEEEVQKKSSRKRKRSDAGSSTPTTSTRS
 RDKDDSEKKQKKRGRPPAEKLSNPNNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYEL
 RKPVDFFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGLSIYEDSIVLQSVFTSVRQKIEKEDDS
 GESEEEEEEGEESSESRSVKVKKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRS
 SGSEED

Protein sequence of human transcription activator BRG1 isoform E (GenBank Accession No. NP_001122319.1)

MSTDPPLGGTTPRPGSPGPGSPGAMLGSPGSPGSAHSMGSPGPPSAGHPIPTQGGGYPQDNMH
 QMHKPMESMHEKMGMSDDPRYNQMKGMGMRSGGHAGMGPPSPMDQHSQGYPSPLGGSEHASSVPASGPS
 SGPQMSGPGGAPLDGADPQALGQQNRGPTTFNQNLHQLRAQIMAYKMLARGQLPDHLQMAVQKGRPM
 PGMQQQMPTLPFPPSVSATGPGPGPGPGPGPPAPPNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGP

PKPWPEGPMANAAAPTSTPQKLI PPQPTGRPSAPPAPVPPAASFVMPPTQSPGQPAQPAFMPVPLHQKQS
 RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGLAGDLRTKATIELKALRLNLFQRLRQEV
 VVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQOKIEQERKRRQKHQEYLNLSILQHAKDFKEYH
 RSVTGKIQLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYRKLIHQKKDKRLAYLLQQTDEY
 VANLTELVRQHKAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 VDAHIIENAKQDVDEYGVSQLARGLQSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPS VVKVSYKGS PAA
 RRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLT
 GTPLQNKLPPELWALLNLLFTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIRRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRIPLKLRATNHHKVLFLCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKTFFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSWNP HQDLQAQDRA
 HRIGQQNEVRVLRRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILHEHEEQDEEE
 DEVPDDET VNQMIARHEEEFDLFMRMDLDRRREARNPKRKPRLMEEDLPSWIIKDDAEVERLTCEEEE
 EKMFGRGSRHRKEVDYSDSLTEKQWLKAIIEEGTLEEEIEEEVROKKSSSRKRKRDS DAGSSTPTTSTRSRDK
 DDES KKKRGRPPAEKLSNPPNLT KKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRK
 PVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGLIYEDSIVLQSVFTSVRQKIEKEDDSEGE
 EEEEEEGEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSG
 SEED





Protein sequence of human transcription activator BRG1 isoform F (GenBank Accession No. NP_001122320.1)

MSTPDPLGGTTPRPGSPGPGSPGAMLGSPGSPGSAHSMGSPSPGPPSAGHP IPTQPGGYPQDNMH
 QMHKPMESMHEKMSDDPRYNQMKGMGRSGGHAGMGPPPSPMDQHSQGYPSPLGGSEHASSPVPASGPS
 SGPQMSSSGPGAPLDGADPQALGQQNRGPTPFNQNLHQLRAQIMAYKMLARGQPLPDHLQMAVQGRPM
 PGMQQQMPTLPPPSVSATGPGPGPGPGPGPGPAFFNYSRPHGMGGPNMPPPGPSGVPPGMPGQPPGGP
 PKPWPEGPMANAAAPTSTPQKLI PPQPTGRPSAPPAPVPPAASFVMPPTQSPGQPAQPAFMPVPLHQKQS
 RITPIQKPRGLDPVEILQEREYRLQARIAHRIQELENLPGLAGDLRTKATIELKALRLNLFQRLRQEV
 VVCMRRDTALETALNAKAYKRSKRQSLREARITEKLEKQOKIEQERKRRQKHQEYLNLSILQHAKDFKEYH
 RSVTGKIQLTKAVATYHANTEREQKKENERIEKERMRRLMAEDEEGYRKLIHQKKDKRLAYLLQQTDEY
 VANLTELVRQHKAQVAKEKKKKKKKKKAENAEGQTPAIGPDGEPLDETSQMSDLPVKVIHVESGKILTG
 TDAPKAGQLEAWLEMNPGYEVAPRSDSEESGSEEEEEEEEEEQPQAAQPPTLPVEEKKKIPDPDSDDVSE
 VDAHIIENAKQDVDEYGVSQLARGLQSYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYN
 NNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPS VVKVSYKGS PAA
 RRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLT
 GTPLQNKLPPELWALLNLLFTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIRRLHKVLRPFLLRRL
 KKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAQGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPY
 MFQHIIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRIPLKLRATNHHKVLFLCQMTSLMTIMEDYFAYRG
 FKYLRLDGTTKAEDRGMLLKTFFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSWNP HQDLQAQDRA
 HRIGQQNEVRVLRRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAFLQAILHEHEEQDEEE
 DEVPDDET VNQMIARHEEEFDLFMRMDLDRRREARNPKRKPRLMEEDLPSWIIKDDAEVERLTCEEEE
 EKMFGRGSRHRKEVDYSDSLTEKQWLKAIIEEGTLEEEIEEEVROKKSSSRKRKRDS DAGSSTPTTSTRSRDK
 DDES KKKRGRPPAEKLSNPPNLT KKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRK
 PVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGLIYEDSIVLQSVFTSVRQKIEKEDDSEGE
 EEEEEEGEEGSESESRSVKVKIKLGRKEKAQDRLKGGRRRPSRGSRAKPVVSDDDSEEEQEEDRSGSGS
 EED

SMARCA2 Antagonists

[0118] SMARCA2 antagonists are known in the art, and include, for example, the compounds shown in Table 2 below:

Table 2: SMARCA2 inhibitors

BMCL 2968	I-BET151	JQ1	PF13
			

[0119] Additional SMARCA2 inhibitors are known in the art, or will be apparent to the person of ordinary skill in the art based on the present disclosure. The disclosure is not limited in this respect.

[0120] In certain aspects of the disclosure an antagonist or inhibitor of SMARCA2 “selectively inhibits” or “selectively antagonizes” SMARCA2 activity of a cell when it inhibits SMARCA2 activity more effectively than it inhibits SMARCA4 activity. For example, in some embodiments the selective inhibitor or antagonist has an IC₅₀ for SMARCA2 that is at least 40 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective inhibitor or antagonist has an IC₅₀ for the SMARCA2 that is at least 50 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective inhibitor or antagonist has an IC₅₀ for the SMARCA2 that is at least 60 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective inhibitor or antagonist has an IC₅₀ for SMARCA2 that is at least 70 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective inhibitor or antagonist has an IC₅₀ for SMARCA2 that is at least 80 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective inhibitor or antagonist has an IC₅₀ for SMARCA2 that is at least 90 percent lower than the IC₅₀ for SMARCA4. In some embodiments, the selective antagonist or inhibitor of SMARCA2 exerts essentially no inhibitory effect on SMARCA4.

[0121] In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 2-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2

activity at least 5- fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 10-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 20-fold fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 50-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 100-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 1000-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 10000-fold more efficiently than SMARCA4 activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 activity at least 100000-fold more efficiently than SMARCA4 activity.

[0122] In some embodiments, reduced expression or function, or loss of function, of SMARCA4 confers sensitivity of said cell to inhibition of SMARCA2.

[0123] In certain aspects of the disclosure, the inhibitor or antagonist targets the helicase domain of SMARCA2. In some embodiments, the inhibitor or antagonist targets the ATP domain of SMARCA2. In some embodiments, the inhibitor or antagonist does not target the bromodomain of SMARCA2. In some embodiments, the inhibitor or antagonist targets the bromodomain of SMARCA2.

[0124] In some aspects, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 10%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 20%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 30%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 40%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 50%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2

helicase activity by at least 60%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 70%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 80%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 90%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 95%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by at least 98%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity by or at least 99%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 helicase activity and abolishes SMARCA2 activity.

[0125] In some aspects, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 10%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 20%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 30%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 40%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 50%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 60%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 70%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 80%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 90%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 95%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity by at least 98%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2

ATPase activity by or at least 99%. In some embodiments, a SMARCA2 antagonist (e.g., a SMARCA2 inhibitor) inhibits SMARCA2 ATPase activity and abolishes SMARCA2 activity [0126] In certain aspects of the disclosure, the SMARCA2 antagonist or inhibitor inhibits SMARCA2 activity. Inhibition of SMARCA2 activity can be detected using any suitable method. The inhibition can be measured, for example, either in terms of rate of SMARCA2 activity or as product of SMARCA2 activity.

[0127] The inhibition is a measurable inhibition compared to a suitable control. In some embodiments, inhibition is at least 10 percent inhibition compared to a suitable control. That is, the rate of enzymatic activity or the amount of product with the inhibitor is less than or equal to 90 percent of the corresponding rate or amount made without the inhibitor. In some embodiments, inhibition is at least 20, 25, 30, 40, 50, 60, 70, 75, 80, 90, or 95 percent inhibition compared to a suitable control. In some embodiments, inhibition is at least 99 percent inhibition compared to a suitable control. That is, the rate of enzymatic activity or the amount of product with the inhibitor is less than or equal to 1 percent of the corresponding rate or amount made without the inhibitor.

Pharmaceutical Formulations

[0128] The disclosure also provides pharmaceutical compositions comprising a compound of the disclosure or pharmaceutically acceptable salts thereof, and one or more other therapeutic agents disclosed herein, mixed with pharmaceutically suitable carriers or excipient(s) at doses to treat or prevent a disease or condition as described herein. The pharmaceutical compositions of the disclosure can also be administered in combination with other therapeutic agents or therapeutic modalities simultaneously, sequentially, or in alternation.

[0129] Mixtures of compositions of the disclosure can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions. For example, some aspects of the disclosure relate to a pharmaceutical composition comprising a therapeutically effective dose of a compound of the disclosure, or a pharmaceutically acceptable salt, hydrate, enantiomer or stereoisomer thereof, one or more other therapeutic agents, and a pharmaceutically acceptable diluent or carrier.

[0130] A “pharmaceutical composition” is a formulation containing the compounds of the disclosure in a form suitable for administration to a subject. A compound of the disclosure and one or more other therapeutic agents described herein each can be formulated individually or in

multiple pharmaceutical compositions in any combinations of the active ingredients.

Accordingly, one or more administration routes can be properly elected based on the dosage form of each pharmaceutical composition. Alternatively, a compound of the disclosure and one or more other therapeutic agents described herein can be formulated as one pharmaceutical composition.

[0131] In some embodiments, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump on an aerosol inhaler or a vial. The quantity of active ingredient (*e.g.*, a formulation of the disclosed compound or salt, hydrate, solvate or isomer thereof) in a unit dose of composition is an effective amount and is varied according to the particular treatment involved. One skilled in the art will appreciate that it is sometimes necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalational, buccal, sublingual, intrapleural, intrathecal, intranasal, and the like. Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. In some embodiments, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.

[0132] As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, anions, cations, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0133] “Pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipient that is acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.

[0134] A pharmaceutical composition of the disclosure is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, oral (*e.g.*, inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

[0135] A composition of the disclosure can be administered to a subject in many of the well-known methods currently used for chemotherapeutic treatment. For example, for treatment of cancers, a compound of the disclosure may be injected directly into tumors, injected into the blood stream or body cavities or taken orally or applied through the skin with patches. The dose chosen should be sufficient to constitute effective treatment but not so high as to cause unacceptable side effects. The state of the disease condition (*e.g.*, cancer, precancer, and the like) and the health of the patient should preferably be closely monitored during and for a reasonable period after treatment.

[0136] The term “therapeutically effective amount”, as used herein, refers to an amount of a pharmaceutical agent to treat, ameliorate, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend upon the subject’s body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation can be determined by routine experimentation that is within the skill and judgment of the clinician. In some aspects, the disease or condition to be treated is cancer. In some aspects, the disease or condition to be treated is a cell proliferative disorder.

[0137] In certain embodiments the therapeutically effective amount of each pharmaceutical agent used in combination will be lower when used in combination in comparison to monotherapy with each agent alone. Such lower therapeutically effective amount could afford for lower toxicity of the therapeutic regimen.

[0138] For any compound, the therapeutically effective amount can be estimated initially either in cell culture assays, *e.g.*, of neoplastic cells, or in animal models, usually rats, mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic/prophylactic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions that exhibit large therapeutic indices are preferred. The dosage may vary within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

[0139] Dosage and administration are adjusted to provide sufficient levels of the active agent(s) or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

[0140] The pharmaceutical compositions containing active compounds of the disclosure may be manufactured in a manner that is generally known, *e.g.*, by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Pharmaceutical compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of the active compounds into preparations that can be used pharmaceutically. Of course, the appropriate formulation is dependent upon the route of administration chosen.

[0141] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol and sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

[0142] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0143] Oral compositions generally include an inert diluent or an edible pharmaceutically acceptable carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid

carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

[0144] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser, which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

[0145] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

[0146] The active compounds can be prepared with pharmaceutically acceptable carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

[0147] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein

refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.

[0148] In therapeutic applications, the dosages of the SMARCA2 antagonists (e.g., inhibitors) described herein, other therapeutic agents described herein, compositions comprising a compound of the disclosure and one or more other therapeutic agents, or the pharmaceutical compositions used in accordance with the disclosure vary depending on the agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dose should be sufficient to result in slowing, and preferably regressing, the growth of the tumors and also preferably causing complete regression of the cancer.

Dosages can range from about 0.01 mg/kg per day to about 5000 mg/kg per day. In some aspects, dosages can range from about 1 mg/kg per day to about 1000 mg/kg per day. In some aspects, the dose will be in the range of about 0.1 mg/day to about 50 g/day; about 0.1 mg/day to about 25 g/day; about 0.1 mg/day to about 10 g/day; about 0.1 mg to about 3 g/day; or about 0.1 mg to about 1 g/day, in single, divided, or continuous doses (which dose may be adjusted for the patient's weight in kg, body surface area in m², and age in years). An effective amount of a pharmaceutical agent is that which provides an objectively identifiable improvement as noted by the clinician or other qualified observer. For example, regression of a tumor in a patient may be measured with reference to the diameter of a tumor. Decrease in the diameter of a tumor indicates regression. Regression is also indicated by failure of tumors to reoccur after treatment has stopped. As used herein, the term "dosage effective manner" refers to amount of an active compound to produce the desired biological effect in a subject or cell.

[0149] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

[0150] The composition of the disclosure is capable of further forming salts. The composition of the disclosure is capable of forming more than one salt per molecule, e.g., mono-, di-, tri-. All of these forms are also contemplated within the scope of the claimed invention.

[0151] As used herein, “pharmaceutically acceptable salts” refer to derivatives of the compounds of the disclosure wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, 1,2-ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluene sulfonic, and the commonly occurring amine acids, *e.g.*, glycine, alanine, phenylalanine, arginine, etc.

[0152] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentane propionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, muconic acid, and the like. The disclosure also encompasses salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, *e.g.*, an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

[0153] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates), of the same salt.

[0154] The composition of the disclosure may also be prepared as esters, for example, pharmaceutically acceptable esters. For example, a carboxylic acid function group in a compound can be converted to its corresponding ester, *e.g.*, a methyl, ethyl or other ester.

Also, an alcohol group in a compound can be converted to its corresponding ester, *e.g.*, acetate, propionate or other ester.

[0155] The composition, or pharmaceutically acceptable salts or solvates thereof, are administered orally, nasally, transdermally, pulmonary, inhalationally, buccally, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally and parenterally. In some embodiments, the compound is administered orally. One skilled in the art will recognize the advantages of certain routes of administration.

[0156] The dosage regimen utilizing the compounds is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof employed. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0157] Techniques for formulation and administration of the disclosed compounds of the disclosure can be found in *Remington: the Science and Practice of Pharmacy*, 19th edition, Mack Publishing Co., Easton, PA (1995). In some embodiments, the compounds described herein, and the pharmaceutically acceptable salts thereof, are used in pharmaceutical preparations in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compounds will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described herein.

[0158] All percentages and ratios used herein, unless otherwise indicated, are by weight. Other features and advantages of the disclosure are apparent from the different examples. The provided examples illustrate different components and methodology useful in practicing the disclosure. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the disclosure.

[0159] As used herein, a “subject in need thereof” is a subject having a disorder associated with a decreased level of activity or function of SMARCA4 compared to a control level, or a subject having an increased risk of developing such disorder relative to the population at large. Preferably, a subject in need thereof has cancer. A “subject” includes a mammal. The

mammal can be *e.g.*, any mammal, *e.g.*, a human, primate, bird, mouse, rat, fowl, dog, cat, cow, horse, goat, camel, sheep or a pig. Preferably, the mammal is a human.

[0160] In some embodiments, the control level is a level of SMARCA4 expression in a subject or cell from a subject that does not have cancer. In some embodiments, the control level may be a level of SMARCA4 expression in a subject or cell from a subject belonging to a certain population, wherein the level is equal or about equal to the average level of expression or function of SMARCA4 observed in said population. In some embodiments, the control level may be a level of expression or function of SMARCA4 that is equal or about equal to the average level of expression or function of SMARCA4 in the population at large.

[0161] The subject of the disclosure includes any human subject who has been diagnosed with, has symptoms of, or is at risk of developing a cancer or a precancerous condition. The subject of the disclosure includes any human subject expressing a mutant SMARCA4 gene. For example, a mutant SMARCA4 comprises one or more mutations, wherein the mutation is a substitution, a point mutation, a nonsense mutation, a missense mutation, a deletion, or an insertion or any other SMARCA4 mutation described herein or otherwise known in the art to be associated with a loss of function of SMARCA4.

[0162] A subject in need thereof may have refractory or resistant cancer. "Refractory or resistant cancer" means cancer that does not respond to an established line of treatment. The cancer may be resistant at the beginning of treatment or it may become resistant during treatment. In some embodiments, the subject in need thereof has cancer recurrence following remission on most recent therapy. In some embodiments, the subject in need thereof received and failed all known effective therapies for cancer treatment. In some embodiments, the subject in need thereof received at least one prior therapy. In certain embodiments the prior therapy is monotherapy. In certain embodiments the prior therapy is combination therapy.

[0163] In some embodiments, a subject in need thereof may have a secondary cancer as a result of a previous therapy. "Secondary cancer" means cancer that arises due to or as a result from previous carcinogenic therapies, such as chemotherapy.

[0164] The subject may also exhibit decreased function or expression of SMARCA4, or loss of function of SMARCA4.

[0165] In some embodiments, the subject is a participant in a clinical trial. In some embodiments, a criterion for participation of a subject in the clinical trial is a decreased activity

or function of SMARCA4, or loss of function of SMARCA4, in said subject or a cell of said subject.

[0166] As used herein, the term “responsiveness” is interchangeable with terms “responsive”, “sensitive”, and “sensitivity”, and it is meant that a subject is showing therapeutic responses when administered a composition of the disclosure, *e.g.*, tumor cells or tumor tissues of the subject undergo apoptosis and/or necrosis, and/or display reduced growing, dividing, or proliferation. This term is also meant that a subject will or has a higher probability, relative to the population at large, of showing therapeutic responses when administered a composition of the disclosure, *e.g.*, tumor cells or tumor tissues of the subject undergo apoptosis and/or necrosis, and/or display reduced growing, dividing, or proliferation.

[0167] As used herein, “sample” means any biological sample derived from the subject, includes but is not limited to, cells, tissues samples, body fluids (including, but not limited to, mucus, blood, plasma, serum, urine, saliva, and semen), tumor cells, and tumor tissues. Preferably, the sample is selected from bone marrow, peripheral blood cells, blood, plasma and serum. Samples can be provided by the subject under treatment or testing. Alternatively samples can be obtained by the physician according to routine practice in the art.

[0168] As used herein, a “normal cell” is a cell that cannot be classified as part of a “cell proliferative disorder”. A normal cell lacks unregulated or abnormal growth, or both, that can lead to the development of an unwanted condition or disease. Preferably, a normal cell possesses normally functioning cell cycle checkpoint control mechanisms.

[0169] As used herein, “contacting a cell” refers to a condition in which a compound or other composition of matter is in direct contact with a cell, or is close enough to induce a desired biological effect in a cell.

[0170] As used herein, “candidate compound” refers to a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, that has been or will be tested in one or more *in vitro* or *in vivo* biological assays, in order to determine if that compound is likely to elicit a desired biological or medical response in a cell, tissue, system, animal or human that is being sought by a researcher or clinician. A candidate compound is a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof. The biological or medical response can be the treatment of cancer. The biological or medical response can be treatment or prevention of a cell proliferative disorder. *In vitro* or *in vivo* biological assays can include,

but are not limited to, enzymatic activity assays, electrophoretic mobility shift assays, reporter gene assays, *in vitro* cell viability assays, and the assays described herein.

[0171] As used herein, “treating” or “treat” describes the management and care of a patient for the purpose of combating a disease, condition, or disorder and includes the administration of a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, to alleviate the symptoms or complications of a disease, condition or disorder, or to eliminate the disease, condition or disorder.

[0172] A composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, can also be used to prevent a disease, condition or disorder. As used herein, “preventing” or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.

[0173] As used herein, the term “alleviate” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased. Importantly, a sign or symptom can be alleviated without being eliminated. In some embodiments, the administration of pharmaceutical compositions of the disclosure leads to the elimination of a sign or symptom, however, elimination is not required. Effective dosages are expected to decrease the severity of a sign or symptom. For instance, a sign or symptom of a disorder such as cancer, which can occur in multiple locations, is alleviated if the severity of the cancer is decreased within at least one of multiple locations.

[0174] As used herein, the term “severity” is meant to describe the potential of cancer to transform from a precancerous, or benign, state into a malignant state. Alternatively, or in addition, severity is meant to describe a cancer stage, for example, according to the TNM system (accepted by the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC)) or by other art-recognized methods. Cancer stage refers to the extent or severity of the cancer, based on factors such as the location of the primary tumor, tumor size, number of tumors, and lymph node involvement (spread of cancer into lymph nodes). Alternatively, or in addition, severity is meant to describe the tumor grade by art-recognized methods (see, National Cancer Institute, www.cancer.gov). Tumor grade is a system used to classify cancer cells in terms of how abnormal they look under a microscope and how quickly the tumor is likely to grow and spread. Many factors are considered when determining tumor grade, including the structure and growth pattern of the cells. The specific factors used to

determine tumor grade vary with each type of cancer. Severity also describes a histologic grade, also called differentiation, which refers to how much the tumor cells resemble normal cells of the same tissue type (see, National Cancer Institute, www.cancer.gov). Furthermore, severity describes a nuclear grade, which refers to the size and shape of the nucleus in tumor cells and the percentage of tumor cells that are dividing (see, National Cancer Institute, www.cancer.gov).

[0175] In some aspects of the disclosure, severity describes the degree to which a tumor has secreted growth factors, degraded the extracellular matrix, become vascularized, lost adhesion to juxtaposed tissues, or metastasized. Moreover, severity describes the number of locations to which a primary tumor has metastasized. Finally, severity includes the difficulty of treating tumors of varying types and locations. For example, inoperable tumors, those cancers which have greater access to multiple body systems (hematological and immunological tumors), and those which are the most resistant to traditional treatments are considered most severe. In these situations, prolonging the life expectancy of the subject and/or reducing pain, decreasing the proportion of cancerous cells or restricting cells to one system, and improving cancer stage/tumor grade/histological grade/nuclear grade are considered alleviating a sign or symptom of the cancer.

[0176] As used herein the term "symptom" is defined as an indication of disease, illness, injury, or that something is not right in the body. Symptoms are felt or noticed by the individual experiencing the symptom, but may not easily be noticed by others. Others are defined as non-health-care professionals.

[0177] As used herein the term "sign" is also defined as an indication that something is not right in the body. But signs are defined as things that can be seen by a doctor, nurse, or other health care professional.

Cancer

[0178] A "cancer cell" or "cancerous cell" is a cell manifesting a cell proliferative disorder that is a cancer. Any reproducible means of measurement may be used to identify cancer cells or precancerous cells. Cancer cells or precancerous cells can be identified by histological typing or grading of a tissue sample (*e.g.*, a biopsy sample). Cancer cells or precancerous cells can be identified through the use of appropriate molecular markers.

[0179] Exemplary cancers include, but are not limited to, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, anorectal cancer, cancer of the anal canal, appendix cancer, childhood cerebellar astrocytoma, childhood cerebral astrocytoma, basal cell carcinoma, skin cancer (non-melanoma), biliary cancer, extrahepatic bile duct cancer, intrahepatic bile duct cancer, bladder cancer, urinary bladder cancer, bone and joint cancer, osteosarcoma and malignant fibrous histiocytoma, brain cancer, brain tumor, brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal, nervous system cancer, nervous system lymphoma, central nervous system cancer, central nervous system lymphoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, colorectal cancer, cutaneous T-cell lymphoma, lymphoid neoplasm, mycosis fungoides, Sezary Syndrome, endometrial cancer, esophageal cancer, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, ovarian germ cell tumor, gestational trophoblastic tumor glioma, head and neck cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, hypopharyngeal cancer, intraocular melanoma, ocular cancer, islet cell tumors (endocrine pancreas), Kaposi Sarcoma, kidney cancer, renal cancer, kidney cancer, laryngeal cancer, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavity cancer, liver cancer, lung cancer, non-small cell lung cancer, small cell lung cancer, AIDS-related lymphoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, Waldenström macroglobulinemia, medulloblastoma, melanoma, intraocular (eye) melanoma, merkel cell carcinoma, mesothelioma malignant, mesothelioma, metastatic squamous neck cancer, mouth cancer, cancer of the tongue, multiple endocrine neoplasia syndrome, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/ myeloproliferative diseases, chronic myelogenous leukemia, acute myeloid leukemia, multiple myeloma, chronic myeloproliferative disorders, nasopharyngeal cancer, neuroblastoma, oral cancer, oral cavity cancer, oropharyngeal cancer, ovarian cancer, ovarian epithelial cancer, ovarian low malignant potential tumor, pancreatic

cancer, islet cell pancreatic cancer, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineoblastoma and supratentorial primitive neuroectodermal tumors, pituitary tumor, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer, renal pelvis and ureter, transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, ewing family of sarcoma tumors, Kaposi Sarcoma, soft tissue sarcoma, uterine cancer, uterine sarcoma, skin cancer (non-melanoma), skin cancer (melanoma), merkel cell skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach (gastric) cancer, supratentorial primitive neuroectodermal tumors, testicular cancer, throat cancer, thymoma, thymoma and thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis and ureter and other urinary organs, gestational trophoblastic tumor, urethral cancer, endometrial uterine cancer, uterine sarcoma, uterine corpus cancer, vaginal cancer, vulvar cancer, and Wilm's Tumor.

[0180] A “cell proliferative disorder of the hematologic system” is a cell proliferative disorder involving cells of the hematologic system. A cell proliferative disorder of the hematologic system can include lymphoma, leukemia, myeloid neoplasms, mast cell neoplasms, myelodysplasia, benign monoclonal gammopathy, lymphomatoid granulomatosis, lymphomatoid papulosis, polycythemia vera, chronic myelocytic leukemia, agnogenic myeloid metaplasia, and essential thrombocythemia. A cell proliferative disorder of the hematologic system can include hyperplasia, dysplasia, and metaplasia of cells of the hematologic system. Preferably, compositions of the disclosure may be used to treat a cancer selected from the group consisting of a hematologic cancer of the disclosure or a hematologic cell proliferative disorder of the disclosure. A hematologic cancer of the disclosure can include multiple myeloma, lymphoma (including Hodgkin's lymphoma, non-Hodgkin's lymphoma, childhood lymphomas, and lymphomas of lymphocytic and cutaneous origin), leukemia (including childhood leukemia, hairy-cell leukemia, acute lymphocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, and mast cell leukemia), myeloid neoplasms and mast cell neoplasms.

[0181] A “cell proliferative disorder of the lung” is a cell proliferative disorder involving cells of the lung. Cell proliferative disorders of the lung can include all forms of cell proliferative disorders affecting lung cells. Cell proliferative disorders of the lung can include lung cancer, a

precancer or precancerous condition of the lung, benign growths or lesions of the lung, and malignant growths or lesions of the lung, and metastatic lesions in tissue and organs in the body other than the lung. Preferably, compositions of the disclosure may be used to treat lung cancer or cell proliferative disorders of the lung. Lung cancer can include all forms of cancer of the lung. Lung cancer can include malignant lung neoplasms, carcinoma *in situ*, typical carcinoid tumors, and atypical carcinoid tumors. Lung cancer can include small cell lung cancer (“SCLC”), non-small cell lung cancer (“NSCLC”), squamous cell carcinoma, adenocarcinoma, small cell carcinoma, large cell carcinoma, adenosquamous cell carcinoma, and mesothelioma. Lung cancer can include “scar carcinoma,” bronchioalveolar carcinoma, giant cell carcinoma, spindle cell carcinoma, and large cell neuroendocrine carcinoma. Lung cancer can include lung neoplasms having histologic and ultrastructural heterogeneity (*e.g.*, mixed cell types).

[0182] Cell proliferative disorders of the lung can include all forms of cell proliferative disorders affecting lung cells. Cell proliferative disorders of the lung can include lung cancer, precancerous conditions of the lung. Cell proliferative disorders of the lung can include hyperplasia, metaplasia, and dysplasia of the lung. Cell proliferative disorders of the lung can include asbestos-induced hyperplasia, squamous metaplasia, and benign reactive mesothelial metaplasia. Cell proliferative disorders of the lung can include replacement of columnar epithelium with stratified squamous epithelium, and mucosal dysplasia. Individuals exposed to inhaled injurious environmental agents such as cigarette smoke and asbestos may be at increased risk for developing cell proliferative disorders of the lung. Prior lung diseases that may predispose individuals to development of cell proliferative disorders of the lung can include chronic interstitial lung disease, necrotizing pulmonary disease, scleroderma, rheumatoid disease, sarcoidosis, interstitial pneumonitis, tuberculosis, repeated pneumonias, idiopathic pulmonary fibrosis, granulomata, asbestosis, fibrosing alveolitis, and Hodgkin's disease.

[0183] A “cell proliferative disorder of the colon” is a cell proliferative disorder involving cells of the colon. Preferably, the cell proliferative disorder of the colon is colon cancer. Preferably, compositions of the disclosure may be used to treat colon cancer or cell proliferative disorders of the colon. Colon cancer can include all forms of cancer of the colon. Colon cancer can include sporadic and hereditary colon cancers. Colon cancer can include malignant colon neoplasms, carcinoma *in situ*, typical carcinoid tumors, and atypical carcinoid tumors. Colon

cancer can include adenocarcinoma, squamous cell carcinoma, and adenosquamous cell carcinoma. Colon cancer can be associated with a hereditary syndrome selected from the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis. Colon cancer can be caused by a hereditary syndrome selected from the group consisting of hereditary nonpolyposis colorectal cancer, familial adenomatous polyposis, Gardner's syndrome, Peutz-Jeghers syndrome, Turcot's syndrome and juvenile polyposis.

[0184] Cell proliferative disorders of the colon can include all forms of cell proliferative disorders affecting colon cells. Cell proliferative disorders of the colon can include colon cancer, precancerous conditions of the colon, adenomatous polyps of the colon, and metachronous lesions of the colon. A cell proliferative disorder of the colon can include adenoma. Cell proliferative disorders of the colon can be characterized by hyperplasia, metaplasia, and dysplasia of the colon. Prior colon diseases that may predispose individuals to development of cell proliferative disorders of the colon can include prior colon cancer. Current disease that may predispose individuals to development of cell proliferative disorders of the colon can include Crohn's disease and ulcerative colitis. A cell proliferative disorder of the colon can be associated with a mutation in a gene selected from the group consisting of *p53*, *ras*, *FAP* and *DCC*. An individual can have an elevated risk of developing a cell proliferative disorder of the colon due to the presence of a mutation in a gene selected from the group consisting of *p53*, *ras*, *FAP* and *DCC*.

[0185] A "cell proliferative disorder of the pancreas" is a cell proliferative disorder involving cells of the pancreas. Cell proliferative disorders of the pancreas can include all forms of cell proliferative disorders affecting pancreatic cells. Cell proliferative disorders of the pancreas can include pancreas cancer, a precancer or precancerous condition of the pancreas, hyperplasia of the pancreas, and dysaplasia of the pancreas, benign growths or lesions of the pancreas, and malignant growths or lesions of the pancreas, and metastatic lesions in tissue and organs in the body other than the pancreas. Pancreatic cancer includes all forms of cancer of the pancreas. Pancreatic cancer can include ductal adenocarcinoma, adenosquamous carcinoma, pleomorphic giant cell carcinoma, mucinous adenocarcinoma, osteoclast-like giant cell carcinoma, mucinous cystadenocarcinoma, acinar carcinoma, unclassified large cell carcinoma, small cell carcinoma, pancreatoblastoma, papillary neoplasm, mucinous cystadenoma, papillary cystic neoplasm, and

serous cystadenoma. Pancreatic cancer can also include pancreatic neoplasms having histologic and ultrastructural heterogeneity (*e.g.*, mixed cell types).

[0186] A “cell proliferative disorder of the prostate” is a cell proliferative disorder involving cells of the prostate. Cell proliferative disorders of the prostate can include all forms of cell proliferative disorders affecting prostate cells. Cell proliferative disorders of the prostate can include prostate cancer, a precancer or precancerous condition of the prostate, benign growths or lesions of the prostate, malignant growths or lesions of the prostate and metastatic lesions in tissue and organs in the body other than the prostate. Cell proliferative disorders of the prostate can include hyperplasia, metaplasia, and dysplasia of the prostate.

[0187] A “cell proliferative disorder of the skin” is a cell proliferative disorder involving cells of the skin. Cell proliferative disorders of the skin can include all forms of cell proliferative disorders affecting skin cells. Cell proliferative disorders of the skin can include a precancer or precancerous condition of the skin, benign growths or lesions of the skin, melanoma, malignant melanoma and other malignant growths or lesions of the skin, and metastatic lesions in tissue and organs in the body other than the skin. Cell proliferative disorders of the skin can include hyperplasia, metaplasia, and dysplasia of the skin.

[0188] A “cell proliferative disorder of the ovary” is a cell proliferative disorder involving cells of the ovary. Cell proliferative disorders of the ovary can include all forms of cell proliferative disorders affecting cells of the ovary. Cell proliferative disorders of the ovary can include a precancer or precancerous condition of the ovary, benign growths or lesions of the ovary, ovarian cancer, malignant growths or lesions of the ovary, and metastatic lesions in tissue and organs in the body other than the ovary. Cell proliferative disorders of the skin can include hyperplasia, metaplasia, and dysplasia of cells of the ovary.

[0189] A “cell proliferative disorder of the breast” is a cell proliferative disorder involving cells of the breast. Cell proliferative disorders of the breast can include all forms of cell proliferative disorders affecting breast cells. Cell proliferative disorders of the breast can include breast cancer, a precancer or precancerous condition of the breast, benign growths or lesions of the breast, and malignant growths or lesions of the breast, and metastatic lesions in tissue and organs in the body other than the breast. Cell proliferative disorders of the breast can include hyperplasia, metaplasia, and dysplasia of the breast.

[0190] A cell proliferative disorder of the breast can be a precancerous condition of the breast. Compositions of the disclosure may be used to treat a precancerous condition of the breast. A precancerous condition of the breast can include atypical hyperplasia of the breast, ductal carcinoma *in situ* (DCIS), intraductal carcinoma, lobular carcinoma *in situ* (LCIS), lobular neoplasia, and stage 0 or grade 0 growth or lesion of the breast (*e.g.*, stage 0 or grade 0 breast cancer, or carcinoma *in situ*). A precancerous condition of the breast can be staged according to the TNM classification scheme as accepted by the American Joint Committee on Cancer (AJCC), where the primary tumor (T) has been assigned a stage of T0 or Tis; and where the regional lymph nodes (N) have been assigned a stage of N0; and where distant metastasis (M) has been assigned a stage of M0.

[0191] The cell proliferative disorder of the breast can be breast cancer. Preferably, compositions of the disclosure may be used to treat breast cancer. Breast cancer includes all forms of cancer of the breast. Breast cancer can include primary epithelial breast cancers. Breast cancer can include cancers in which the breast is involved by other tumors such as lymphoma, sarcoma or melanoma. Breast cancer can include carcinoma of the breast, ductal carcinoma of the breast, lobular carcinoma of the breast, undifferentiated carcinoma of the breast, cystosarcoma phyllodes of the breast, angiosarcoma of the breast, and primary lymphoma of the breast. Breast cancer can include Stage I, II, IIIA, IIIB, IIIC and IV breast cancer. Ductal carcinoma of the breast can include invasive carcinoma, invasive carcinoma *in situ* with predominant intraductal component, inflammatory breast cancer, and a ductal carcinoma of the breast with a histologic type selected from the group consisting of comedo, mucinous (colloid), medullary, medullary with lymphocytic infiltrate, papillary, scirrhous, and tubular. Lobular carcinoma of the breast can include invasive lobular carcinoma with predominant *in situ* component, invasive lobular carcinoma, and infiltrating lobular carcinoma. Breast cancer can include Paget's disease, Paget's disease with intraductal carcinoma, and Paget's disease with invasive ductal carcinoma. Breast cancer can include breast neoplasms having histologic and ultrastructural heterogeneity (*e.g.*, mixed cell types).

[0192] Preferably, compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, may be used to treat breast cancer. A breast cancer that is to be treated can include familial breast cancer. A breast cancer that is to be treated can include sporadic breast cancer. A breast cancer that is to be treated can arise in a male subject. A breast cancer that is to be

treated can arise in a female subject. A breast cancer that is to be treated can arise in a premenopausal female subject or a postmenopausal female subject. A breast cancer that is to be treated can arise in a subject equal to or older than 30 years old, or a subject younger than 30 years old. A breast cancer that is to be treated has arisen in a subject equal to or older than 50 years old, or a subject younger than 50 years old. A breast cancer that is to be treated can arise in a subject equal to or older than 70 years old, or a subject younger than 70 years old.

[0193] A breast cancer that is to be treated can be typed to identify a familial or spontaneous mutation in BRCA1, BRCA2, or p53. A breast cancer that is to be treated can be typed as having a HER2/neu gene amplification, as overexpressing HER2/neu, or as having a low, intermediate or high level of HER2/neu expression. A breast cancer that is to be treated can be typed for a marker selected from the group consisting of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2, Ki-67, CA15-3, CA 27-29, and c-Met. A breast cancer that is to be treated can be typed as ER-unknown, ER-rich or ER-poor. A breast cancer that is to be treated can be typed as ER-negative or ER-positive. ER-typing of a breast cancer may be performed by any reproducible means. ER-typing of a breast cancer may be performed as set forth in Onkologie 27: 175-179 (2004). A breast cancer that is to be treated can be typed as PR-unknown, PR-rich, or PR-poor. A breast cancer that is to be treated can be typed as PR-negative or PR-positive. A breast cancer that is to be treated can be typed as receptor positive or receptor negative. A breast cancer that is to be treated can be typed as being associated with elevated blood levels of CA 15-3, or CA 27-29, or both.

[0194] A breast cancer that is to be treated can include a localized tumor of the breast. A breast cancer that is to be treated can include a tumor of the breast that is associated with a negative sentinel lymph node (SLN) biopsy. A breast cancer that is to be treated can include a tumor of the breast that is associated with a positive sentinel lymph node (SLN) biopsy. A breast cancer that is to be treated can include a tumor of the breast that is associated with one or more positive axillary lymph nodes, where the axillary lymph nodes have been staged by any applicable method. A breast cancer that is to be treated can include a tumor of the breast that has been typed as having nodal negative status (*e.g.*, node-negative) or nodal positive status (*e.g.*, node-positive). A breast cancer that is to be treated can include a tumor of the breast that has metastasized to other locations in the body. A breast cancer that is to be treated can be classified as having metastasized to a location selected from the group consisting of bone, lung,

liver, or brain. A breast cancer that is to be treated can be classified according to a characteristic selected from the group consisting of metastatic, localized, regional, local-regional, locally advanced, distant, multicentric, bilateral, ipsilateral, contralateral, newly diagnosed, recurrent, and inoperable.

[0195] A compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, may be used to treat or prevent a cell proliferative disorder of the breast, or to treat or prevent breast cancer, in a subject having an increased risk of developing breast cancer relative to the population at large. A subject with an increased risk of developing breast cancer relative to the population at large is a female subject with a family history or personal history of breast cancer. A subject with an increased risk of developing breast cancer relative to the population at large is a female subject having a germ-line or spontaneous mutation in BRCA1 or BRCA2, or both. A subject with an increased risk of developing breast cancer relative to the population at large is a female subject with a family history of breast cancer and a germ-line or spontaneous mutation in BRCA1 or BRCA2, or both. A subject with an increased risk of developing breast cancer relative to the population at large is a female who is greater than 30 years old, greater than 40 years old, greater than 50 years old, greater than 60 years old, greater than 70 years old, greater than 80 years old, or greater than 90 years old. A subject with an increased risk of developing breast cancer relative to the population at large is a subject with atypical hyperplasia of the breast, ductal carcinoma *in situ* (DCIS), intraductal carcinoma, lobular carcinoma *in situ* (LCIS), lobular neoplasia, or a stage 0 growth or lesion of the breast (*e.g.*, stage 0 or grade 0 breast cancer, or carcinoma *in situ*).

[0196] A breast cancer that is to be treated can histologically graded according to the Scarff-Bloom-Richardson system, wherein a breast tumor has been assigned a mitosis count score of 1, 2, or 3; a nuclear pleiomorphism score of 1, 2, or 3; a tubule formation score of 1, 2, or 3; and a total Scarff-Bloom-Richardson score of between 3 and 9. A breast cancer that is to be treated can be assigned a tumor grade according to the International Consensus Panel on the Treatment of Breast Cancer selected from the group consisting of grade 1, grade 1-2, grade 2, grade 2-3, or grade 3.

[0197] A cancer that is to be treated can be staged according to the American Joint Committee on Cancer (AJCC) TNM classification system, where the tumor (T) has been assigned a stage of TX, T1, T1mic, T1a, T1b, T1c, T2, T3, T4, T4a, T4b, T4c, or T4d; and where the regional

lymph nodes (N) have been assigned a stage of NX, N0, N1, N2, N2a, N2b, N3, N3a, N3b, or N3c; and where distant metastasis (M) can be assigned a stage of MX, M0, or M1. A cancer that is to be treated can be staged according to an American Joint Committee on Cancer (AJCC) classification as Stage I, Stage IIA, Stage IIB, Stage IIIA, Stage IIIB, Stage IIIC, or Stage IV. A cancer that is to be treated can be assigned a grade according to an AJCC classification as Grade GX (*e.g.*, grade cannot be assessed), Grade 1, Grade 2, Grade 3 or Grade 4. A cancer that is to be treated can be staged according to an AJCC pathologic classification (pN) of pNX, pN0, PN0 (I-), PN0 (I+), PN0 (mol-), PN0 (mol+), PN1, PN1(mi), PN1a, PN1b, PN1c, pN2, pN2a, pN2b, pN3, pN3a, pN3b, or pN3c.

[0198] A cancer that is to be treated can include a tumor that has been determined to be less than or equal to about 2 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be from about 2 to about 5 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be greater than or equal to about 3 centimeters in diameter. A cancer that is to be treated can include a tumor that has been determined to be greater than 5 centimeters in diameter. A cancer that is to be treated can be classified by microscopic appearance as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. A cancer that is to be treated can be classified by microscopic appearance with respect to mitosis count (*e.g.*, amount of cell division) or nuclear pleiomorphism (*e.g.*, change in cells). A cancer that is to be treated can be classified by microscopic appearance as being associated with areas of necrosis (*e.g.*, areas of dying or degenerating cells). A cancer that is to be treated can be classified as having an abnormal karyotype, having an abnormal number of chromosomes, or having one or more chromosomes that are abnormal in appearance. A cancer that is to be treated can be classified as being aneuploid, triploid, tetraploid, or as having an altered ploidy. A cancer that is to be treated can be classified as having a chromosomal translocation, or a deletion or duplication of an entire chromosome, or a region of deletion, duplication or amplification of a portion of a chromosome.

[0199] In some embodiments, a cancer that is to be treated is a cancer in which a member of the SWI/SNF complex, *e.g.*, SMARCA4, is mutated or exhibits a loss of function (*e.g.*, a decrease of enzymatic activity). For example, a cancer to be treated may be a cancer in which SMARCA4 is mutated. Non limiting examples of cancers in which SMARCA4 mutations

occur include small cell carcinoma of the ovary of the hypercalcemic type (SCCOHT), bladder cancer, stomach cancer, lung cancer (e.g., non-small cell lung cancer), glioblastoma brain tumors (glioma, GBM), head and neck cancer, kidney cancer, uterine cancer, cervical cancer, and pancreatic cancer.

[0200] A cancer that is to be treated can be evaluated by DNA cytometry, flow cytometry, or image cytometry. A cancer that is to be treated can be typed as having 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of cells in the synthesis stage of cell division (e.g., in S phase of cell division). A cancer that is to be treated can be typed as having a low S-phase fraction or a high S-phase fraction.

[0201] Cancer is a group of diseases that may cause almost any sign or symptom. The signs and symptoms will depend on where the cancer is, the size of the cancer, and how much it affects the nearby organs or structures. If a cancer spreads (metastasizes), then symptoms may appear in different parts of the body.

[0202] Treating cancer can result in a reduction in tumor volume. Preferably, after treatment, tumor volume is reduced by 5% or greater relative to its size prior to treatment; more preferably, tumor volume is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75% or greater. Tumor volume may be measured by any reproducible means of measurement.

[0203] Treating cancer can result in a decrease in number of tumors. Preferably, after treatment, tumor number is reduced by 5% or greater relative to number prior to treatment; more preferably, tumor number is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. Number of tumors may be measured by any reproducible means of measurement. The number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2x, 3x, 4x, 5x, 10x, or 50x.

[0204] Treating cancer can result in a decrease in number of metastatic lesions in other tissues or organs distant from the primary tumor site. Preferably, after treatment, the number of

metastatic lesions is reduced by 5% or greater relative to number prior to treatment; more preferably, the number of metastatic lesions is reduced by 10% or greater; more preferably, reduced by 20% or greater; more preferably, reduced by 30% or greater; more preferably, reduced by 40% or greater; even more preferably, reduced by 50% or greater; and most preferably, reduced by greater than 75%. The number of metastatic lesions may be measured by any reproducible means of measurement. The number of metastatic lesions may be measured by counting metastatic lesions visible to the naked eye or at a specified magnification. Preferably, the specified magnification is 2x, 3x, 4x, 5x, 10x, or 50x.

[0205] Treating cancer can result in an increase in average survival time of a population of treated subjects in comparison to a population receiving carrier alone. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.

[0206] Treating cancer can result in an increase in average survival time of a population of treated subjects in comparison to a population of untreated subjects. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.

[0207] Treating cancer can result in increase in average survival time of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the disclosure, or a pharmaceutically acceptable salt, solvate, analog or derivative

thereof. Preferably, the average survival time is increased by more than 30 days; more preferably, by more than 60 days; more preferably, by more than 90 days; and most preferably, by more than 120 days. An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with an active compound. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with an active compound.

[0208] Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving carrier alone. Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. Treating cancer can result in a decrease in the mortality rate of a population of treated subjects in comparison to a population receiving monotherapy with a drug that is not a compound of the disclosure, or a pharmaceutically acceptable salt, solvate, analog or derivative thereof. Preferably, the mortality rate is decreased by more than 2%; more preferably, by more than 5%; more preferably, by more than 10%; and most preferably, by more than 25%. A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means. A decrease in the mortality rate of a population may be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with an active compound. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with an active compound.

[0209] Treating cancer can result in a decrease in tumor growth rate. Preferably, after treatment, tumor growth rate is reduced by at least 5% relative to number prior to treatment; more preferably, tumor growth rate is reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. Tumor growth rate may be measured by any reproducible means of measurement. Tumor growth rate can be measured according to a change in tumor diameter per unit time.

[0210] Treating cancer can result in a decrease in tumor regrowth. Preferably, after treatment, tumor regrowth is less than 5%; more preferably, tumor regrowth is less than 10%; more preferably, less than 20%; more preferably, less than 30%; more preferably, less than 40%; more preferably, less than 50%; even more preferably, less than 50%; and most preferably, less than 75%. Tumor regrowth may be measured by any reproducible means of measurement. Tumor regrowth is measured, for example, by measuring an increase in the diameter of a tumor after a prior tumor shrinkage that followed treatment. A decrease in tumor regrowth is indicated by failure of tumors to reoccur after treatment has stopped.

[0211] Treating or preventing a cell proliferative disorder can result in a reduction in the rate of cellular proliferation. Preferably, after treatment, the rate of cellular proliferation is reduced by at least 5%; more preferably, by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. The rate of cellular proliferation may be measured by any reproducible means of measurement. The rate of cellular proliferation is measured, for example, by measuring the number of dividing cells in a tissue sample per unit time.

[0212] Treating or preventing a cell proliferative disorder can result in a reduction in the proportion of proliferating cells. Preferably, after treatment, the proportion of proliferating cells is reduced by at least 5%; more preferably, by at least 10%; more preferably, by at least 20%; more preferably, by at least 30%; more preferably, by at least 40%; more preferably, by at least 50%; even more preferably, by at least 50%; and most preferably, by at least 75%. The proportion of proliferating cells may be measured by any reproducible means of measurement. Preferably, the proportion of proliferating cells is measured, for example, by quantifying the number of dividing cells relative to the number of nondividing cells in a tissue sample. The proportion of proliferating cells can be equivalent to the mitotic index.

[0213] Treating or preventing a cell proliferative disorder can result in a decrease in size of an area or zone of cellular proliferation. Preferably, after treatment, size of an area or zone of cellular proliferation is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by

at least 75%. Size of an area or zone of cellular proliferation may be measured by any reproducible means of measurement. The size of an area or zone of cellular proliferation may be measured as a diameter or width of an area or zone of cellular proliferation.

[0214] Treating or preventing a cell proliferative disorder can result in a decrease in the number or proportion of cells having an abnormal appearance or morphology. Preferably, after treatment, the number of cells having an abnormal morphology is reduced by at least 5% relative to its size prior to treatment; more preferably, reduced by at least 10%; more preferably, reduced by at least 20%; more preferably, reduced by at least 30%; more preferably, reduced by at least 40%; more preferably, reduced by at least 50%; even more preferably, reduced by at least 50%; and most preferably, reduced by at least 75%. An abnormal cellular appearance or morphology may be measured by any reproducible means of measurement. An abnormal cellular morphology can be measured by microscopy, *e.g.*, using an inverted tissue culture microscope. An abnormal cellular morphology can take the form of nuclear pleiomorphism.

[0215] As used herein, the term “selectively” means tending to occur at a higher frequency in one population than in another population. The compared populations can be cell populations. Preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, acts selectively on a cancer or precancerous cell but not on a normal cell. Preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, acts selectively to modulate one molecular target (*e.g.*, a target helicase, such as SMARCA2) but does not significantly modulate another molecular target (*e.g.*, a different helicase, such as SMARCA4, or a non-helicase enzyme, *e.g.*, in the case of a SMARCA2 ATPase inhibitor, the ATPase activity of a different helicase, or a different protein having ATPase activity). The disclosure also provides a method for selectively inhibiting the activity of an enzyme, such as a helicase (*e.g.*, SMARCA2). Preferably, a SMARCA2 inhibitor selectively inhibits SMARCA2, *e.g.*, a helicase or ATPase activity of SMARCA2, relative to inhibiting a second, different enzyme, *e.g.*, a different helicase (*e.g.*, SMARCA4) or a different enzyme exhibiting ATPase activity, if the inhibition of SMARCA2 is greater than two times the inhibition of the second, different enzyme. In some embodiments, selective SMARCA2 inhibition occurs if the inhibition of SMARCA2 is greater than five times, greater than 10 times, greater than fifty times, greater than 100 times, or greater than 1000 times the inhibition of the second, different

enzyme. For example, in some embodiments, SMARCA2 inhibition would be said to occur selectively over SMARCA4 inhibition if SMARCA2 helicase activity inhibition is greater than 2-fold the SMARCA4 inhibition.

[0216] A composition of the disclosure, e.g., a composition comprising SMARCA2 inhibitor, and one or more other therapeutic agents, such as prednisone, can modulate the activity of a molecular target (*e.g.*, a target helicase). Modulating refers to stimulating or inhibiting an activity of a molecular target. Preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 2-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. More preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. The activity of a molecular target may be measured by any reproducible means. The activity of a molecular target may be measured *in vitro* or *in vivo*. For example, the activity of a molecular target may be measured *in vitro* by an enzymatic activity assay or a DNA binding assay, or the activity of a molecular target may be measured *in vivo* by assaying for expression of a reporter gene.

[0217] A composition of the disclosure, e.g., a composition comprising SMARCA2 inhibitor, and one or more other therapeutic agents, such as prednisone, can modulate the activity of a molecular target (*e.g.*, a target helicase). Modulating refers to stimulating or inhibiting an activity of a molecular target. Preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 2-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. More preferably, a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, modulates the activity of a molecular target if it stimulates or inhibits the activity of the molecular target by at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound. The activity of a molecular target may be measured by

any reproducible means. The activity of a molecular target may be measured *in vitro* or *in vivo*. For example, the activity of a molecular target may be measured *in vitro* by an enzymatic activity assay or a DNA binding assay, or the activity of a molecular target may be measured *in vivo* by assaying for expression of a reporter gene.

[0218] A composition of the disclosure does not significantly modulate the activity of a molecular target if the addition of the compound does not stimulate or inhibit the activity of the molecular target by greater than 10% relative to the activity of the molecular target under the same conditions but lacking only the presence of said compound.

[0219] Administering a composition of the disclosure to a cell or a subject in need thereof can result in modulation (*i.e.*, stimulation or inhibition) of an activity of a helicase of interest.

[0220] Administering a compound of the disclosure, *e.g.*, a composition comprising aSMARCA2 inhibitor, and one or more other therapeutic agents, such as prednisone, to a cell or a subject in need thereof results in modulation (*i.e.*, stimulation or inhibition) of an activity of an intracellular target (*e.g.*, substrate). Several intracellular targets can be modulated with the compounds of the disclosure, including, but not limited to, helicases.

[0221] Activating refers to placing a composition of matter (*e.g.*, protein or nucleic acid) in a state suitable for carrying out a desired biological function. A composition of matter capable of being activated also has an unactivated state. An activated composition of matter may have an inhibitory or stimulatory biological function, or both.

[0222] Elevation refers to an increase in a desired biological activity of a composition of matter (*e.g.*, a protein or a nucleic acid). Elevation may occur through an increase in concentration of a composition of matter.

[0223] As used herein, “a cell cycle checkpoint pathway” refers to a biochemical pathway that is involved in modulation of a cell cycle checkpoint. A cell cycle checkpoint pathway may have stimulatory or inhibitory effects, or both, on one or more functions comprising a cell cycle checkpoint. A cell cycle checkpoint pathway is comprised of at least two compositions of matter, preferably proteins, both of which contribute to modulation of a cell cycle checkpoint. A cell cycle checkpoint pathway may be activated through an activation of one or more members of the cell cycle checkpoint pathway. Preferably, a cell cycle checkpoint pathway is a biochemical signaling pathway.

[0224] As used herein, “cell cycle checkpoint regulator” refers to a composition of matter that can function, at least in part, in modulation of a cell cycle checkpoint. A cell cycle checkpoint regulator may have stimulatory or inhibitory effects, or both, on one or more functions comprising a cell cycle checkpoint. A cell cycle checkpoint regulator can be a protein or not a protein.

[0225] Treating cancer or a cell proliferative disorder can result in cell death, and preferably, cell death results in a decrease of at least 10% in number of cells in a population. More preferably, cell death means a decrease of at least 20%; more preferably, a decrease of at least 30%; more preferably, a decrease of at least 40%; more preferably, a decrease of at least 50%; most preferably, a decrease of at least 75%. Number of cells in a population may be measured by any reproducible means. A number of cells in a population can be measured by fluorescence activated cell sorting (FACS), immunofluorescence microscopy and light microscopy. Methods of measuring cell death are as shown in Li *et al.*, *Proc Natl Acad Sci U S A*. 100(5): 2674-8, 2003. In some aspects, cell death occurs by apoptosis.

[0226] Preferably, an effective amount of a composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, is not significantly cytotoxic to normal cells. A therapeutically effective amount of a compound is not significantly cytotoxic to normal cells if administration of the compound in a therapeutically effective amount does not induce cell death in greater than 10% of normal cells. A therapeutically effective amount of a compound does not significantly affect the viability of normal cells if administration of the compound in a therapeutically effective amount does not induce cell death in greater than 10% of normal cells. In some aspects, cell death occurs by apoptosis.

[0227] Contacting a cell with a composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, can induce or activate cell death selectively in cancer cells.

Administering to a subject in need thereof a compound of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, can induce or activate cell death selectively in cancer cells.

Contacting a cell with a composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, can induce cell death selectively in one or more cells affected by a cell proliferative disorder. Preferably, administering to a subject in need thereof a composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, induces cell death selectively in one or more cells affected by a cell proliferative disorder.

[0228] The disclosure relates to a method of treating or preventing cancer by administering a composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, to a subject in need thereof, where administration of the composition of the disclosure, or a pharmaceutically acceptable salt or solvate thereof, results in one or more of the following: prevention of cancer cell proliferation by accumulation of cells in one or more phases of the cell cycle (e.g. G1, G1/S, G2/M), or induction of cell senescence, or promotion of tumor cell differentiation; promotion of cell death in cancer cells via cytotoxicity, necrosis or apoptosis, without a significant amount of cell death in normal cells, antitumor activity in animals with a therapeutic index of at least 2. As used herein, “therapeutic index” is the maximum tolerated dose divided by the efficacious dose.

[0229] One skilled in the art may refer to general reference texts for detailed descriptions of known techniques discussed herein or equivalent techniques. These texts include Ausubel *et al.*, *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (2005); Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual* (3rd edition), Cold Spring Harbor Press, Cold Spring Harbor, New York (2000); Coligan *et al.*, *Current Protocols in Immunology*, John Wiley & Sons, N.Y.; Enna *et al.*, *Current Protocols in Pharmacology*, John Wiley & Sons, N.Y.; Fingl *et al.*, *The Pharmacological Basis of Therapeutics* (1975), Remington's *Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 18th edition (1990). These texts can, of course, also be referred to in making or using an aspect of the disclosure.

Example 1:

[0230] Sensitivity to knockout of SMARCA2 through CRISPR/Cas9-mediated gene knockout was determined by CRISPR/Cas9 pooled screening. A large population of cells was infected with a pooled library of barcoded sgRNA guides to genes of interest. For proliferation-based screens, the barcode/CRISPR representation was measured at the start and end of the experiment by sequencing of genomic DNA, and the relative enrichment/decrease in CRISPR sgRNAs identified genes for which knockout altered proliferation rate. A custom CRISPR lentiviral library with 6500 small guide RNAs targeting over 600 epigenetic genes was generated, and screened against 195 cell lines over a time course of up to 40 days. KRas was included as a positive control in the CRISPR/Cas9 library, and it was observed that sensitivity to KRas knockout was highly correlated with KRas mutations. SMARCA4 null or

mutant cells, including A549 and NCIH1299 lung cancer cell lines, were found to be sensitive to SMARCA2 knockout (Figure 1). The synthetic lethal relationship between SMARCA2 and SMARCA4 was further validated in the literature (Hoffman et al. PNAS, 2013, 111(8), 3128-3133; Wilson et al, Mol. Cell Biol., 2014, 34(6), 1136-44; Vangamundi et al. Cancer Res. 2015, 75(18):3865-78; and Oike et al., Cancer Res. 2013 Sep 1; 73(17), 5508-18; the contents of each of which are incorporated herein by reference in their entireties)

[0231] To further investigate the relationship between SMARCA4 expression and sensitivity to SMARCA2 inhibition, a panel of non-small cell lung cancer (NSCLC) lines was tested for protein levels of SMARCA2 and SMARCA4. A transcriptomic analysis of NSCLC cell lines that have RNA seq. data available in Cancer Cell Line Encyclopedia (CCLE) is shown in Figure 2. Cell lines with low SMARCA4 expression were found to be sensitive to SMARCA2 inhibition, suggesting that loss of SMARCA4 predicts response to SMARCA2 inhibition and is a potential patient stratification biomarker. It is also suggested that SMARCA4 mutations under-predict protein loss, and that hence, an understanding of protein levels of SMARCA2 and SMARCA4 expression is critical, calling for better analysis of this patient population, e.g. via immunohistochemistry assays or multiplex protein assays to assess protein expression in clinical samples.

Example 2: SMARCA2/4 immunohistochemistry assay to assess protein expression in clinical samples

[0232] A panel of 226 non-small cell lung cancer tumor samples was screened for SMARCA2/4 protein expression via an immunohistochemistry (IHC) assay that was optimized for SMARCA2 and SMARCA4 detection. The IHC slides are shown in Figure 3A - 3E. The results are summarized in Table 3.

Table 3: Frequencies of SMARCA2 and SMARCA4 loss in NSCLC tumor samples.

	SMARCA2	
SMARCA4	<i>Negative</i>	<i>Positive</i>
<i>Negative</i>	3% (6)	1% (2)
<i>Positive</i>	35% (80)	61% (138)

Example 3: Anti-proliferative effect of SMARCA2 inhibition in cells

[0233] The anti-proliferative effect of SMARCA2 knockout or inhibition in SMARCA4 mutant cell lines, suggested by the CRISPR pooled screen results described in Example 1, was further evaluated in 3 target validation assays: a genotype sequencing assay, a fluorescent competition assay, and CRISPR domain-centric screening.

[0234] The genotype sequencing assay (NGS) confirmed dependence of cell proliferation on SMARCA2 sensitivity. The fluorescent competition assay validated. Phenotypic validation of CRISPR pooled screen results is challenging for single genes due to strong selection for wild-type or non-functional mutations.

[0235] The CRISPR domain-centric screening demonstrated dependence of the anti-proliferative effect on the targeted catalytic domain. Specifically, inhibition of the SMARCA2 ATPase domain, was found to drive the anti-proliferative effect of SMARCA2 knockout in cells.





[0236] CRISPR guides targeting the SMARCA2 helicase domain were found to have the strongest anti-proliferative effect. Guides targeting the SMARCA2 bromodomain showed minimal effect (Figure 5). Furthermore, treatment with the SMARCA2/4 bromodomain inhibitor PFI-3 has no functional effect on cell growth in SMARCA4 wild-type or mutant cell lines (Figure 6, Panels A-C).

Example 4: Screening for ATPase inhibitors

[0237] Known inhibitors, targeting the bromodomain, were found to have no effect on SMARCA2 ATPase activity (See Table 4). ATPase and not bromodomain function of SMARCA2 is required for viability of SMARCA4 loss of function cells. As such, the development of viable antagonists or inhibitors (i.e., ATPase inhibitors) requires methods of monitoring ATPase activity.

Table 4: Inhibition of SMARCA2 with known bromodomain inhibitors

	BMCL 2968	I-BET151	JQ1	PFI3
--	------------------	-----------------	------------	-------------

				
% inh SMARCA2 at 10 nM	9.8	-5.2, 15	4.9	5

[0238] SMARCA2 is normally found in a multidomain complex. Hence, a first step in the screening and development of suitable compounds was to determine if the isolated full length protein behaves similar to the cellular system and if a suitable construct for biophysics could be produced.

[0239] Isolated full length SMARCA2 (FL-SMARCA2) was found to be well behaved in activity assays. The signal to background ratio, ATPase activity as a function of protein concentration, and the dependence of ATP activity on mononucleosome substrate were determined for the isolated full length SMARCA2 and SMARCA4 in a high throughput screening bioluminescent assay (HTS ADP-Glo™ format). The results are summarized in Figure 7, panels A-C and Figure 8, panels A-C, respectively. The purified SWI/SNF complex demonstrated mononucleosome dependent ATPase activity in an ATPase assay. ATPase activity as a function of concentration for the purified complex was found exhibit a 16-18 fold higher slope in the presence of mononucleosome (Figure 9, panel C). The activity and dependence on nucleosome were shown to be similar between the isolated full length SMARCA2 and the SWI/SNF complex. In addition, the purified protein complex and isolated SMARCA2 demonstrated similar kinetic parameters (Figure 10, panels A-D). Consequently, isolated SMARCA2 was used for further development and a 474K HTS was completed.

[0240] Hits from the HTS assay were further evaluated and prioritized for IC₅₀ and affinity interactions (SMARCA2 binding) determined in Surface Plasmon Resonance (SPR),

wherein the IC₅₀ was determined in a 2-amino-6-mercapto-7-methylpurine ribonucleoside/Purine Nucleoside Phosphorylase (MESG/PNP) assay (Figure 11).

[0241] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Unless specifically stated or obvious from context, as used herein, the terms “a,” “an,” and “the” are understood to be singular or plural. Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive.

[0242] Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. About can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from the context, all numerical values provided herein are modified by the term “about.”

[0243] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not admitted to be prior art to the claimed invention. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting. Where names of cell lines or genes are used, abbreviations and names conform to the nomenclature of the American Type Culture Collection (ATCC) or the National Center for Biotechnology Information (NCBI), unless otherwise noted or evident from the context.

[0244] The invention can be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.

[0245] It is to be understood that the disclosure encompasses all variations, combinations, and permutations in which one or more limitation, element, clause, or descriptive term, from one or more of the claims or from one or more relevant portion of the description, is introduced into another claim. For example, a claim that is dependent on another claim can be modified to include one or more of the limitations found in any other claim that is dependent on the same base claim. Furthermore, where the claims recite a composition, it is to be understood that methods of making or using the composition according to any of the methods of making or using disclosed herein or according to methods known in the art, if any, are included, unless otherwise indicated or unless it would be evident to one of ordinary skill in the art that a contradiction or inconsistency would arise.

[0246] Where elements are presented as lists, *e.g.*, in Markush group format, it is to be understood that every possible subgroup of the elements is also disclosed, and that any element or subgroup of elements can be removed from the group. It is also noted that the term “comprising” is intended to be open and permits the inclusion of additional elements or steps. It should be understood that, in general, where an embodiment, product, or method is referred to as comprising particular elements, features, or steps, embodiments, products, or methods that consist, or consist essentially of, such elements, features, or steps, are provided as well. For purposes of brevity those embodiments have not been individually spelled out herein, but it will be understood that each of these embodiments is provided herein and may be specifically claimed or disclaimed.

[0247] Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value within the stated ranges in some embodiments, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise. For purposes of brevity, the values in each range have not been individually spelled out herein, but it will be understood that each of these values is provided herein and may be specifically claimed or disclaimed. It is also to be understood that unless otherwise indicated or otherwise evident from the context and/or the understanding of one of ordinary skill in the art, values expressed as ranges can assume any subrange within the given range, wherein the endpoints of the subrange are expressed to the same degree of accuracy as the tenth of the unit of the lower limit of the range.

[0248] In addition, it is to be understood that any particular embodiment of the present disclosure may be explicitly excluded from any one or more of the claims. Where ranges are given, any value within the range may explicitly be excluded from any one or more of the claims. Any embodiment, element, feature, application, or aspect of the compositions and/or methods of the invention, can be excluded from any one or more claims. For purposes of brevity, all of the embodiments in which one or more elements, features, purposes, or aspects are excluded are not set forth explicitly herein.

CLAIMS

1. A method comprising modulating a SMARCA2 activity in a cell exhibiting a decreased activity or function of SMARCA4.
2. The method of claim 1, wherein the cell is in vivo, ex vivo, in vitro, or in situ.
3. The method of any one of claims 1-2, wherein the cell is in a subject, and the method comprises administering a SMARCA2 antagonist to the subject.
4. The method of any one of claims 1-3, wherein the cell is ex vivo or in vitro, and wherein the cell is isolated or derived from a subject that has a tumor.
5. The method of claim 4, wherein the tumor is malignant.
6. The method of claim 4 or claim 5, wherein the tumor is metastatic.
7. A method of treating cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a SMARCA2 antagonist to the subject or a cell of the subject, wherein said subject or cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.
8. The method of claim 7, wherein the control level is the level of activity or function of SMARCA4 in a subject that does not have cancer.
9. The method of any of claims 1-8, wherein the method comprises administering the SMARCA2 antagonist to the cell or the subject based on the decreased activity or function of SMARCA4 in the cell or the subject.
10. A method of identifying a subject having a cancer as a candidate for treatment with a SMARCA2 antagonist, comprising
 - detecting a level of activity or function of SMARCA4 in a cancer cell in the subject,
 - comparing the level of activity or function of SMARCA4 detected in the cancer cell to a control or reference level, wherein the subject is identified as a candidate for treatment with a

SMARCA2 antagonist, if the level of activity or function of SMARCA4 in the cancer cell is decreased as compared to the control or reference level.

11. The method of claim 10, wherein the method comprises obtaining a sample comprising a cancer cell from the subject.

12. A method of identifying a cancer cell as sensitive to treatment with a SMARCA2 antagonist, comprising

detecting a level of activity or function of SMARCA4 in the cancer cell,

comparing the level of activity or function of SMARCA4 detected in the cancer to a control or reference level,

wherein the cell is identified as a sensitive to treatment with a SMARCA2 antagonist, if the level of activity or function of SMARCA4 is decreased as compared to the control or reference level.

13. The method of any one of claims 10-12, wherein the control or reference level of SMARCA4 activity or function is a level of SMARCA4 observed or expected in a healthy cell of the same origin as the cancer cell.

14. The method of any one of claims 1-13, wherein the SMARCA2 antagonist inhibits SMARCA2 helicase activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or abolishes SMARCA2 activity.

15. The method of any one of claims 1-14, wherein the SMARCA2 antagonist inhibits SMARCA2 ATPase activity by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99%, or abolishes SMARCA2 activity.

16. The method of any one of claims 1-15, wherein the SMARCA2 antagonist is a selective SMARCA2 antagonist.

17. The method of any one of claims 1-16, wherein the SMARCA2 antagonist inhibits SMARCA2 activity at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-

fold, at least 100-fold, at least 1000-fold, at least 10000-fold, or at least 100000-fold more efficiently than SMARCA4 activity.

18. The method of any one of claims 16 or 17, wherein the SMARCA2 antagonist does not inhibit SMARCA4.

19. The method of any one of claims 1-18, wherein the SMARCA2 antagonist targets a helicase domain of SMARCA2.

20. The method of any one of claims 1-19, wherein the SMARCA2 antagonist targets an ATPase domain of SMARCA2.

21. The method of any one of claims 1-20, wherein the SMARCA2 antagonist does not target a bromodomain activity of SMARCA2.

22. The method of any of the preceding claims, wherein the decreased activity of SMARCA4 is caused by a genetic mutation.

23. The method of any of the preceding claims, wherein the decreased activity of SMARCA4 is caused by an epigenetic alteration.

24. The method of any one of the preceding claims, wherein the decreased activity of SMARCA4 is caused by a decrease in SMARCA4 gene transcription, by a decrease in SMARCA4 gene transcript translation, by a post-translational modification, by a loss of protein-protein interaction, or a combination thereof.

25. The method of any one of claims 1-24, wherein the SMARCA2 antagonist is a SMARCA2 inhibitor.

26. The method of any one of claims 1-25, wherein the SMARCA2 antagonist is selected from the group consisting of antisense RNA, shRNA, siRNA, CRISPR/Cas9, transcription activator-like effector nucleases (TALEN), Zinc Finger nucleases (ZFN), antibodies, antibody fragments and antibody mimetics.

27. The method of any one of claims 1-15 and 22-26, wherein the SMARCA2 antagonist is PFI-3.
28. A SMARCA2 antagonist for use in treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.
29. A SMARCA2 antagonist for use as a medicament for treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.
30. Use of SMARCA2 antagonist in the manufacture of a medicament for treating cancer in a subject in need thereof, wherein said subject or a cell of the subject exhibits a decreased activity or function of SMARCA4 when compared to a control level of the activity or the function of SMARCA4.

FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7





FIGURE 7 - CONTINUED



E

1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400																																																												
4340	4341	4342	4343	4344	4345	4346	4347	4348	4349	4350	4351	4352	4353	4354	4355	4356	4357	4358	4359	4360	4361	4362	4363	4364	4365	4366	4367	4368	4369	4370	4371	4372	4373	4374	4375	4376	4377	4378	4379	4380	4381	4382	4383	4384	4385	4386	4387	4388	4389	4390	4391	4392	4393	4394	4395	4396	4397	4398	4399	4400	4401	4402	4403	4404	4405	4406	4407	4408	4409	4410	4411	4412	4413	4414	4415	4416	4417	4418	4419	4420	4421	4422	4423	4424	4425	4426	4427	4428	4429	4430	4431	4432	4433	4434	4435	4436	4437	4438	4439	4440	4441	4442	4443	4444	4445	4446	4447	4448	4449	4450	4451	4452	4453	4454	4455	4456	4457	4458	4459	4460	4461	4462	4463	4464	4465	4466	4467	4468	4469	4470	4471	4472	4473	4474	4475	4476	4477	4478	4479	4480	4481	4482	4483	4484	4485	4486	4487	4488	4489	4490	4491	4492	4493	4494	4495	4496	4497	4498	4499	4500
8800	8801	8802	8803	8804	8805	8806	8807	8808	8809	8810	8811	8812	8813	8814	8815	8816	8817	8818	8819	8820	8821	8822	8823	8824	8825	8826	8827	8828	8829	8830	8831	8832	8833	8834	8835	8836	8837	8838	8839	8840	8841	8842	8843	8844	8845	8846	8847	8848	8849	8850	8851	8852	8853	8854	8855	8856	8857	8858	8859	8860	8861	8862	8863	8864	8865	8866	8867	8868	8869	8870	8871	8872	8873	8874	8875	8876	8877	8878	8879	8880	8881	8882	8883	8884	8885	8886	8887	8888	8889	8890	8891	8892	8893	8894	8895	8896	8897	8898	8899	8900																																																												
12800	12801	12802	12803	12804	12805	12806	12807	12808	12809	12810	12811	12812	12813	12814	12815	12816	12817	12818	12819	12820	12821	12822	12823	12824	12825	12826	12827	12828	12829	12830	12831	12832	12833	12834	12835	12836	12837	12838	12839	12840	12841	12842	12843	12844	12845	12846	12847	12848	12849	12850	12851	12852	12853	12854	12855	12856	12857	12858	12859	12860	12861	12862	12863	12864	12865	12866	12867	12868	12869	12870	12871	12872	12873	12874	12875	12876	12877	12878	12879	12880	12881	12882	12883	12884	12885	12886	12887	12888	12889	12890	12891	12892	12893	12894	12895	12896	12897	12898	12899	12900																																																												
16800	16801	16802	16803	16804	16805	16806	16807	16808	16809	16810	16811	16812	16813	16814	16815	16816	16817	16818	16819	16820	16821	16822	16823	16824	16825	16826	16827	16828	16829	16830	16831	16832	16833	16834	16835	16836	16837	16838	16839	16840	16841	16842	16843	16844	16845	16846	16847	16848	16849	16850	16851	16852	16853	16854	16855	16856	16857	16858	16859	16860	16861	16862	16863	16864	16865	16866	16867	16868	16869	16870	16871	16872	16873	16874	16875	16876	16877	16878	16879	16880	16881	16882	16883	16884	16885	16886	16887	16888	16889	16890	16891	16892	16893	16894	16895	16896	16897	16898	16899	16900																																																												
20800	20801	20802	20803	20804	20805	20806	20807	20808	20809	20810	20811	20812	20813	20814	20815	20816	20817	20818	20819	20820	20821	20822	20823	20824	20825	20826	20827	20828	20829	20830	20831	20832	20833	20834	20835	20836	20837	20838	20839	20840	20841	20842	20843	20844	20845	20846	20847	20848	20849	20850	20851	20852	20853	20854	20855	20856	20857	20858	20859	20860	20861	20862	20863	20864	20865	20866	20867	20868	20869	20870	20871	20872	20873	20874	20875	20876	20877	20878	20879	20880	20881	20882	20883	20884	20885	20886	20887	20888	20889	20890	20891	20892	20893	20894	20895	20896	20897	20898	20899	20900																																																												
24800	24801	24802	24803	24804	24805	24806	24807	24808	24809	24810	24811	24812	24813	24814	24815	24816	24817	24818	24819	24820	24821	24822	24823	24824	24825	24826	24827	24828	24829	24830	24831	24832	24833	24834	24835	24836	24837	24838	24839	24840	24841	24842	24843	24844	24845	24846	24847	24848	24849	24850	24851	24852	24853	24854	24855	24856	24857	24858	24859	24860	24861	24862	24863	24864	24865	24866	24867	24868	24869	24870	24871	24872	24873	24874	24875	24876	24877	24878	24879	24880	24881	24882	24883	24884	24885	24886	24887	24888	24889	24890	24891	24892	24893	24894	24895	24896	24897	24898	24899	24900																																																												
28800	28801	28802	28803	28804	28805	28806	28807	28808	28809	28810	28811	28812	28813	28814	28815	28816	28817	28818	28819	28820	28821	28822	28823	28824	28825	28826	28827	28828	28829	28830	28831	28832	28833	28834	28835	28836	28837	28838	28839	28840	28841	28842	28843	28844	28845	28846	28847	28848	28849	28850	28851	28852	28853	28854	28855	28856	28857	28858	28859	28860	28861	28862	28863	28864	28865	28866	28867	28868	28869	28870	28871	28872	28873	28874	28875	28876	28877	28878	28879	28880	28881	28882	28883	28884	28885	28886	28887	28888	28889	28890	28891	28892	28893	28894	28895	28896	28897	28898	28899	28900																																																												
32800	32801	32802	32803	32804	32805	32806	32807	32808	32809	32810	32811	32812	32813	32814	32815	32816	32817	32818	32819	32820	32821	32822	32823	32824	32825	32826	32827	32828	32829	32830	32831	32832	32833	32834	32835	32836	32837	32838	32839	32840	32841	32842	32843	32844	32845	32846	32847	32848	32849	32850	32851	32852	32853	32854	32855	32856	32857	32858	32859	32860	32861	32862	32863	32864	32865	32866	32867	32868	32869	32870	32871	32872	32873	32874	32875	32876	32877	32878	32879	32880	32881	32882	32883	32884	32885	32886	32887	32888	32889	32890	32891	32892	32893	32894	32895	32896	32897	32898	32899	32900																																																												
36800	36801	36802	36803	36804	36805	36806	36807	36808	36809	36810	36811	36812	36813	36814	36815	36816	36817	36818	36819	36820	36821	36822	36823	36824	36825	36826	36827	36828	36829	36830	36831	36832	36833	36834	36835	36836	36837	36838	36839	36840	36841	36842	36843	36844	36845	36846	36847	36848	36849	36850	36851	36852	36853	36854	36855	36856	36857	36858	36859	36860	36861	36862	36863	36864	36865	36866	36867	36868	36869	36870	36871	36872	36873	36874	36875	36876	36877	36878	36879	36880	36881	36882	36883	36884	36885	36886	36887	36888	36889	36890	36891	36892	36893	36894	36895	36896	36897	36898	36899	36900																																																												
40800	40801	40802	40803	40804	40805	40806	40807	40808	40809	40810	40811	40812	40813	40814	40815	40816	40817	40818	40819	40820	40821	40822	40823	40824	40825	40826	40827	40828	40829	40830	40831	40832	40833	40834	40835	40836	40837	40838	40839	40840	40841	40842	40843	40844	40845	40846	40847	40848	40849	40850	40851	40852	40853	40854	40855	40856	40857	40858	40859	40860	40861	40862	40863	40864	40865	40866	40867	40868	40869	40870	40871	40872	40873	40874	40875	40876	40877	40878	40879	40880	40881	40882	40883	40884	40885	40886	40887	40888	40889	40890	40891	40892	40893	40894	40895	40896	40897	40898	40899	40900																																																												
44800	44801	44802	44803	44804	44805	44806	44807	44808	44809	44810	44811	44812	44813	44814	44815	44816	44817	44818	44819	44820	44821	44822	44823	44824	44825	44826	44827	44828	44829	44830	44831	44832	44833	44834	44835	44836	44837	44838	44839	44840	44841	44842	44843	44844	44845	44846	44847	44848	44849	44850	44851	44852	44853	44854	44855	44856	44857	44858	44859	44860	44861	44862	44863	44864	44865	44866	44867	44868	44869	44870	44871	44872	44873	44874	44875	44876	44877	44878	44879	44880	44881	44882	44883	44884																																																																												

FIGURE 7 - CONTINUED





FIGURE 8




FIGURE 9





FIGURE 10

A



B





FIGURE 10-CONTINUED

C



D





FIGURE 11

A



B




FIGURE 11-CONTINUED

C




FIGURE 12

